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Abstract 
 
Background 
 
Chest pain makes up a quarter of medical admissions in the United Kingdom.  A 
diagnostic strategy that prevents unnecessary hospital admission in a large proportion 
of this patient group would have significant benefits for healthcare services by 
reducing hospital admission rates, ED overcrowding, duplication of staff time and 
resource use.  A clinically applicable protocol that allows the discharge of a significant 
proportion of patients after a single blood draw at presentation to the emergency 
department remains an attractive yet elusive goal.   
 
Objective 
To establish whether a novel accelerated diagnostic protocol (ADP) for suspected 
acute coronary syndrome (ACS) could successfully identify low-risk patients suitable for 
discharge after a single high-sensitivity troponin T (hs-cTnT) taken at presentation to 
the Emergency Department (ED).  Comparison of the diagnostic accuracy of this ADP 
with strategies utilising initial undetectable hs-cTnT was made.  
  
Methods 
This prospective observational study evaluated the ability of the Triage Rule-out Using 
high-Sensitivity Troponin (TRUST) ADP to identify low-risk patients with suspected ACS.  
The ADP incorporated a single presentation hs-cTnT of <14ng/L, a non-ischaemic 
electrocardiogram and a modified Goldman risk score.  Diagnostic performance of the 
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ADP was compared with the detection limit cut-offs of hs-cTnT (<5ng/L and <3ng/L).  
The primary endpoint was major adverse cardiac events (MACE) occurring within 30 
days. 
 
Results  
960 participants were recruited, mean age 58.0 years, 97 (10.1%) had MACE.  The 
TRUST ADP classified 382 (39.8%) as low-risk with a sensitivity for identifying MACE of 
99.0% (95%CI 93.7-99.9).  Hs-cTnT detection limits (<5ng/L and <3ng/L) had a 
sensitivity of 96.8% (90.6-99.2) and 98.9% (93.8-99.9) respectively.  The TRUST ADP 
identified more patients suitable for early discharge at 39.8% vs 29.3% (<5ng/L) and 
7.9% (<3ng/L) (P<0.001) with a lower false-positive rate for MACE detection; specificity 
44.1% (95%CI 43.6-44.3) vs 32.3% (95%CI 31.6-32.6) and 8.7% (95%CI 8.1-8.8) 
respectively. 
 
Conclusion 
The TRUST ADP, which incorporates structured risk-assessment and a single 
presentation hs-cTnT blood draw, has potential to allow early discharge in 40% of 
patients with suspected ACS and has greater clinical utility than undetectable hs-cTnT 
strategies. 
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Key Messages 
What is already known about the subject?  The use of undetectable high-sensitivity 
troponin levels and risk scores in combination with early biomarker testing have 
recently been put forward as diagnostic tools aiming to reduce door-to-discharge 
times in patients with suspected acute coronary syndromes.  However, a clinically 
applicable protocol that allows the discharge of a significant proportion of patients 
after just a single high sensitivity troponin blood draw at presentation to the 
emergency department remains an attractive yet elusive goal.   
 
What does this study add?  Using a simple clinical risk score, together with the results 
of a single high-sensitivity troponin result, the Triage Rule-out Using high-Sensitivity 
Troponin Accelerated Diagnostic Protocol, may enable immediate discharge in up to 
40% of patients.  This strategy identifies more patients suitable for early discharge, 
with lower false-positive rates than undetectable troponin strategies. 
 
How might this impact on clinical practice?  Chest pain makes up a quarter of medical 
admissions in the United Kingdom.  A diagnostic strategy that prevents unnecessary 
hospital admission in a large proportion of this patient group would have significant 
benefits for healthcare services by reducing hospital admission rates, ED overcrowding, 
duplication of staff time and resource use. 
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1.1 Background 
 
Chest pain makes up a significant proportion of Emergency Department (ED) 
attendances. In fact, 6% of all presentations to UK EDs are due to chest pain which 
amounts to 700,000 patients per year UK-wide (Goodacre et al. 2005). Due to the 
potentially catastrophic consequences of missed Acute Myocardial Infarction (AMI) 
both medically and medico-legally, the majority of chest pain patients are admitted for 
further assessment. As a result, although 25% of all acute medical admissions to 
hospitals are due to chest pain, 85% are subsequently shown not to have a final 
diagnosis of a AMI (Pollack et al. 2006).  Since each chest pain admission costs on 
average £2500 this has a huge impact on National Health Service resources (Oluboyede 
et al. 2008). 
The author has developed a novel Accelerated Diagnostic Protocol (ADP) (Figure 1) for 
the assessment of patients with suspected cardiac chest pain that, if proven to be safe, 
will allow the early discharge of over 30% of patients after a single blood test at 
presentation. This pathway combines the use of an established risk-stratification tool 
and a sensitive biomarker of myocardial necrosis called high-sensitivity troponin (hs-
cTn).  The use of hs-cTn has been shown to be highly sensitive in the detection of AMI 
(Keller et al. 2009 and Reichlin et al. 2009) but whether it is also effective in rapid rule-
out strategies that incorporate structured clinical assessment, has yet to be 
established. The TRUST study will investigate whether the ADP will enable early 
identification of low risk patients on the basis of a normal ECG, a low score on a 
questionnaire-based risk assessment tool (the modified Goldman Score) and a low hs-
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cTn level taken within the first hour of arrival in the Emergency Department (ED).  
These patients are suitable for early discharge and do not need hospital admission.  It 
is estimated that the TRUST ADP will demonstrate a safe reduction in the number of 
hospital admissions due to chest pain by 30%.  This single-centre prospective 
observational cohort study has been designed to test the accuracy of the TRUST ADP in 
an acute hospital setting through analysis of AMI rates and 30 day major adverse 
cardiac events (MACE) in the study population. 
Figure 1. The diagnostic elements of an Accelerated Diagnostic Protocol for the 
assessment of suspected cardiac chest pain. 
 
The following discussion covers the evidence base behind each element of the TRUST 
ADP, cardiac troponin testing, clinical risk scores and ECG testing.  
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1.2  Cardiac Troponin Testing 
 
1.2.1 Troponin: The Biomarker of Choice for the Detection of Myocardial Injury 
 
Biomarkers that are released when myocardial necrosis occurs are needed to assist in 
the diagnosis of those AMIs that are not clinically obvious.  Biomarkers in earlier use, 
such as creatinine kinase and myoglobin, are not specific to myocardial tissue, and this 
limits their clinical utility (Wu et al. 1999).  Therefore cardiac troponin is currently the 
biomarker of choice for the detection of myocardial injury.   
The troponin complex (cTnT, cTnI and cTnC), together with tropomysin, is located on 
the actin filament, and is essential for the calcium-mediated contraction of skeletal 
and cardiac muscle (Takeda et al. 2003).  Because the cardiac isoform of troponin C is 
shared by slow-twitch skeletal muscles, troponin C does not have cardiac specificity 
and thus is not used in assays for the diagnosis of myocardial injury (Schreier et al. 
1990). Cardiac troponins are largely bound into the myofibrillar array, although small 
amounts (<10%) are in a free cytosolic pool. Cardiomyocyte necrosis firstly releases the 
cytosolic pool, but as cardiomyocytes die further myofibrilar troponins are released 
(Apple and Collinson 2012) (Figure 2). As these assays specifically target cardiac 
troponins, they are extremely specific to necrosis of cardiac muscle (Korff et al. 2006).  
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Figure 2.  The binding and subsequent release of cardiac troponin after ischaemic 
injury 
 
cTnT/cTnI/cTnC: Cardiac troponin T/C/I complex 
Image adapted from Gaze and Collinson 2008 
 
The proportion of troponin that reaches the plasma after myocardial injury is greater 
for troponin than for earlier biomarkers, such as creatine kinase (Vatner et al. 1978).  
Katus et al. demonstrated (1991) that elevated troponin levels persist in the blood 
after myocardial injury.  This prolonged window of troponin elevation leads increased 
detection of myocardial injury and enables use in a clinical environment. 
1.2.2 Troponin and the Third Universal Definition of Myocardial Infarction 
 
In 2000 AMI was redefined by an international consensus group as being a “rise and/or 
fall of cardiac biomarkers (preferably troponin)” with at least one value above the 
reference limit together with clinical evidence of myocardial ischaemia from 
symptoms, ECG, or cardiac imaging (Alpert et al. 2000). The reference limit is defined 
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as the 99th percentile of a sample of troponin levels from a normal population, i.e. the 
highest troponin levels normally detected.   
 
The Third Universal Definition of Myocardial Infarction 
 
 
 
 
 
 
After Thygesen et al. 2012a 
 
The universal definition mandated the level of assay precision expected of troponin 
tests in terms of the degree of agreement between repeated tests at the reference 
limit (the coefficient of variation), but very few of the tests available at the time of the 
original definition were able to achieve this, which stimulated active development of 
improved tests (Jesse 2010). The limits of detection (see critical definitions below) of 
troponin assays have steadily improved during their development (Table 1).  Early 
assays had a limit of detection of 500 nanograms per litre (then generally expressed as 
0.5 micrograms per litre or nanograms per millilitre), and this threshold has fallen with 
successive generations of assays. The limit at which assays have an acceptable 
coefficient of variability has also fallen – so both assay threshold and accuracy have 
improved.  
Criteria for AMI: 
BOTH of 
 Rise and/or fall of troponin (or another cardiac 
biomarker) 
o One value must be above the 99th 
percentile reference limit 
 Evidence of myocardial ischaemia from 
symptoms, ECG, or cardiac imaging. 
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Critical definitions in the use of troponin assays: 
 
Table 1. Classification of cardiac troponin assays 
  
 Introduction 
into Clinical 
Practice 
Ability to 
measure cTn 
levels 
Lower 
limit of 
detection 
(ng/L) 
Detection in a 
normal 
reference 
population 
Consensus 
Recommend
ations on 
Time to 
Testing 
1st Generation Late 1980s  High 
abnormal 
only 
500 <1% 12 hours 
2nd Generation 
 
Late 1990s  Abnormal 
only 
100 <1% 12 hours 
3rd Generation 
“Contemporary” 
2000s Abnormal to 
near-normal   
50 1-2% 10-12 hours 
4th Generation 
High-sensitivity 
2010-2012 High-normal  1-3 >50% 3-6 hours  
5th Generation 
Ultra-high 
sensitivity 
In pre-clinical 
use 
Normal levels  0.2 >95% To be 
confirmed 
After Jesse (2010) and Apple and Collinson (2012)   
99th Percentile Value:   
Cut-off concentration used to discriminate myocardial necrosis.  In laboratory 
medicine, the 99th percentile is typically determined from a normal, healthy 
population.  This is usually the “positive/negative” cut-off used in clinical practice.  
 
The Limit of Blank (LoB): 
The highest apparent analyte concentration expected to be found when replicates 
of a blank sample containing no analyte are tested (Armbruster and Pry 2008).   
 
The Limit of Detection (LoD):  
The lowest analyte concentration likely to be reliably distinguished from the LoB at 
which detection is feasible (Armbruster and Pry 2008).   
 
Coefficient of Variation (CV): 
 A measure of how consistently an assay is able to produce the same result on the 
same sample. A CV of 10% is the level of precision suggested for troponin assays. 
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1.2.3  Characteristics of Troponin Assays 
 
There is one cTnI isoform in myocardial tissue which has a significant dissimilarity in 
amino acid sequencing when compared to other isoforms.  This dissimilarity has 
enabled the development of highly specific monoclonal antibodies to allow their 
detection in circulating plasma (Babuin and Jaffe 2005).  Myocardial tissue contains 
four cTnT isoforms, but only one is characteristic of the normal adult human heart 
(Anderson et al. 1995).  Highly specific antibodies have been made for this isoform.  
Patent restrictions mean that production of assays which detect the cTnT isoform are 
only available through one diagnostics company, (Roche, Switzerland) whereas 
numerous companies produce cTnI assays.  
For all intents and purposes cTnI and cTnT provide comparable information with 
regards to myocardial injury (Babuin and Jaffe 2005).  However, it must be recognized 
that there is huge variability in the sensitivity of the assays available, from various 
manufacturers, due to variation in epitope recognition by antibodies. Table 2a 
summarizes the analytical characteristics and target epitopes of troponin assays in 
common clinical and research use, declared by manufacturer.  The 99th percentile cut-
off value can be applied consistently across assays even if the assays change.  For some 
assays there may be a need to alter the 99th centile value depending on race, age or 
sex (Apple and Murakami 2004 and Eggers et al. 2014) 
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Table 2a.  Analytical characteristics of commonly used clinical and research troponin 
assays 
Company/Platform/Assay LoB 
(ng/L) 
LoD 
(ng/L) 
99th 
Percentile 
(ng/L) 
10% 
CV 
(ng/L) 
Epitopes 
recognized by 
assay 
antibodies 
Abbott AxSYM ADV 20  40 160 C 87-91, 41-49; D 24-40 
Abbott Architect <10  28 32 C 87-91, 24-40; D: 41-
49 
Abbott Architect STAT hs-cTnI 0.7 – 
1.3 
1.1 – 
1.9 
26.2 4.7 C: 24-40; D: 41-49 
Abbott i-STAT 20  80 100 C: 41-49, 88-91; D: 28-
39, 62-78 
Alere Triage Cardio 3 2 10 17 37 C: 27-39; D: 83-93, 
190-196 
Beckman Coulter Access Accu 10  40 60 C: 41-49; D: 24-40 
bioMerieux Vidas Ultra <10 <10 10 110 C: 41-49, 22-29; D: 87-
91, 7B9 
Mitsubishi PATHFAST cTnI-II 2 8 29 3.1 C: 41-49; D: 71-116, 
163-209 
Ortho VITROS Troponin I ES 7 12 34 34 C: 24-40, 41-49; D: 87-
91 
Radiometer AQT90 FLEX TnI  9.5 23 39 C: 41-49, 190-196; D: 
137-149 
Roche E 2010 /cobas e 411 /  
E 170 / cobas e 601 / 602 TnT (4th gen) 
10   30 C: 125-131; D:136-147 
Roche E 2010/cobas e 411 /  
E 170 / cobas e 601 / 602 hs-cTnT 
3 5 14 13 C: 87-91, 190-196; D: 
23-29, 27-43 
Siemens ADVIA Centaur TnI-Ultra 6  40 30 C: 41-49, 87-91; D: 27-
40 
Singulex Erenna hs-cTnI* 0.09  10.1 0.88 C: 41-49; D: 27-41 
*Research use only 
LoB: Level of Blank, LoD: Level of Detection, CV: Coefficient of Variation 
Adapted from International Federation of Clinical Chemistry and Laboratory Medicine 2013   
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1.2.4 High-Sensitivity Troponin 
 
The previously limited ability of troponin assay to detect low levels of troponin 
circulating in the blood resulted in the need to wait for the release of reliably 
detectable levels after chest pain onset.  Accordingly it has not been possible to safely 
rule-out AMI until 10-12 hours after onset of the patient’s worst pain (National 
Institute for Health and Care Excellence (NICE) 2010) and this has resulted in large 
resource expenditures in many hospitals as large numbers of patients occupy beds 
whilst they wait for troponin results (Hwang et al. 2010). 
Time and performance pressures have stimulated development of a new generation of 
assays called high-sensitivity troponin (hs-cTn). Hs-cTn assays demonstrate normal 
levels of circulating troponin, such that they can detect troponin in over 50% of normal 
people (Giannitsis et al. 2010 and Thygesen et al. 2012b) and in even higher 
proportions of those with risk factors or chronic coronary disease (Reiter et al. 2011 
and Saunders et al. 2011). The ability to detect much lower levels of troponin allows 
for testing at earlier time points and opens up a range of possibilities for use in early 
rule-out of AMI. 
The one hs-cTnT assay which is available (Roche Elecsys Troponin T high-sensitivity) 
has a coefficient of variation of 9% at 14ng/L, which is below its 99th centile and thus it 
meets the Universal Definition of myocardial infarction criteria (Thygesen et al. 2012a). 
The upper limit of normal (99th centile) in a reference healthy population of blood 
donors, is 14ng/L (Giannitsis et al 2010).   
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While many manufacturers supply cTnI assays, in 2014 NICE determined that only the 
Abbott Architect STAT hs-cTnI assay fulfilled the definition of a high-sensitivity assay.  
The current high-sensitivity assays available and their performance characteristics are 
summarized in Table 2b.    
A recent study has suggested that hs-cTnI may have a better ability to identify patients 
with higher cardiovascular risk than hs-cTnT (Omland et al. 2013).  Both hs-cTnT and 
hs-cTnI have been tested in the acute clinical situation but their performance 
characteristics in this patient group remains poorly understood (Hoeller et al. 2013). 
Table 2b.  Analytical characteristics of commercially available (U.K. 2015) high-
sensitivity troponin assays 
Manufacturer Name Assay 99th 
percentile 
value 
Coefficient 
of variation 
at 99th 
centile value 
Laboratory 
turnaround 
time 
Roche Elecsys hs-cTnT 14ng/L <10% 18 minutes 
Abbott Architect hs-cTnI 26.2ng/L 4% 16 minutes 
Adapted from NICE 2014 
1.2.5 High-Sensitivity Troponin: Ruling-in Acute Myocardial Infarction 
 
While the focus of the TRUST study is on the early rule-out of AMI, an important area 
that must be discussed are the implications that high-sensitivity assays may have for 
the adjudication of major adverse cardiac events, and more specifically AMI, both 
within the context of a research study and in clinical practice.   
Although cardiac troponin is by definition completely specific for myocardial injury it is 
not specific for the diagnosis of AMI.  This leads to a problem for hs-cTn where 
specificity has been reported to be 80-85% in comparison to figures of 97% for earlier 
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generation troponins (Reichlin et al. 2009).  This may have considerable impact on the 
utility of hs-cTn testing, as higher false-positive rates may lead to unnecessary 
subsequent invasive investigations, such as angiography, and misdiagnosis. However 
these lower specificities are based upon hs-cTn testing at much earlier time points and 
under-estimate the specificity of hs-cTn.  In fact Aldous et al. (2011a), demonstrated 
that if early hs-cTn testing is assessed against diagnoses made on the basis of serial hs-
cTn testing, specificity is improved to 92%.  
Also, the issue of lower diagnostic specificity may not be relevant in clinical practice 
and conversely the implementation of an hs-cTn assay has been demonstrated by Mills 
et al. (2011) to increase the proportion of patients diagnosed with AMI and identify 
patients at high risk of recurrent AMI or death, while lowering the diagnostic threshold 
of the plasma concentration of hs-cTn was associated with major reductions in 
morbidity and mortality.  
Despite taking these points into account the lower specificity of hs-cTn testing remains 
a limitation in accurately diagnosing AMI.  To improve this, serial sampling is required – 
which is in fact necessary to satisfy the agreed criteria for a diagnosis of AMI.  The 
Universal Definition (Thygesen et al. 2012a) requires a change in troponin to be 
detected, although this has been frequently ignored in clinical practice, perhaps due to 
unwanted complexity or lack of general understanding of this concept. Sampling hs-
cTn at admission and then a later time point allows calculation of the change between 
the two samples (known as the “delta” value). If this is small it is considered to be a 
product of analytical or biological variation, whereas larger changes represent 
continuing troponin leak from damaged cells and hence suggest an AMI.  
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The extent of change in troponin levels required to diagnose an AMI is recommended 
by the European Society of Cardiology (Thygesen et al. 2012b) guidance as over a 20% 
relative change (in those patients with an elevated initial hs-cTn).  However this figure 
of 20% is based on research using older troponin assays, and although it is widely 
quoted in guidelines, there is evidence that in particular for hs-cTnT testing an 
absolute change of 9.2ng/L provides better discrimination (Mueller et al. 2012), but 
this remains experimental.   Figure 3 is a suggested clinical pathway incorporating 
serial hs-cTn testing for the diagnosis of AMI. 
Figure 3. Clinical use of high-sensitivity troponin testing – a suggested framework 
Note that excluding AMI does not exclude unstable angina or ischaemic heart disease 
ECG: Electrocardiogram, STEMI: ST-elevation Myocardial Infarction, NSTEMI: Non-ST segment 
elevation Myocardial Infarction, ACS: Acute Coronary Syndrome, HsTn: High-sensitivity troponin  
After Collinson 2011 
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Many clinicians will agree that there is a problem in daily practice whereby any 
abnormal troponin result is automatically assumed to represent an AMI. This problem 
will potentially worsen as our ability to detect much lower levels of troponin increases. 
Hs-cTn is detectable in the majority of unwell patients, which reflects low-level 
myocardial injury rather than myocardial infarction (Rosjo et al. 2011). Elevated levels 
often represent myocardial injury induced by numerous acute non-cardiac disease, 
such as pulmonary embolism, subarachnoid haemorrhage or renal failure (Newby et al, 
2012).  In some cases, troponin release will be due to a mismatch between myocardial 
blood supply and demand, or injuries not related to ischaemia, resulting in a “Type 2 
AMI” (Table 3).  Table 4 summarises the expected degree of hs-cTn elevation for the 
Abbott and Roche hs-cTn assays according to possible diagnoses. 
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Table 3.  Causes of elevations of cardiac troponin due to myocardial injury and Type 
2 acute myocardial infarction 
Type 1 Acute Myocardial Infarction: Injury related to primary myocardial ischaemia   
Atherosclerotic plaque rupture 
Intraluminal coronary artery thrombus formation 
Type 2 Acute Myocardial Infarction 
Injury related to supply/demand imbalance of 
myocardial ischaemia 
Tachy-/brady-arrhythmias 
Aortic dissection or severe aortic valve disease 
Hypertrophic cardiomyopathy 
Cardiogenic, hypovolaemic, or septic shock 
Severe respiratory failure 
Severe anaemia 
Hypertension with or without LVH 
Coronary spasm 
Coronary embolism or vasculitis 
Coronary endothelial dysfunction without significant coronary artery disease 
Injury not related to myocardial ischaemia 
Cardiac contusion, surgery, ablation, pacing, or defibrillator shocks 
Rhabdomyolysis with cardiac involvement 
Myocarditis 
Cardiotoxic agents, e.g. anthracyclines, Herceptin 
Multifactorial or indeterminate myocardial injury 
Heart failure 
Stress (Takotsubo) cardiomyopathy 
Severe pulmonary embolism or pulmonary hypertension 
Sepsis and critically ill patients 
Renal failure 
Severe acute neurological diseases, e.g. stroke, subarachnoid 
haemorrhage 
Infiltrative diseases, e.g. amyloidosis, sarcoidosis 
Strenuous exercise 
Adapted from Thygesen et al. 2012b 
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Table 4.  The expected degree of elevation for the Abbott and Roche hs-cTn assays 
according to underlying diagnosis 
Level Abbott Architect Hs-
cTnI  
ng/L 
Roche Elecsys Hs-
cTnT 
ng/L 
Possible Diagnoses 
 >1000 >10000 Large AMI/Severe 
Myocarditis 
500 1000 Medium AMI, PE, 
Takotsubo, Critical 
Illness 
100 100 Small AMI, myocarditis, 
sepsis, PE, 
subarachnoid, chronic 
renal failure 
50 14-30 Micro AMI, 
myocarditis, congestive 
cardiac failure, sepsis, 
PE, subarachnoid, 
chronic renal failure 
99th Percentile 
Value 
<26.2 <14 Stable Angina, LVH, 
subclinical heart 
disease, old age, 
comorbidities 
Level of Detection <1.9 <5 Healthy Patient 
Hs-cTn: High-sensitivity cardiac troponin, AMI: Acute Myocardial Infarction, PE: Pulmonary 
Emebolism, LVH: Left Ventricular Hypertrophy 
Adapted from Agewall et al. 2011 
 
Even when hs-cTn elevation is not caused by AMI, it still provides important 
information.  In every condition in which it has been assessed, elevated troponin levels 
correlate with an adverse prognosis.  Examples would include heart failure (Nagarajan 
et al. 2012), atrial fibrillation (Van den Bos et al. 2011), pulmonary embolism (Lankeit 
et al, 2011) and chronic obstructive pulmonary disease (Hoiseth et al. 2011).  These 
findings are not confined to acute illness but also apply to chronic stable disease.  For 
example, in stable outpatients with risk factors for coronary disease, the level of hs-
cTnT detected in stored blood samples correlated closely with prognosis, with the 
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highest risk group, who had hs-cTnT of over 14ng/L, having a four times higher risk of 
death over a mean follow up period of 9.4 years (Omland et al. 2013).  
The use of hs-cTn assays has important implications in the diagnosis of acute 
myocardial infarction and both clinicians and researchers must be aware of the 
diagnostic criteria for AMI and the other possible cause of hs-cTn elevation. 
1.2.6 High-Sensitivity Troponin: The Early Rule-Out of Acute Myocardial Infarction 
 
The key concept in the TRUST study is the ability of a single presentation high-
sensitivity troponin to allow safe discharge of patients presenting to the ED with chest 
pain. Time pressures, ED crowding and the high frequency with which patients present 
with suspected cardiac chest pain has led to the development and testing of numerous 
strategies that attempt to assist with the early rule-out of AMI.  The advent of hs-cTn 
assays has allowed researchers to utilize the exquisitely sensitive properties of these 
assays to try to develop strategies that allow rule-out of AMI earlier in patient 
presentation safely, these are discussed below.   
The 99th Percentile Value at Presentation 
Multiple observational studies (Table 5) have demonstrated that a single hs-cTnT result 
of below the 99th percentile value at presentation has an inadequate sensitivity to rule-
out AMI (Range 83.3%-95%).  However, sensitivities improve over the hours following 
presentation to somewhere approaching 100% at 3 hours, enabling the strategy of 
testing at admission and at 3 hours after admission advocated by the European Society 
of Cardiology (Thygesen et al. 2012b).  
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Table 5.  Published papers demonstrating the ability of hs-cTnT to rule-out AMI when 
tested at presentation using the 99th percentile value (14ng/L) 
 
 
Author/year    
Study Design N 
Admission 
Sensitivity 
(95% CI) 
Admission 
Negative 
Predictive 
Value (95% 
CI) 
End-point Critique 
Reichlin et al. 
2009   
Prospective Multi-
center 
Observational 
718 
95%                                        
(90-98) 
99% (97-
100) 
AMI 
Blanket testing 
of all ED 
patients-
including those 
with ECG 
abnormalities 
Aldous et al. 
2011    
Prospective 
Single-center 
Observational 
332 
                               
83.6% (77.4-
88.6) 
                            
91.2% 
(87.8-
93.9) 
AMI 
Only 23% of 
patients 
recruited who 
fulfilled 
inclusion 
criteria 
Body et al. 
2011   
Prospective 
Single-Center 
Observational 
703 
85.4% (78.1-
91) 
96.1 
(94.0-
97.7) 
AMI 
Samples tested 
had been 
frozen for 2.5 
years 
Aldous et al. 
2012b    
Prospective 
Single-center 
Observational 
939 
88.3% (83.3-
91.8) 
                 
96.2% 
(94.7-
97.3) 
1. 
Diagnosis 
of 
NSTEMI 
on 
admission   
2. 1 year 
MACE 
Convenience 
sampling 
resulted in 
high-risk 
population 
studied 
Aldous et al. 
2012a    
Prospective 
Single-center 
Observational 
385 
90.7% (82.9-
94.8) 
97.0% 
(94.6-
98.5) 
AMI 
Only 40% of 
patients 
recruited who 
fulfilled 
inclusion 
criteria 
Hoeller et 
al.2014   
Prospective Multi-
center 
Observational 
207
2 
89.6% (86.4-
92.3) 
96.5 
(95.4-
97.4) 
AMI 
AMI 
adjudicated 
using the 
research assay 
AMI: Acute Myocardial Infarction, NSTEMI: Non-ST segment Elevation Myocardial Infarction, 
MACE: Major Adverse Cardiac Events, ED: Emergency Department, ECG: Electrocardiogram 
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Undetectable High-Sensitivity Troponin at Presentation to ED 
Strategies that utilize a high-sensitivity troponin level of below the level of detection 
(LoD) taken at presentation to the ED have been explored and give promise as a 
discharge tool.  Several studies have demonstrated that it may be possible to exclude 
AMI on arrival if patients have an ECG with no evidence of cardiac ischaemia and the 
initial hs-cTnT result is undetectable.  Both the level of blank (LoB), and the level of 
detection (LoD), have been used as thresholds to define detectability.  
In 2014, NICE produced a guidance statement regarding the clinical use of high 
sensitivity troponin assays.  In the systematic review that informed the guidelines, 14 
studies reported accuracy of hs-cTnT for the detection of acute MI on single samples 
taken at presentation.  Five of these studies used diagnostic thresholds equivalent to 
the LoB and LoD (Body et al. 2011, Aldous et al. 2011a, Reiter et al. 2011, Aldous et al. 
2012b and Hoeller et al. 2013). Two studies that described the LoD reported a summary 
estimate for using the LoD threshold of 5ng/L at 95% (95% CI 92% to 97%) sensitivity for 
AMI (Aldous et al. 2012b and Aldous et al. 2011a).  The three studies reporting the LoB 
(3ng/L) had a 98% (95% CI 95% to 99%) sensitivity for AMI.  These studies were published 
near the time of the release of a technical bulletin recommending recalibration of the 
hs-cTnT assay (Kuster et al. 2013).  Unfortunately, only one (Hoeller et al. 2013) out of 
five hs-cTnT studies used in the NICE guidance address this issue directly.  The results of 
at least some of the other studies were affected by this need for recalibration.  
Calibration issues also apply to the hs-cTnT assay batch being used at the time of the 
cohort studied by Bandstein et al. (2014) which may have contributed to the very high 
numbers of hs-cTnT results reported as below 5ng/l.  It should also be noted that 
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variation between batches is a recognised phenomenon and that such variation may be 
especially important at low levels of detection at which there is decreased analytical 
reproducibility. This may limit the on-going reliability of this diagnostic strategy using 
future batches of hs-cTnT. 
Through informal collaboration with worldwide researchers in the field, unpublished 
data from a worldwide validation of the LoD strategy in 6275 chest pain patients, has 
been obtained.  In this cohort the index test strategy (no ischaemic changes on initial 
ECG and presentation hs-cTnT < 5ng/L) classified 11.4% to 73.5% as being at low-risk for 
AMI (Table 6). The negative predictive value for this strategy varied from 98.9% (95% 
confidence interval 97.7% to 99.5%) to 100% (98.3% to 100%).  Peer review and 
publication of these results is eagerly anticipated. 
Table 6.  Unpublished data from an informal international collaborative examining 
the diagnostic utility of a presentation hs-cTnT of <5ng/L (LoD) and non-ischaemic 
ECG for AMI in 6275 ED chest pain patients  
Reference Study Sensitivity Specificity NPV PPV Proportion 
defined as 
Low Risk 
Prevale
nce of 
AMI 
Collinson 
et al. 2012 RATPAC 89.6 % 79.0 % 98.9 % 27.1 % 73.5% 8.0% 
Than et al. 
2012a 
ADAPT-
Brisbane 98.5 % 35.2 % 99.6 % 11.7 % 32.5% 8.1% 
Body et al. 
2011 Manchester 100 % 40.5 % 100 % 27.6 % 33.0% 18.5% 
Rubini 
Giminez et 
al. 2013 APACE 99.8 % 28.0 % 99.8 % 26.6 % 22.2% 20.8% 
Than et al. 
2012a 
ADAPT-
Christchurch 99.6 % 14.8 % 99.2 % 26.3 % 11.4% 23.4% 
NPV: Negative Predictive Value, PPV: Positive Predictive Value, AMI: Acute Myocardial 
Infarction, RATPAC: Randomised Assessment of Treatment using Panel Assay of Cardiac 
markers, ADAPT: Accelerated Diagnostic Protocol to Assess Patients with Chest Pain Symptoms 
Using Troponin, APACE: Advantageous Predictors of Acute Coronary Syndromes Evaluation 
Data kindly provided by Prof Martin Than, January 2015 
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While it is undeniable that undetectable hs-cTn troponin strategies hold promise, 
currently, as a result of batch variation and inaccuracy of measurement at low levels, 
expert consensus (Thygesen et al. 2012 and NICE 2014) suggests that levels below the 
LoD and LoB should not be reported or used in clinical practice. 
Early Rule-Out Strategies Utilizing Troponin Change over Time 
An algorithm developed by Reichlin et al. in 2012 used a presentation hs-cTnT level 
lower than 12ng/L and an absolute change within an hour of less than 3ng/L, and 
allowed AMI to be ruled-out with 100% sensitivity in 1 hour using only these two 
samples in 77% of patients.   Carlton et al. (2012) identifies two fundamental flaws 
with the study methodology which may impact this algorithm’s applicability.  Firstly, a 
large cohort of high-risk patients were excluded prior to analysis and convenience 
sampling was undertaken, both of which may lead to selection bias.  Secondly, due to 
laboratory turnaround times and staff availability it may be questionable whether a 1-
hour sampling strategy is feasible outside of a research environment.  Publication and 
external and multicenter validation of this strategy is anticipated. 
The use of a single hs-cTn for the rule out of AMI at presentation to the ED would be 
cost-effective, as suggested by Thokala et al. (2012)  but as yet evidence that it’s use 
may be unsafe remains unequivocal (Shah et al. 2013).  The TRUST Study explores a 
novel approach to using a single hs-cTn result at presentation to the ED. 
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1.3 Clinical Risk Assessment-The Chest Pain History 
 
Chest pain history remains the cornerstone of clinical assessment in patients with 
suspected ACS, complemented by electrocardiogram (ECG) and the results of cardiac 
troponin testing (Panju et al. 1998 and Amsterdam et al. 2010).  A proportion of 
patients will have a non-diagnostic ECG (Panju et al. 1998) and the results of troponin 
testing may not be immediately available, therefore ED physicians are reliant upon 
chest pain history to make rapid management decisions.   
It is well recognized that typical features provide useful diagnostic and prognostic 
information in patients with stable coronary artery disease (Diamond and Forrester, 
1979, Pryor et al. 1993 and Genders et al. 2011).  Yet, in the acute population the 
widely held assertion that these typical features can be used to identify high-risk 
patients has come into question (Goodacre 2002, Henrikson et al. 2003, Chun and 
McGee 2004, Swap and Nagurney 2005, Goodacre et al. 2009b,  Body et al. 2010, 
Greenslade et al. 2012 and Rubini-Gimenez et al. 2014).  Despite this, both American 
Heart Association (AHA) (Jneid et al. 2012) and European Society of Cardiology (ESC) 
(Hamm et al. 2011) guidelines for patients presenting to the ED with suspected ACS 
advocate the use of typical features.  For example, AHA guidelines suggest that “chest 
or left arm pain or discomfort as the chief symptom reproducing prior documented 
angina” is associated with a high likelihood of ACS.  Whilst the European Society of 
Cardiology (ESC) guidelines state that “the typical clinical presentation of (non-ST 
elevation) ACS is retrosternal pressure or heaviness radiating to the left arm, neck or 
jaw” and that “symptoms occurring at rest have a worse prognosis.”  Conversely, chest 
pain features that do not fall into the typical category have been termed “atypical.”  
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However authors and clinicians often disagree on the definition of atypical chest pain, 
making its use potentially confusing (Swap and Nagurney 2005).        
While it is evident that certain features of chest pain history may change the 
probability that a patient may or may not have an AMI (Table 7), ruling out an acute 
cardiac cause in an individual presenting with chest pain from the history alone is 
almost impossible.  Add to this the wide differential of possible causes of chest pain, 
which includes the pulmonary, musculoskeletal, gastrointestinal, dermatologic, 
psychiatric and cardiovascular systems (Spalding 2003) and the task for the diagnosing 
emergency physician becomes even harder.  So what features of the chest pain history 
are useful to the ED physician who wishes to rule-out AMI? 
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Table 7. Value of specific components of the chest pain history for the diagnosis of 
acute myocardial infarction 
*The likelihood ratio (LR) estimates the diagnostic value of each piece of information.  The 
higher the LR is above 1 the more useful the finding is for ruling in AMI.  The lower the LR below 
1 the more useful the finding is for ruling out AMI. 95% CI: 95% Confidence Interval. 
 
 
 
 
 
 
 
Pain Descriptor Reference Number of 
Patients 
Positive 
Likelihood 
Ratio* (95% CI) 
Increased Likelihood of 
Acute Myocardial 
Infarction 
   
Radiation to the Right 
arm or Shoulder 
 
Chun and McGee 
2004 
770 4.7 (1.9-12) 
Radiation to both arms 
or shoulders 
Goodacre 2002 893 4.1 (2.5-6.5) 
Associated with Exertion 
 
Goodacre 2002 893 2.4 (1.5-3.8) 
Radiation to the Left 
arm 
Panju 1998 278 2.3 (1.7-3.1) 
Associated with 
sweating/diaphoresis 
Panju 1998 8426 2.0 (1.9-2.2) 
Associated with nausea 
and vomiting 
Panju 1998 970 1.9 (1.7-2.3) 
Worse than previous 
angina or similar to 
previous MI  
Chun and McGee 
2004 
7734 1.8 (1.6-2.0) 
Decreased Likelihood of 
Acute Myocardial 
Infarction 
   
Described as Pleuritic Chun and McGee 
2004 
8822 0.2 (0.1-0.3) 
Described as positional Chun and McGee 
2004 
8330 0.3 (0.2-0.5) 
Described as sharp Chun and McGee 
2004 
1088 0.3 (0.2-0.5) 
Reproducible with 
palpation 
Chun and McGee 
2004 
8822 0.3 (0.2-0.4) 
Not associated with 
exertion 
Goodacre 2002 893 0.8 (0.6-0.9) 
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1.3.1 Pain Quality 
 
Traditional teaching dictates that chest pain described as pressure or aching is 
indicative of chest pain of cardiac origin.  However, meta-analysis by Panju et al. 
(1998), Chun and McGee (2004) and Swap and Nagurney (2005) consistently 
demonstrate that these typical features of pain are not independently useful in ruling-
in an AMI.   
What may be more useful is the presence of atypical qualities.  Pain described as sharp 
or stabbing significantly decreases the likelihood of chest pain representing an AMI 
(Body et al. 2010) though may make other important diagnosis such as pulmonary 
embolism more likely (Kline and Stubblefield 2013).  However, this finding may also be 
subject to cultural and ethnic differences (Greenslade et al. 2012). 
Significantly, pain described as similar, or worse than a previous ischaemia has been 
consistently demonstrated to be a useful predictor for AMI (Goldman et al. 1988 and 
Chun and McGee 2004). This quality also shows excellent inter-observer variability 
with a kappa score of 0.92/absolute agreement of 97%, albeit in a study with only 38 
independent ratings (Body et al. 2010). 
  
1.3.2  Pain Location 
 
Few studies have examined the location of chest pain as a predictor for AMI.  Everts et 
al. (1997) concluded that the localisation of chest pain to the centre or left of the chest 
had limited use in predicting AMI in a Coronary Care population.  However, more 
recently, Body et al. (2010) found in an undifferentiated ED population that patients 
with central chest pain were more likely to be having an AMI compared to those with 
left anterior chest pain.  
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1.3.3 Radiation 
 
Radiation is the term that describes pain originating in the chest but moving to non-
chest areas such as the arms, shoulder, jaw/throat and back.  Radiation has 
consistently been found to be a useful positive predictor for AMI in multiple studies 
(Panju et al. 1998, Goodacre et al. 2002, Chun and McGee 2004 and Body et al. 2010). 
However, contrary to traditional teaching (Silverman 1987) and media campaigns 
(British Heart Foundation 2014) radiation of pain down solely the right arm may be a 
more useful predictor than the left in the undifferentiated ED population (Berger et al. 
1990 and Body et al. 2010).  A possible explanation for this may be the impact of public 
health campaigns (British Heart Foundation 2014) meaning that patients will attend 
with any pain in the left arm due to the concern for “heart attack”, whereas they will 
only attend with right arm pain under exceptional circumstances (Goodacre et al. 
2009b) . 
Mackay et al. (2011) used percutaneous coronary intervention balloon inflation as a 
model of myocardial ischaemia and concluded that women were more likely to report 
radiation to the throat/jaw (OR 2.91; 95% CI 1.58-5.37).  However gender-specific 
variations are not large enough to be of clinical use when tested in the 
undifferentiated ED population (Canto et al. 2007). 
 
1.3.4 Severity 
 
Mandated pain scales have been shown to improve the frequency of ED analgesic 
administration for a variety of conditions (Nelson et al. 2004) however, there appears 
to be no prognostic significance in the severity of chest pain in predicting the likelihood 
of AMI (Edwards et al. 2011). 
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1.3.5 Duration of Pain 
 
UK National Institute for Health and Care Excellence (NICE 2010) Chest pain of recent 
onset guidance states that pain lasting longer than 15 minutes is suggestive of an acute 
coronary syndrome, however, there remains a paucity of data to support this. 
Goldman et al. (1996) reported that pain of longer duration than previous angina is 
predictive of adverse cardiac events however no lower or upper time limit is defined. 
Importantly however, Goodacre et al. (2009b) illustrated that patients with an ACS 
were more likely to have a longer duration of pain (Mean 53.6 minutes) compared to 
those without ACS (P=0.03).  Body et al. (2010) found that pain of greater than 60 
minutes duration had a sensitivity of 77% for AMI.  Evidence remains limited with 
regards to the significance of prolonged pain and requires further exploration. 
 
1.3.6 Associated Features 
  
Symptoms such as nausea, vomiting and sweating (diaphoresis) have been shown to 
be predictive of AMI in two meta-analyses (Chun and McGee 2004 and Panju et al. 
1998). Body at al. (2010) demonstrated that the most exquisite sign for the rule-in of 
AMI was if sweating was observed by the ED clinician, with a specificity of 94.3% and 
positive LR of 6.39, however this finding is yet to be validated. 
 
1.3.7 Risk Factors for Chronic Coronary Disease 
 
Since the Framingham Heart Study (Kannel et al. 1978) physicians have used risk 
factors for development of chronic cardiac disease to empirically establish 
cardiovascular risk in those patients presenting with acute chest pain.  These markers 
include hypertension, hyperlipidaemia (Csastelli and Anderson 1986), tobacco smoking 
(Doyle et al. 1988), diabetes mellitus (Kannel and McGee 1979) and family history 
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(Myers et al. 1990).  However their utility for predicting the presence of acute events 
in patients presenting to the ED may come into question.  
Jayes et al. (1992) demonstrated in a large epidemiological cohort study, that in 
women, the presence of classical risk factors does not increase the risk of acute 
ischaemia.  In men, only family history and diabetes were of any value (relative risks 
2.1 and 2.4 respectively).  This work was supported by that of Han et al. (2007) albeit 
through retrospective registry analysis, who concluded that cardiac risk factor burden 
had limited clinical value in diagnosing acute coronary syndromes in the ED. 
Most recently Body et al. (2008) prospectively examined the risk factor burden of ED 
patients presenting with suspected cardiac chest pain compared to the final diagnosis 
of MI.  Although limited by small study numbers, there was no trend towards 
increasing incidence of MI with increasing numbers of risk factors. The authors 
concluded that risk factor burden is not useful in the diagnosis or exclusion of AMI in 
ED patients.       
 
The presence or absence of certain clinical features in the context of chest pain may be 
used to shift the pre-test probability of an acute coronary syndrome being present.  No 
single clinical finding can be used to confirm or exclude AMI. However, when used in 
combination, or with other diagnostic tools, such as the ECG and biomarkers, clinical 
features may be used to direct further testing (Goldman et al. 1996) or identify those 
suitable for early discharge (Than et al. 2011, Than et al. 2012a and Cullen et al. 2013).  
By combining clinical features with ECG and cardiac biomarkers the concept of the 
clinical decision rule or accelerated diagnostic pathway (ADP) has been developed. 
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1.4 Clinical Risk Scores 
 
Accelerated diagnostic protocols (ADPs) are tools designed to be used at the bedside 
to assist rapid physician decision making, they may also be described as clinical 
decision rules (McGinn et al. 2000).  They are derived from original research and 
incorporate variables from the history, physical examination and basic laboratory tests 
(Stiell and Wells 1999).  Since Pozen et al. (1980) researchers have been refining 
decision rules for use in the assessment of suspected cardiac chest pain, in order to 
improve service quality, ED efficiency and overcrowding (Steurer et al. 2010).  These 
rules use a varying combination of history and examination findings, ECG and 
biomarker testing to identify those patients at low risk of major adverse cardiac events 
(MACE-serious outcomes that emergency physicians would wish to avoid after 
discharge), who may be suitable for early discharge or to identify those at higher risk 
who may benefit from early aggressive intervention.  
 
 
Major Adverse Cardiac Events 
(MACE) 
Serious outcomes that Emergency 
Physicians would wish to avoid 
following discharge from the 
Emergency Department. 
MACE include: death, cardiac 
arrest, emergency 
revascularization procedure, 
cardiogenic shock, ventricular 
arrhythmia or high-degree 
atrioventricular block needing 
intervention, and acute 
myocardial infarction (Cullen et al. 
2010). 
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A persistent concern in the assessment of patients presenting with suspected cardiac 
chest pain is the diagnosis of unstable angina and it is these patients that may drive 
the development of ADPs. By definition, patients with unstable angina will not have a 
troponin rise and as such their rule-out is a clinical diagnosis (Keller et al. 2009 and 
Korley and Jaffe 2013).  From a prognostic perspective at least some of these patients 
benefit from early intervention and are at a higher risk of adverse events (Hamm et al. 
2011). It seems that the vital factor in assessing troponin results is tying this 
information closely to the clinical assessment of the patient.  Yet, data is critically 
needed to establish the optimal methods of integrating clinical prediction rules and 
early troponin testing into emergency department clinical practice (Thygesen et al. 
2012b). 
 
1.4.1 Methodological Standards for the Development of Clinical Decision Rules 
 
Laupacis et al. (1997) and Stiell and Wells (1999) summarized the methodological 
standards for the development and validation of clinical decision rules; these may be 
summarized as follows:  
 
1) The outcome or diagnosis to be predicted should be clearly defined and the 
assessment of this outcome should be blinded.  
2) The clinical findings to be used as predictors must be clearly defined and 
standardized and their assessment must be done without knowledge of the outcome.   
3) The reliability or reproducibility of the clinical findings must be demonstrated.   
4) The subjects should be selected without bias and should represent a wide spectrum 
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of clinical and demographic characteristics to increase generalizability of results.   
5) The mathematical techniques for deriving the rule must be identified.   
6) Clinical decision rules should be sensible.   
7) The accuracy of the decision rule in classifying patients with (sensitivity) and without 
(specificity) the targeted outcome should be demonstrated.   
8) Prospective validation on a new set of patients is an essential test of accuracy as 
misclassification is commonly higher when decision rules are tested on a population 
other than derivation set.   
9) Implementation to demonstrate a true effect on patient care is the ultimate test of 
a clinical decision rule. 
 
Both Hess et al. (2008) and Steurer et al. (2010) in systematic reviews of the available 
literature concluded that prediction rules for chest pain had substantial 
methodological flaws, had not been successfully implemented in a clinical setting and 
did not fulfil the safety requirements for physicians, limiting their role in the rapid rule-
out of AMI.  However risk prediction rules have been shown to aid clinicians in 
prioritising patients for investigations (Reilly et al. 2002) and identify those patients at 
higher risk who may benefit from invasive strategies (Goldman et al. 1996 and Pollack 
et al. 2006). 
Although expert consensus (Thygesen et al. 2012b) and national guidelines (NICE 2010)  
suggest that formal risk stratification and risk scores aid in the assessment of 
suspected cardiac chest pain and should be implemented in clinical practice there is no 
consensus as to which risk score should be used in the ED.  
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1.4.2 Selecting a Risk Score for the TRUST Study 
 
The Original Goldman Rule 
 
In 1996 Goldman et al. described the derivation and validation of a straightforward 
clinical approach to assessing the risk of major adverse events at 72 hours in patients 
presenting to the emergency department with suspected cardiac chest pain.  This 
group used recursive partitioning to assess the ability of 50 predictive variables from 
history, examination and ECG to discriminate between patients with adverse events 
and those without adverse events in a cohort of 10,682 North American patients.   
Goldman identified older age, male sex, description of pain as the same as previous 
myocardial infarction or worse than prior angina, systolic blood pressure below 100 
mmHg, rales above the bases on clinical examination of the chest and initial ECG 
changes suggestive of acute myocardial infarction as factors associated with MACE 
(Table 8). 
 
 
 
 
 
 
 
 
 
PhD Thesis. Dr Edward W. Carlton 
 
54 
 
Table 8.  Factors which act as positive predictors for major adverse cardiac events 
included in the Goldman rule 
 
Factors at presentation Derivation Set (N=10,682) 
 
Relative Risk (95%CI) 
Validation Set (N=4656) 
 
Relative Risk (95%CI) 
Age ≥60 years 1.9 (1.5-2.4) 2.2 (1.4-3.4) 
Male Sex 1.7 (1.4-2.1) 1.6 (1.2-2.3) 
Pain same as previous 
myocardial infarction or 
worsening angina 
2.8 (2.3-3.4) 4.2 (3.1-5.7) 
Systolic Blood Pressure <100 5.0 (3.6-7.1) 2.0 (1.0-3.9) 
Rales above bases 4.5 (3.4-5.9) 3.3 (1.9-5.6) 
ECG abnormalities (ST 
depression or T wave inversion 
not known to be old) 
6.8 (5.4-8.6) 5.1 (3.6-7.3) 
Adapted from Goldman et al. 1996 
 
Through consideration of the factors present at presentation to the ED, Goldman was 
able to define 4 separate risk groups which accurately predicted MACE in an 
independent validation set of 4656 patients (Figure 4 and Table 9): 
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Figure 4.  Goldman risk stratification on the basis of data available at time of 
presentation to the Emergency Department  
 
 
Risk factors included systolic blood pressure < 100mmHg, rales heard above lung bases on 
physical examination, and known unstable ischaemic heart disease, defined as worsening of 
previously stable angina, new onset of post-infarction angina, or pain the same as previous 
myocardial infarction Reproduced from Goldman et al. 1996   
 
 
Table 9. Rate of major adverse cardiac events at 72 hours according to Goldman level 
of risk at presentation to the Emergency Department   
 Percentage of Major 
Adverse Cardiac Events at 
72 Hours 
 
Risk Derivation Validation 
High  21.5 16.1 
Moderate 8.1 7.8 
Low  3.6 3.9 
Very Low 0.8 0.6 
Adapted from Goldman et al. 1996. 
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The exquisite derivation of four separate risk groups enabled Goldman et al. to 
conclude that this approach to risk-stratification would enable a rationalisation of the 
use of inpatient hospital facilities, however they did not explore its use in the early 
discharge of patients from the Emergency Department. 
Further analysis into the use of the Goldman strategy and its impact on physician 
decision making was undertaken by Reilly et al. in 2002.  At this time modifications 
were made to Goldman’s original rule.  Reilly explored the safety and efficiency of a 
modified Goldman (m-Goldman) rule by establishing firstly the proportion of patients 
with MACE admitted to inpatient cardiac care beds and secondly the proportion of 
patients without major complications who were triaged to an ED observation unit, in a 
prospective before-after impact analysis conducted at a large, urban US public 
hospital.  The intervention group included over 1000 patients in whom the diagnosis of 
acute cardiac ischaemia remained possible after evaluation by the ED physician. 
Reilly et al. demonstrated a reduction in inappropriate admission to intensive inpatient 
settings, using the m-Goldman criteria, of 15% (95% CI 8-21%, p<0.001) without a 
reduction in safety (difference 5%, 95% CI -11%-39%, p=0.57). However, sample 
numbers were not large enough to detect differences in events between pre-
intervention and intervention groups.  Importantly, rates of MACE at 72 hours were 
similar to those illustrated by Goldman et al. (1996). Table 10 compares the 
proportions of patients in each risk category according to Goldman et al. (1996) and 
Reilly et al. (2002). 
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Table 10. A comparison of the proportion of patients in each of the four Goldman 
risk categories together with rates of major adverse cardiac events  
 Goldman et al. 1996 Reilly et al. 2002 
Risk Proportion MACE 72hr Proportion MACE 72hr 
High 9.7% 21.5% 9% 11% 
Moderate 18.2% 8.1% 25% 4%* 
Low 14.1% 3.6% 17% 6%* 
Very Low 57.9% 0.8% 48% 0.8% 
*The difference between MACE events is not significant (P=0.06) and may explain the 
discrepancy between Low and Moderate Risk categories. 
MACE: Major Adverse Cardiac Events 
Adapted from Goldman et al. 1996 and Reilly et al. 2002 
 
In 2001 Limkakeng et al. became the first group to prospectively test the original 
Goldman rule in combination with troponin testing to attempt to identify a subgroup 
of patients suitable for early discharge from the ED.  This observational study of 998 
low-risk patients concluded that the combination of Goldman risk of ≤4% (i.e. very-low 
or low risk) and second generation cardiac Troponin I of ≤ 0.3ng/mL did not identify a 
subgroup with <1% likelihood of MACE at 30 days.  Therefore this group concluded 
that these patients would not be suitable for immediate discharge.   
The fact that the Limkakeng study used a second generation troponin assay with the 
ability to detect only highly abnormal levels (see Table 1) limits the interpretation of 
the results in the era of high-sensitivity troponin.  Several other methodological issues 
may limit the interpretation and applicability of the Limkakeng results:  Firstly, broad 
inclusion criteria (Age >24 and having an ECG for chest pain symptoms) will have 
resulted in recruitment of a large number of participants with clearly non-cardiac chest 
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pain, creating selection bias.  Next, data for calculation of the Goldman criteria was 
taken from clinical notes by trained research assistants rather than calculated by 
physicians themselves, a potential source for misclassification.  In not utilising the 
physicians own judgement specificity may have been reduced (Goldman et al. 1996).  
Finally, the most recent and best validated m-Goldman criteria were not utilised as 
suggested by Reilly et al. (2002), leaving the score with less discriminatory power.  As a 
result of these methodological weaknesses, it may be concluded that the m-Goldman 
criteria require further evaluation as a discharge tool in the era of high-sensitivity 
troponin. 
The Modified Goldman Rule 
 
It is important to identify the modifications made to Goldman’s original decision rule 
which were made for institutional pragmatic reasons by Reilly et al. in 2002.  These 
may be summarised as follows:   
a) The presence of Left bundle-branch block (not known to be old) was also 
considered as evidence of ischaemia on the ECG.   
b) Two further subgroups of patients were also considered moderate-high risk in 
the absence of other Goldman risk factors:  Firstly, if patients had ongoing angina 
despite maximal medical therapy in the ED and secondly if they had a high probability 
of significant coronary artery disease using the Diamond and Forrester criteria (1979).  
The addition of responsiveness to medical therapy, prolonged duration of pain and the 
presence of ‘typical’ anginal chest pain according to the Diamond and Forrester criteria 
(Table 11) became important clinical variables in the m-Goldman risk score. 
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Table 11.  The Diamond and Forrester criteria for angina  
Typical Angina: (1) Substernal chest discomfort with a characteristic quality and 
duration that is (2) provoked by exertion or emotional stress and (3) relieved by rest 
or nitro-glycerine 
Atypical angina (probable):    Meets 2 of the above characteristics 
Non-cardiac chest pain:           Meets ≤1 of the typical angina characteristics 
  Adapted from Diamond 1983 
 
As a result of modifications by Reilly et al. (2002) and clinical use over time the current 
8 point m-Goldman risk score (Table 12) has been introduced into everyday practice.  It 
is this score that is incorporated into the TRUST ADP.  Despite modifications, the m-
Goldman criteria remains the most methodologically robust risk-stratification system 
developed and validated in a low risk ED population with factors easily available at 
presentation.  There is currently no published data available on its performance as a 
risk stratification tool in allowing early discharge or rationalising existing resources in 
the era of high-sensitivity troponin. 
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Table 12.  The modified Goldman risk score  
Predictive variable Reason for Inclusion 
1.  Typical new onset chest pain at 
rest 
Introduced by Reilly et al. after 
incorporation of the Diamond and 
Forrester criteria 
2.  Pain same as previous 
Myocardial Infarction 
From original derivation set 
3.  Pain not relieved by GTN within 
15 minutes 
 
4.  Pain lasting more than 60 
minutes 
Further clarification of worsening of 
previously stable angina: after Reilly 
5.  Pain occurring with increasing 
frequency 
 
6.  Hypotension (Systolic Blood 
Pressure <100 mmHg) 
From original derivation set 
7.  Acute Shortness of Breath Adapted for clinical use from original 
derivation set as surrogate for “rales 
heard above bases” 
8.  Pain within 6 weeks of a 
Myocardial Infarction or 
Revascularisation 
From original derivation set 
1 Point given for each variable present.  Patients defined as low risk if only 0 or 1 variable 
present. 
GTN: Glyceryl Trinitrate  
After Goldman et al. 1996 and Reilly et al. 2002  
 
 
 
1.4.3 Other Risk Scores 
 
The Thrombolysis in Myocardial Infarction Score 
 
The most commonly used and best validated risk score is the Thrombolysis in 
Myocardial Infarction (TIMI) risk score (Hess et al. 2010).  The TIMI Score (Table 13) 
was originally developed for use in high risk patients with acute coronary syndromes to 
predict myocardial infarction, revascularization or death and to guide therapeutic 
decision making (Antman et al. 2000).  However since 2000 its use has become 
increasingly commonplace in assessing prognosis in ED patients with suspected cardiac 
chest pain.   
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Hess’ meta-analysis of 2010 evaluated 10 prospective cohort studies validating the 
TIMI risk score in ED patients demonstrated a sensitivity of 97.2% (95%CI 96.4-97.8), 
specificity of 25.0% (95%CI 24.3-25.7) in patients with a score of 0 (Figure 5).  Hess 
concluded that this sensitivity and specificity was insufficient to recommend the TIMI 
risk score as the sole means for determining patient disposition and that the risks may 
be more relevant to general cardiology practices rather than undifferentiated ED 
patients.  This broad sample of 17265 patients supports the consistent performance of 
TIMI in the ED population however suffers from one major limitation:  the fact that the 
reporting characteristics of biomarkers used, an integral part of the risk score (e.g. 
type, thresholds and sample times) were unreported.  It is likely that 12-hour 
biomarker testing was used, in line with consensus guidance at the time of publication 
(NICE, 2010), meaning the applicability of these results may come into question in the 
era of hs-cTn. 
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Table 13. The Thrombolysis in Myocardial Infarction Score  
 
   
Characteristic *OR (95% CI) for 
prediction of Death/MI or 
Revascularisation at 14 
days 
1.  Age ≥65 years 1.75 (1.35-2.25) 
2.  ≥ 3 risk factors for 
Coronary Artery Disease† 
1.54 (1.16-2.06) 
3.  Significant coronary artery 
stenosis (Prior myocardial 
infarction/Stenosis >50%) 
1.70 (1.30.2.21) 
4.  ST Deviation on ECG 1.51 (1.13-2.02) 
5.  Severe angina (≥2 episodes 
in prior 24hrs) 
1.53 (1.20-1.96) 
6.  Use of aspirin in last 7 days 1.74 (1.17-2.59) 
7.  Elevated serum cardiac 
markers†† 
1.56 (1.21-1.99) 
Each variable = 1 point 
*OR: Odd’s Ratio taken from the original derivation study in a high-risk 
ACS Cohort  
† Risk factors: family history of coronary disease (<65years), hypertension, 
hyperlipidaemia, diabetes mellitus, current smoker 
†† As per standard guidance: Cardiac Troponin 
Adapted from Antman et al. 2000 
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Figure 5.  The diagnostic accuracy of the TIMI score for the detection of acute 
myocardial infarction in the Emergency Department population incorporating 2nd or 
3rd generation troponin assays  
 
Error bars: 95% Confidence Intervals 
TIMI: Thrombolysis in Myocardial Infarction 
Adapted from Hess et al. 2010 
 
 
TIMI within an Accelerated Diagnostic Protocol 
 
Since the Hess meta-analysis (2010) one group in particular, led by Professor Martin 
Than of Christchurch, New Zealand have continued to develop and use the TIMI score 
in combination with various biomarkers for the rapid rule-out of MACE.  Results of 
sequential studies performed by this group are summarised in Table 14. 
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Table 14.  Studies testing the TIMI Score within an accelerated diagnostic protocol 
 
ASPECT: Asia-Pacific Evaluation of Chest pain trial, ADAPT: ADAPT: Accelerated Diagnostic 
Protocol to Assess Patients with Chest Pain Symptoms Using Troponin, APACE: Advantageous 
Predictors of Acute Coronary Syndromes Evaluation, RCT: Randomised Controlled Trial, TIMI: 
Thrombolysis in Myocardial Infarction Score, NPV: Negative Predictive Value, CKMB: Creatine 
Kinase, TnI: Troponin I 
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Within these papers, the Christchurch group have demonstrated that by using 
increasingly sensitive biomarkers (hs-cTn) and increasing the cut-off values of the TIMI 
score used (TIMI≤1) a strategy that allows discharge of 40% of patients can be 
achieved, albeit using serial biomarker testing over a 2-hour period (Cullen et al. 2013). 
The robust nature of the various strategies suggested by Than and colleagues are 
compelling.  However, it is important to identify the methodological weaknesses of 
these studies in order to identify how they can be improved upon.  
The ASPECT Study (Than et al. 2011), a large multicentre study, used point-of-care 
biomarkers (CKMB, Myoglobin) in addition to 3rd generation troponin, which have 
been shown to lack cost effectiveness (Fitzgerald et al. 2012) and add nothing to 
diagnostic accuracy when compared to 3rd generation troponin alone (Collinson et al. 
2012) .  This finding was confirmed in 2012 by Than et al. when, utilising the same 
cohort as the ASPECT study for the ADAPT trial. This analysis demonstrated that by 
using 3rd generation troponin as a single biomarker the proportion of patients suitable 
for early discharge could be doubled to 20% (Than et al. 2012a).  This was further 
increased to 40% through the use of high-sensitivity troponin and by raising the TIMI 
score cut-off to 1 (Cullen et al. 2013).  However, these cohorts of patients were 
recruited during working hours (selection bias), had risk scores calculated by research 
nurses (work-up bias) and the strict research protocols used for blood sampling at 
early time points may limit their applicability to the real-world.  
In order to address these methodological flaws and assess pragmatic utility of the TIMI 
ADP, Than et al. (2014a) undertook a randomised controlled trial comparing the TIMI 
ADP (TIMI Score 0; ECG; and 0/2 hour 3rd generation troponin testing) to standard care 
(prolonged observation and troponin testing 6-12 hours after onset of pain), in which 
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clinicians performed risk scores.  Discharge from hospital within 6 hours without MACE 
was chosen as the primary outcome measure and a statistically significant difference 
between experimental (19.3%) and standard care (11.0%) pathways was found, albeit 
with wide 95% confidence intervals (1.8%-14%).   The authors of this analysis argue 
that by using old 3rd generation troponin assays, a larger proportion of patients were 
suitable for early discharge due to the potential for false positive results when using 
high-sensitivity assays.  However, this argument may be counter-intuitive and 
therefore the impact on both the safety and efficiency of this pathway utilising high-
sensitivity troponin assays early remains unknown.     
A fundamental problem with recent studies incorporating TIMI into an ADP remains 
the requirement for two separate blood samples for troponin analysis at 0 and 2 
hours.  The RCT by Than et al. (2014a) demonstrates that in real terms, by requiring a 
troponin sample at 2 hours after patient arrival, there is no impact on discharge times 
until the patient has been in the ED for over 4 hours (Figure 6).  Outside of a research 
environment, a 2 hour sampling time will be affected by the availability of staff to 
undertake blood draws, speed the sample reaches the central laboratory, laboratory 
processing time , which itself is affected by ED patient volume (Hwang et al. 2010) and 
the availability of ED physicians to acknowledge and interpret results (Thokala et al. 
2012). 
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Figure 6.  Illustrating the reduction in time to discharge when using the 2-hour TIMI 
ADP   
 
 
Of note there is no improvement in time to discharge before 4 hours   
ADP: Accelerated Discharge Protocol 
Reproduced from Than et al. 2014a 
 
 
Although the TIMI risk score remains popular in both the literature and clinical use 
(Dunham et al. 2010) for the assessment of patients with acute suspected cardiac 
chest pain it may be argued that this popularity may be counter-intuitive.  Although 
validated in a low risk ED cohort, the score itself was developed in a high-risk ACS 
population.  It also fails to incorporate any of the useful variables present in patient 
history and by doing so removes the utility of clinician judgement.  Therefore, it may 
be hypothesised that by utilising a risk score developed specifically to identify those 
patients at low-risk of MACE, incorporating clinician judgement and patient history, 
PhD Thesis. Dr Edward W. Carlton 
 
68 
 
such as m-Goldman, it may be possible to use just a single high-sensitivity troponin 
result taken at presentation to identify patients suitable for early discharge.  
 
Other Validated Risk Scores (HEART, GRACE, Vancouver, MACS)  
 
As previously discussed, symptomatic history and the presence of chronic risk factors 
for coronary artery disease may not be as predictive of acute coronary syndromes in 
an ED setting as previously thought (Goodacre et al. 2002, Body et al. 2008, Goodacre 
et al. 2009b, Body et al. 2010 and Greenslade et al. 2012).  Therefore, it may be argued 
that there remains a clear need for a well-developed and effective ED-based chest pain 
prediction rule.  Even though recent focus has been on the TIMI risk score, other 
scoring systems may be better suited to the ED setting.  In 2011, Challen and Goodacre 
identified 27 risk-stratification tools for use in ED patients with ACS or potential ACS 
and this list has since grown, with development and validation of the History, ECG, 
Age, Risk factors and Troponin (HEART) Score (Backus et al. 2013), Manchester Acute 
Coronary Syndromes (MACS) rule (Body et al. 2014a) and Emergency Department 
Assessment of Chest Pain Score (EDACS) (Than et al. 2014b).  Such rules vary greatly in 
their popularity with regards to clinical use (Dunham et al. 2010) and many rules have 
been developed retrospectively or have methodological flaws limiting their 
applicability in practice (Steurer et al. 2010). 
The Global Registry of Acute Cardiac Events (GRACE) (Brieger et al. 2009) score was 
developed in high-risk ACS cohorts and as such its use in a low-risk ED population 
remains counter-intuitive. In fact, despite guideline recommendations (NICE, 2010) to 
the contrary, evidence to support the GRACE score in this population is unfavourable, 
with some suggestion that it is little better than age alone as a predictor of MACE at 30 
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days (Goodacre et al. 2012).  
The HEART Score, has been shown to compare favourably with the TIMI score and has 
been validated in a multinational ED cohort where up to 28% are identified as low risk 
(Six et al. 2013).  However, the score was developed through literature review and 
clinical experience rather than from a selection of candidate clinical variables and its 
negative predictive value with a single troponin (not high-sensitivity) at presentation 
was only 98.3% in the multinational validation cohort. 
In an attempt to identify ED patients that may be successfully discharged, the 
Vancouver chest pain rule, using troponin as the only biomarker has been developed 
(Hess et al. 2012a).  This rule has been validated externally with hs-cTn (Cullen et al. 
2014a), to demonstrate that up to 20% of patients may be discharged with a sensitivity 
of 99.1% (95%CI 97.4-99.7).  Despite this promise, the specificity of the rule, 16.1% 
(95%CI 14.2-18.2) may be too low to allow clinical application.  Both this low specificity 
and relatively low number of patients suitable for discharge may be improved upon.   
To date, most existing risk scores remain untested as rule-out tools in conjunction with 
a single hs-cTn taken at presentation to the ED and the resultant diagnostic accuracy 
has never been compared.    A clinically applicable protocol that allows safe discharge 
of a significant proportion of patients with suspected ACS, after just a single hs-cTn 
result remains an attractive yet elusive goal. 
Variables to calculate TIMI, GRACE, HEART, and Vancouver scores are summarised in 
Table 15.  These variables will be obtained during data collection for the TRUST study.  
This will enable cross-comparison of all strategies for early discharge in combination 
with a single hs-cTn taken at presentation.  This will provide novel comparative data 
that does not exist in the literature.  
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Table 15.  Variables that make up the TIMI, GRACE, HEART scores and the Vancouver 
chest pain rule, incorporating a single hs-cTn result to identify low risk patients 
 
 
 
 
Risk Score TIMI GRACE HEART Vancouver Chest 
Pain Rule 
Clinical 
Variables 
Age≥65 yrs. 
≥3 Risk factors* for 
coronary artery 
disease 
Use of aspirin in last 7 
days 
Significant coronary 
stenosis (>50%) 
Recent severe angina 
(≥angina events in 
preceding 24h) 
Killip Class:  
I: 0 points 
II: 20 
III: 39 
IV: 59  
Systolic BP (mmHg): 
≤80: 58 points 
80-99: 53 
100-119: 43 
120-139: 34 
140-159: 24 
160-199: 10 
≥200: 0 
Heart Rate: 
≤50: 0 points 
50-69: 3 
70-89: 9 
90-109: 15 
110-149: 24 
150-199: 38 
≥200: 46 
Age: 
≤30: 0 points 
30-39: 8 
40-49: 25 
50-59: 41 
60-69: 58 
70-79: 75 
Creatinine Level 
(µmol/L): 
≤35: 1 point 
36-70: 4 
71-105: 7 
106-140: 10 
141-175: 13 
176-350: 21 
>350: 28  
 
hs-cTnT >14ng/L or 
hs-cTnI >26.2ng/L: 15 
points 
History:  
Highly suspicious: 2 
Moderately suspicious: 1 
Slightly suspicious: 0 
 
ECG: 
Significant ST depression: 2 
Non-specific repolarisation 
disturbance: 1 
Normal: 0 
Age: 
≥65 years: 2 
45-65 years: 1 
<45 years: 0 
Risk Factors: 
≥3 Risk factors† for coronary 
artery disease: 2 
1 or 2 risk factors: 1 
No risk factors: 0 
Troponin  
hs-cTnT: 
≥30ng/L†: 2 
>14ng/L to <30ng/L†: 1 
≤14ng/L: 0 
OR hs-cTnI: 
≥78.6ng/L††: 2 
>26.2ng/L to <78.6ng/L††: 1 
≤26.2ng/L: 0 
 
 
Score 
calculation 
1 point for each factor present Total score depending on 
categorical data 
Total score dependent on 
presence of clinical variables 
Binary rule-out decision tool 
Definition 
of low-risk 
for both hs-
cTn assays 
hs-cTnT ≤14ng/L/hs-
cTnI≤26.2ng/L, non-ischaemic 
ECG, TIMI Score 0 or 1 
 
Non-ischaemic ECG and GRACE 
Score <60 OR <80 points 
(GRACE incorporates hs-cTn) 
Heart Score 2 or 3 (HEART 
Incorporates ECG and hs-cTn) 
Non-ischaemic  ECG,  and 
clinical features as described in 
decision tree 
 
Presentation hs-
cTnT>14ng/L or hs-
cTnI>26.2ng/L 
Prior acute coronary 
syndrome, or nitrate 
use 
Does palpation 
reproduce pain? 
Age≥50  
Does pain radiate to 
the neck, jaw or left 
arm? 
Yes to any: 
High Risk 
No 
to all 
Yes: Low 
Risk 
No 
Yes to any: 
High Risk 
No: Low 
Risk 
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The Manchester Acute Coronary Syndromes (MACS) Decision Rule and the Incorporation 
of Heart-Type Fatty Acid Binding Protein 
 
In 2014, Body et al. published a derivation and external validation of their MACS 
decision rule.  This computer-based algorithm risk-stratifies patients with chest pain 
according to symptoms and signs present at presentation, together with hs-cTnT 
results and a novel biomarker assay, Heart-type fatty acid binding protein (H-FABP).  H-
FABP is a small cytoplasmic protein released from cardiac myocytes following an 
episode of ischaemia.  In 2010, Bruins and colleagues demonstrated in a systematic 
review, encompassing 3709 patients, that H-FABP did not fulfil the requirements 
needed for safe and early diagnosis of AMI when used as a stand-alone test.  Yet, Body 
et al. (2014) have demonstrated a potential additive role for H-FABP as part of a 
combination strategy with clinical findings and hs-cTnT.   
The components of the MACS rule are detailed in Table 16.  This rule achieved 
excellent discriminatory ability for the prediction of MACE; area under the curve (see 
Text Box below) of 0.95 (95% CI 0.93-0.97) and 0.92 (95% CI 0.89-0.95 during 
derivation (698 patients) and validation (463 patients) respectively.  The authors 
concluded that the MACS decision rule could identify 25% of patients that could be 
immediately discharged as well as identify high-risk patients.   
The MACS rule undeniably holds excellent promise and validation within a randomised 
controlled trial is currently underway (personal communication).  However, the 
moderate numbers of patients in the validation study lead to wide confidence intervals 
for the sensitivity of the rule (93-99.8%) and the requirement for an additional blood 
test (H-FABP), which is not currently widely available, may limit the applicability of the 
study results.  Though not included in the primary analysis, data from the TRUST Study, 
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to include H-FABP testing, has been used in the first external validation of the MACS 
rule (Appendix 15). 
 
 
 
 
 
 
Table 16.  Components of the MACS decision rule 
Clinical Variable Odds Ratio (95% Confidence Interval) for 
Prediction of MACE 
High Sensitivity Troponin T 1.1 (1.0-1.1) 
Heart-type fatty acid binding protein 1.2 (1.0-1.4) 
ECG ischaemia 5.8 (3.1-10.8) 
Sweating observed 6.3 (3.0-13.3) 
Vomiting  5.6 (1.9-16.6) 
Systolic blood pressure <100mmHg 4.3 (1.2-15.1) 
Worsening angina 2.5 (1.2-5.2) 
Pain radiating to the right arm 2.4 (1.0-5.6) 
Adapted from Body et al. 2014a  
 
 
 
 
 
 
Area Under the Curve (AUC):  The c-statistic or AUC is 
derived from receiver-operating characteristic curves 
(ROC) and is used to determine the discriminatory 
ability of a diagnostic test.  AUC equals 0.5 when the 
diagnostic test corresponds to random chance (null 
hypothesis) and 1.0 indicates perfect diagnostic 
accuracy. 
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1.5 The Electrocardiogram 
 
American Heart Association guidelines define ECGs with new, or presumably new, 
transient ST-segment deviation (≥0.1 mm) or T-wave inversion in multiple precordial 
leads as diagnostic for ischaemia secondary to coronary artery disease (Table 17) 
(Amsterdam et al. 2010). 
Table 17.  ECG criteria representing an acute coronary syndrome secondary to 
coronary artery disease 
 High Likelihood Intermediate 
Likelihood 
Low Likelihood 
ECG Criteria New, or presumably 
new, transient ST-
segment 
deviation (≥0.1 mm) 
or T-wave inversion 
in 
multiple precordial 
leads 
Fixed Q waves 
ST depression 0.05 
to 0.1 mm or 
T-wave inversion 
>0.1 mm 
T-wave flattening 
or inversion 0.1 mm 
in leads with 
dominant R waves 
or 
normal ECG 
ECG: Electrocardiogram 
Adapted from Amsterdam et al. 2010 
 
An important limitation to the majority of studies evaluating symptoms associated 
with ACS is that they have included patients with abnormal or diagnostic ECG’s.  The 
ECG is a quick and simple tool that allows the clinician to identify those patients with 
ST segment changes and who would benefit from early aggressive treatment and 
admission.  The ECG is therefore a vital tool in the assessment of patients with 
suspected ACS (Panju et al. 1998).  Clinical features that help to confirm a diagnosis of 
ACS in a patient with a diagnostic ECG will be of limited practical value to the clinician.  
Therefore by including those patients with diagnostic ECG’s in any analysis of 
symptoms may not be relevant when identifying those suitable for early rule-out 
pathways and this requires further evaluation. 
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1.6  Additional Analysis Within the TRUST Study 
1.6.1  The Role of Nursing Staff 
 
ED nursing staff remain in a unique position to apply evidence based protocols during 
the initial assessment of patients shortly after arrival in the ED.  Despite this, the 
potential for nurse-led protocols to improve quality of care remains unexplored in the 
ED setting. 
Advanced nursing interventions during initial patient assessment have been proven to 
reduce time to treatment and diagnosis, improve patient flow through the ED and 
reduce length of stay across a wide variety of emergency presentations (Lee et al. 
1996, Graff et al. 2000, Campbell et al. 2004, Cooper et al. 2008, Rowe et al. 2011, 
Stauber 2013).  It is also evident that chest pain-specific risk scores, such as a modified 
TIMI score, can improve the accuracy of nursing assessments (Ho and Suen 2013).  Yet, 
the ability of ED nursing staff to safely risk-stratify low-risk patients with suspected ACS 
who may be suitable for early rule-out biomarker testing and therefore early discharge 
has never been investigated.  Consequently, ED nursing staff remain a potentially 
underused resource in the assessment of chest pain. 
In the assessment of suspected cardiac chest pain, rapid identification of those 
patients suitable for early discharge protocols utilising high-sensitivity troponin by ED 
nursing staff may facilitate early physician decision-making and decrease treatment 
time or ED length of stay.  However, the unintended consequences of such protocols 
and unnecessary diagnostic testing remain unexplored.  Therefore the TRUST study will 
analyse the accuracy of nursing risk-stratification through inter-observer reliability 
assessments between untrained nursing assistants, ED nursing staff and physicians 
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which will give vital insights into this previously unexplored area of diagnostic 
literature. 
 
1.6.2 Patient Satisfaction with Early Discharge Protocols 
 
 
Patient satisfaction, patient involvement and care related to patient needs have been 
highlighted as key elements in the development of quality emergency care (Pham et al. 
2011).  Any new clinical intervention should provide some evidence of patient 
acceptability in addition to clinical effectiveness.  The recent drive to implement rapid 
rule-out protocols to allow the early discharge of low-risk patients with suspected 
cardiac chest pain directly from the ED comes from physicians and healthcare 
providers.  Previously, such patients would have been admitted to a hospital bed for 
delayed biomarker testing and a period of observation.  However, to date, there has 
been little assessment of patient perspectives of such strategies, in what is known to 
be a high-anxiety presentation (Webster et al. 2012). 
The two patient satisfaction studies of relevance compared protocolized management 
of patients admitted to chest pain units with standard inpatient care (Rydman et al. 
1997 and Richards et al. 2002).  While these studies concluded that rapid assessment 
of patients with chest pain was acceptable from a patient perspective, both suffered 
from the methodological and practical problems inherent in such studies.   Such 
studies are at risk of bias from low response rates, when and by whom questionnaires 
are administered and the fact that patients are part of a clinical trial.  The patients’ 
evaluation will ultimately be subjective, which can be influenced by a number of 
factors including demographics and previously held opinions (Calnan 1988) , while it is 
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also known that patient satisfaction surveys tend to generate very high levels of 
satisfaction even if patients have been unhappy with certain aspects of care (Hall and 
Dornan 1998) . 
A more recent study by Tekwani (2013) identified reduced satisfaction in patients 
discharged from an ED during times of high occupancy rate.  While no conclusions can 
be drawn from this single-centre retrospective study, the themes discussed are 
consistent with the recurring themes of the ED quality improvement agenda.  
Therefore, the TRUST study will attempt to explore patient perspectives on whether 
early discharge after a rapid rule-out biomarker testing is acceptable in a low risk 
short-stay suspected ACS population. 
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1.7 Risk and Measures of Diagnostic Accuracy 
 
Croskerry and colleagues (2009) define risk in medicine as “the probability of danger, 
loss or injury within the health system.”  This may be both risk to the patient or to the 
physician as a result as missed diagnosis.  Both may apply in the context of patients 
who present with acute chest pain where missing the diagnosis of an acute myocardial 
infarction may have both medical (heart failure, sudden death) and medico-legal 
consequences.  However the miss rate that clinicians are willing to accept in the 
context of AMI or MACE is poorly understood. 
Only one study has sought to establish an acceptable standard of care with regards to 
diagnosis in chest pain (Than et al. 2012b).  This survey of over 1000 emergency 
physicians suggest that a miss rate between 1/100 and 1/1000 with the majority 
accepting a miss rate of 0.5% or less.  However, this subjective opinion may not 
represent a standard approach to diagnosis as this study may be subject to bias.  The 
emergency physicians chosen to undertake the survey were mainly conference 
delegates (the conference theme is not mentioned) and had a survey response rate of 
84%.  Subjective opinion may be subject to bias also.  Where this study is useful is 
highlighting that a small level of risk may be acceptable when discharging patients 
from the ED which is useful when developing a diagnostic strategy to rule-out MACE.  
In broad terms therefore a test sensitivity above 99% and ideally >99.5% may be 
acceptable to most ED physicians.  In the absence of expert consensus guidance on the 
diagnostic accuracy thresholds needed for a rule-out protocol to be implemented in a 
clinical environment these cut-offs are a reasonable compromise. 
A key concept in the evaluation of diagnostic strategies examining early rule-out of ACS 
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is the reporting and interpretation of diagnostic accuracy statistics, primarily sensitivity 
and negative predictive value (NPV).  The NPV is directly related to the prevalence of 
the target disease in the specific population under consideration and represents the 
post-test probability of a negative test.  When considering clinical implementation of a 
diagnostic strategy, it is important to establish the NPV for each hospital so that an 
attending clinician can best interpret a negative test, i.e. how does the test perform in 
a given clinical population.  NPV should therefore not be used to recommend 
generalization of a test across populations with varying disease prevalence.  Sensitivity, 
on the other hand, is not affected by the disease prevalence and represents the true 
positive rate.  This is more useful to clinicians in establishing the validity of a diagnostic 
test on an individual patient level.  The primary marker as to whether a rule-out 
strategy is ready for implementation in a clinical environment is safety, and this can 
only be truly gauged from the reporting of sensitivity.  Therefore, the primary measure 
of diagnostic performance of the TRUST ADP, and other rule-out strategies tested 
within this thesis, is sensitivity. 
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Summary 
Identifying a significant proportion of patients with suspected cardiac chest pain who 
may be suitable for early discharge remains a critical challenge to improving ED care.  
The recent development of high-sensitivity troponin assays has enabled a reduction in 
the time to biomarker testing, however no strategy so far tested has enabled the use 
of a single hs-cTn at presentation to safely rule-out AMI or medium-term (30 day) 
MACE.  Clinical variables available from history and examination may alter the 
likelihood of a patient with chest pain having a final diagnosis of acute myocardial 
infarction and they have been used in the form of risk scores to improve clinician 
decision making and facilitate early discharge.  Yet, there remains a clear need for a 
well-developed clinical decision rule that allows safe discharge of a large proportion of 
ED chest pain patients.  The modified Goldman Score fulfils all the necessary 
methodological criteria and held early promise however it remains untested in the era 
of high-sensitivity troponin. The TRUST study aims to test a novel accelerated 
diagnostic protocol which incorporates a single hs-cTn test at presentation, together 
with electrocardiogram and m-Goldman Score results in a real world emergency 
department setting.  
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Key Points: 
 
1.  Chest pain makes up a quarter of medical admissions in the United 
Kingdom.  A diagnostic strategy that prevents unnecessary hospital 
admission in a large proportion of this patient group would have 
significant benefits for healthcare services by reducing hospital 
admission rates, ED overcrowding, duplication of staff time and resource 
use. 
 
2.  High-sensitivity Troponin (hs-cTn) assays may allow earlier safe 
discharge of patients presenting to the Emergency Department with 
chest pain. 
 
3. A clinically applicable protocol that allows the discharge of a 
significant proportion of patients after just a single hs-cTn blood draw at 
presentation remains an attractive yet elusive goal. 
 
4. The adjunctive use of risk scores may rapidly identify low-risk patients 
suitable for early discharge when used in combination with hs-cTn 
assays, in a strategy called an accelerated diagnostic protocol (ADP).  
Currently, ADPs require serial troponin testing and remain untested with 
a single hs-cTn result. 
 
5.  The ability of ED nursing staff to safely risk-stratify low-risk patients 
with suspected ACS who may be suitable for early rule-out biomarker 
testing and therefore early discharge has never been investigated.  ED 
nursing staff remain a potentially underused resource in the assessment 
of chest pain. 
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CHAPTER 2. 
Study Development 
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2.1 Hypothesis 
 
The TRUST accelerated diagnostic pathway (ADP) can identify up to 30% of patients 
who present to the Emergency Department with suspected acute coronary syndrome 
(ACS) who are at 0% risk of MACE at 30 days, and are therefore suitable for early 
discharge. 
 
2.2 Study Aims 
 
The primary aim of the TRUST study is: 
 
To establish whether the TRUST ADP for suspected ACS patients consisting of hs-cTn, a 
non-ischaemic ECG and the m-Goldman score, could successfully identify low risk 
patients suitable for discharge after a single blood draw at presentation to the ED.   
 
Secondary aims are: 
1. To establish potential improvements in system efficiency using the TRUST ADP 
through time-and-motion analysis of hs-cTnT testing 
 
2. To compare the diagnostic accuracy of the TRUST ADP with strategies utilising 
initial undetectable hs-cTnT levels 
 
3. To compare the ability of five established risk scores, when used in conjunction 
with either high-sensitivity troponin T (Elecsys hs-cTnT) or I (Architect hs-cTnI), to 
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identify low risk patients with chest pain symptoms suggestive of ACS suitable for early 
discharge after a single blood draw at presentation to ED. 
 
4. To establish the diagnostic accuracy of ED nursing staff risk assessment, using 
the TRUST ADP, with regard to prediction of future MACE in patients with suspected 
ACS, and evaluate the inter-observer reliability of nursing and physician assessments 
within a chest pain specific risk score. 
 
5. To establish the discriminatory value of physician interpretation of typicality of 
chest pain, in patients with a non-diagnostic ECG, considered to have a potential ACS, 
and the impact of clinical experience upon diagnostic accuracy, for the prediction of 
acute myocardial infarction (AMI) and significant coronary artery disease (CAD) with 
and without high-sensitivity troponin (hs-cTn) elevation.   
 
6. To investigate patient perspectives on whether early discharge after a rapid 
rule-out biomarker testing is acceptable in a low-risk short-stay suspected ACS 
population. 
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2.3 The TRUST Accelerated Diagnostic Protocol 
 
The pre-designed TRUST ADP (Table 18) defines a patient as ’low risk’ if the following 
conditions are satisfied at presentation to the ED:   
1. A modified Goldman score of ≤1 (Table 18) 
 
2. A normal or non-ischaemic ECG 
Defined as the absence of: 
Either: 
ST-segment elevation ≥1 mm or Q-waves of 0.04 s or more, in 2 or more 
consecutive leads. 
Or: 
ST-segment depression ≥1 mm or T-wave inversion consistent with the presence 
of ischemia. 
Or: 
Arrhythmias: new-onset atrial fibrillation, atrial flutter, sustained 
supraventricular tachycardia, second-degree or complete heart block, or 
sustained or recurrent ventricular arrhythmias. 
(Amsterdam et al. 2010)  
 
3. A single central laboratory hs-cTnT (Roche Diagnostics) of <14ng/L (99th 
centile value) taken at presentation to the ED.   
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Table 18.  The modified Goldman score and the TRUST ADP  
 
MODIFIED GOLDMAN RISK SCORE 1 point for each variable present  
Typical new onset chest pain at rest  
Pain the same as previous myocardial infarction  
Pain not relieved by Glyceryl Trinitrate (GTN) 
within 15 minutes 
 
Pain lasting more than 60 minutes  
Pain occurring with increasing frequency  
Hypotension (Systolic Blood Pressure 
<100mmHg) 
 
Acute shortness of breath  
Pain within 6 weeks of a myocardial infarction or 
revascularisation 
 
Modified Goldman Total:  
TRUST ACCELERATED DIAGNOSTIC PROTOCOL 
(TRUST ADP) 
 
Low risk* 
(Suitable for discharge) 
1. Modified Goldman Score ≤1 
2. Non-ischaemic ECG 
3. Presentation high-sensitivity 
troponin T <14ng/L 
Not Low Risk 
 
1. Modified Goldman Score >1 
2. Ischaemic ECG 
3. Presentation high-sensitivity 
troponin T ≥14ng/L 
*Safety Point:  Protocol not validated in age ≥80 years 
ECG: Electrocardiogram 
From Carlton et al. 2015a 
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2.4 Outcome Measures 
2.4.1 Primary Outcome Measure: 
 
30 Day Major Adverse Cardiac Events  
MACE are defined according to standardised data definitions (Cullen et al. 2010) (these 
include events during initial hospital inpatient stay) and are identical to large scale 
studies investigating rapid discharge protocols (Than et al. 2011, Collinson et al. 2012, 
Cullen et al. 2013): 
  1.  Death secondary to ischaemic heart disease 
2.  Diagnosis of acute myocardial infarction (AMI) as per standard 
guidance (see below) (Thygesen et al. 2012a)  
3.  Emergency or urgent symptom induced revascularisation (to 
include Emergency or Urgent Percutaneous Coronary Intervention or 
Coronary Artery Bypass Graft and/or procedure required during the 
same admission to minimize chance of further clinical deterioration).  
4.  Cardiogenic shock, ventricular arrhythmia, high-degree 
atrioventricular block needing intervention. 
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2.4.2 Secondary Outcome Measures: 
 
1.  Acute Myocardial Infarction 
The presence of AMI is defined according to the Third Universal Definition of MI which 
states that a rise and/or fall in troponin, with at least one value above the 99th centile 
value in the context of a patient with ischaemic symptoms or signs (ECG changes or 
imaging evidence) would satisfy the diagnosis (Thygesen et al. 2012a).  Based on 
current consensus guidance for high-sensitivity troponin assays, a rise or fall of 20% 
(delta) is considered statistically significant and consistent with a diagnosis of AMI 
(Thygesen et al., 2012b). 
2.  Significant Coronary Artery Disease 
In order to overcome the diagnostic adjudication challenges associated with high-
sensitivity troponin assays and small elevations in troponin (Mills et al. 2011) the 
diagnostic outcome measure of significant CAD (available only in those patients 
subsequently referred for coronary angiography within 30 days) was included for some 
analysis.  This is defined as ≥70% luminal diameter narrowing of at least one major 
coronary artery as reported on visual assessment by the angiographic operator (Pryor 
et al. 1993). 
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2.5 Justification of Research 
 
The TRUST Study is novel and justified for the following reasons: 
1. No pragmatic prospective study analysing the diagnostic accuracy of an ADP, 
which incorporates a clinical risk score, and a single high-sensitivity troponin 
test at presentation to the ED, to identify low-risk patients suitable for early 
discharge has been undertaken. 
 
2. No study has compared the diagnostic accuracy of an ADP, which incorporates 
clinical assessment, with alternative discharge strategies which utilise initially 
undetectable hs-cTn results. 
 
3. To date, existing risk scores remain untested as rule-out tools in conjunction 
with a single hs-cTn taken at presentation to the ED and the resultant 
diagnostic accuracy has never been compared. 
 
4. No study has compared the accuracy of nursing with physician-based 
assessment of chest pain using a cardiac risk-assessment tool. 
 
5. No study has investigated the diagnostic value of physician interpretation of 
typicality of chest pain, and the impact of clinical experience upon diagnostic 
accuracy. 
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6. No published data exists to allow us to understand whether patients with chest 
pain want more rapid diagnosis and discharge. 
 
2.5.1 Benefits of Research 
 
Should this study demonstrate that the TRUST ADP is capable of delivering a much 
earlier discharge in patients presenting to the ED with chest pain the main benefits 
would be: 
1.  For Patients: to allow a reduction in the anxiety, inconvenience and risks of hospital 
admission.  
2.  For Acute Services: by avoiding unnecessary admissions, duplication of staff 
activities and overcrowding. 
3.  For Healthcare Services in general: to allow potential cost-savings and to help 
achieve the Department of Health Quality Indicator Target for total time spent in ED 
(4-hours).  The TRUST Study addresses an international health delivery issue. 
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2.6 Phases of the Study 
This thesis summarises the work undertaken over a 4 year period from 2011-2015.  
Registration for post-graduate study (PhD Studentship Bournemouth University), 
occurred in September 2012.  It should be noted that design and planning of the 
TRUST study began a year before commencement of the Studentship during a 
postgraduate Quality Improvement Fellowship funded by South Central Strategic 
Health Authority.  Study design and planning was carried out by the student 
investigator with the support of Professor Kim Greaves.  The overall timeline for the 
study is illustrated in Figure 7. 
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Figure 7.   Phases of the TRUST Study over the period of the Studentship 
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2.7  Literature Search 
An initial literature search was conducted during the first phase of the study.  
However, it is acknowledged that due to the relatively new introduction of hs-cTn 
assays into clinical practice that this is a very active area in the literature, therefore 
new papers are being published almost weekly (Figure 8).  The literature search phase 
has therefore been dynamic and ongoing throughout all phases of the study.  All 
searches were conducted using EMBASE, MEDLINE AND CINAHL and Cochrane 
Databases searched through NHS Evidence.  The student has also utilised contacts 
within the field of research and social media (Twitter™) to keep up to date with new 
publication releases. 
The following were excluded as it was recognised that sufficient evidence would exist 
without analysis of:  
 Conference Abstracts 
 Case Report Series 
 Foreign Language Journals 
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Figure 8.  Publications per year including the search term “High-Sensitivity Troponin” 
 
 
Data from Pubmed.gov (Accessed March, 2014) 
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2.8 Grant Funding 
Grant funding was obtained through open international competition and peer review 
of study methodology.  The TRUST Study won funding of £10,000 from the UK College 
of Emergency Medicine during the 2012 funding competition.   
The TRUST Study has obtained industry funding from Abbott Laboratories, USA, for 
high-sensitivity Troponin I analysis and Randox Life Sciences, Ireland, for Heart Fatty 
Acid Binding Protein Analysis (as part of a collaborative study to validate the 
Manchester Acute Coronary Syndromes Rule (Body et al. 2014a)). 
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2.9 Ethical Considerations 
Full Ethical Approval was granted by the Frenchay Research Ethics Committee 
(Appendix 1) 12/SW/0133 on 30/05/2012 for Study Protocol 3.0. 
Major Amendments to the protocol have been approved as follows: 
Version 3.1 09/06/2013:  To allow change in Chief Investigator, alteration of 
final recruitment numbers and collection of data from those patients missed 
from the consent process. 
Version 3.2 17/01/2014:  To allow extension of follow-up from 30 days to 1 
year and enable testing of Abbott high-sensitivity troponin I on frozen serum 
samples. 
 
The following Ethical Issues were specifically taken into account during the 
application process: 
i) An upper cut-off age of 79 was chosen as in the host institution patients 
aged 80 and above were admitted for assessment by an entirely separate 
clinical team who had not been consulted in the design of the study, and 
whose standard care of this group of patients may vary considerably from 
other inpatient teams.    
 
ii) Participants will not be required to attend the department for any longer 
than the time required to perform the procedures that are done as part of 
routine care. All patients will have blood sampling from a vein in either arm 
as part of standard care within 1 hour of arrival, it is at this time we request 
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an extra 3.5mls (half a teaspoon) is given for high- sensitivity troponin 
testing and storage of serum.   No patient will be subjected to an extra 
needle procedure for the sake of this study.   
 
iii) On discharge participants will be asked to fill out a short questionnaire 
regarding their satisfaction with their admission.   This will be fully 
anonymised and participants will be reassured that it will not affect their 
ongoing care.   It will take approximately 5 minutes to complete.   The 
questionnaire has been designed with direct patient involvement and is 
written in layman's English.      
 
iv) For 30 day follow up, the data for adverse events will be taken from the 
hospital electronic patient record.   Where data from this is insufficient we 
will contact the participants GP for further clarification.   Participant 
involvement will not be required after discharge.  
 
v) There may be no direct benefit to research participants.  It is hoped that the 
results we obtain may provide evidence to support service improvement 
recommendations in care pathways for this group of patients in the future.  
Participants may benefit from the knowledge that their feedback regarding 
services may contribute directly to improving practice.  
 
vi) All patients will receive a participant information sheet.   Due to the 
pragmatic and emergency nature of the study participants will not be 
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informed at sampling that an extra 3.5mls of blood will be taken for 
research purposes.   Written consent for use of this sample will be obtained 
after participants have read a patient information leaflet detailing the 
study, have had the opportunity to ask questions and have them answered 
satisfactorily and are comfortable and pain free.  The consent form is 
attached (Appendix 3).  Patients will be entitled to withdraw their consent 
at this time.   
 
vii) Nursing staff will also be classed as research participants for the purpose of 
this study.   A written participant information sheet will be provided for all 
members of the ED nursing team.   Written consent to participate will be 
requested prior to study commencement but may be withdrawn at any 
time during the duration of the study.  
 
viii) For reasons of practicality consent will not be obtained from potential 
participants who are unable to understand English fully.   They will 
therefore not be recruited as study participants.   Due to the short period of 
time that patients will have to consider taking part it will be impractical to 
find an independent translator in this time.   It may sometimes take hours 
to find an independent registered translator.  Our institution has very low 
numbers of non-English speaking patients.   
 
ix) Access to medical records (electronic patient records) will be required by 
authorised members of the research governance department for the 
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purposes of monitoring and auditing the study to ensure it is conducted 
correctly.      
 
x) Personal data will be kept in paper files within a locked and alarmed room 
on trust property.  Patient data will only be kept electronically on secure 
hospital servers.   Only anonymised data may be transferred to another 
NHS computer, this will be carried out using an encrypted memory stick.  
Consent will be obtained from participants to allow members of the 
Sponsor (Poole Hospital NHS Foundation Trust) to access personal data. 
 
xi) No clinical decisions will be made upon review of research troponin results 
when reviewed at 30 days.  All patients will have been through a standard 
treatment pathway and as such their treatment should not be altered on 
the basis of results from a research study. 
 
xii) Risks to Patients- Patients enrolled in the study are covered by standard 
NHS Indemnity Arrangements for clinical negligence claims in the NHS. 
Risks to patients were determined to be negligible.   
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2.10  Study Preparation 
 
During Phase 1-3 of the study specific documentation was prepared as follows: 
a.  Participant Information Sheet (Patient): Appendix 2 
b. Participant Information Sheet (Nursing Staff): Appendix 3 
c. Consent Form (Patient):  Appendix 4 
d. Consent Form (Nursing):  Appendix 5 
e. Nursing Risk Assessment Sheet: Appendix 6 
f. Patient Questionnaire: Appendix 7 
 
2.11 Sponsorship 
The TRUST Study is a Bournemouth University/NHS collaboration.  Poole Hospital NHS 
Foundation Trust agreed to act as Sponsor for the TRUST Study.  The hospital Research 
Governance Department have undertaken regular audit of study procedures to ensure 
compliance with the sponsor’s terms and conditions. 
 
2.12  Trial Registration 
 
The study is registered with the Controlled Trials Database ISRCTN No. 21109279.   
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Chapter 3. 
Methods 
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3.1  Study Design 
 
A single-centre prospective blinded diagnostic observational cohort study. 
 
The protocol was designed to be truly pragmatic in order to enhance the widespread 
applicability of the study results (Tunis et al. 2003); with attending clinicians 
performing m-Goldman risk scores, rostered clinical (not research) staff undertaking 
blood sampling, real-time sample processing and 24/7 recruitment.   The study was 
designed using the Standards for Reporting Diagnostic Accuracy (STARD) (Bossuyt et al. 
2003). 
 
3.2  Setting 
 
The TRUST study was carried out in Poole Hospital NHS Foundation Trust Emergency 
Department.  This Emergency Department (ED) is situated in a large acute general 
hospital, in Dorset, United Kingdom.  The hospital provides a range of district hospital 
care for the 270,000 people living in Poole and East Dorset (NHS Choices 2013).  The 
ED has an annual census of 62000 and an estimated 3600 presentations with 
atraumatic chest pain per annum (personal review of ED demographic data and 
retrospective sampling).  This estimate is similar to that of prospective data which 
estimated that 6% of all ED attendances nationwide were due to chest pain and 
related complaints (Goodacre et al. 2005). All patients from the local catchment area 
with acute ECG findings ST-elevation myocardial infarction (STEMI) bypass the ED and 
were transferred directly to a nearby angioplasty centre. 
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Key population demographics from census data highlight a higher proportion of age 
>65 (26.2% as opposed to 17.0% nationally) and predominantly white British 
population (98.99% as opposed to 90.92% nationally) (Dorset County Council 2011).    
Patients with suspected ACS were managed according to the Poole hospital protocol, 
which involved risk assessment by ED physician staff using the m-Goldman risk score 
and blood drawn for hs-cTnT at 6 hours after presentation.  As part of the study 
protocol, blood was also taken at presentation for hs-cTnT analysis.  Historical clinical 
protocols, at the time of this study, did not include troponin measurement at 
presentation, in contravention of consensus guidance (Amsterdam et al. 2010 and 
NICE 2010).  However, this had the methodological benefit of ensuring that treating 
physicians were blinded to the initial hs-cTnT result to avoid selection bias (Stiell and 
Wells 1999) and ensured the decision to admit or investigate further was made by the 
treating physician independently of any cardiac biomarker result.  All patients who 
required a 6 hour troponin test were admitted to an inpatient assessment unit under 
the care of an acute general physician, the decision to admit being at the discretion of 
the assessing ED physician.  Onward cardiology consultation, stress testing or discharge 
for outpatient follow-up was at the discretion of the acute physician.   
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3.3  Trial Schema 
 
Figure 9, is a schema demonstrating TRUST Study interventions alongside clinical 
practice.  During initial assessment in the ED clinical staff drew blood for routine 
admission samples (not including cardiac biomarkers) and an additional 3.5mls of 
whole blood in a pre-labelled study specific serum settling tube for hs-cTnT analysis.  
Treating physicians were blinded to the presentation hs-cTnT result.  All serum 
samples were tested prior to freezing by laboratory staff blinded to patient outcomes. 
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Figure 9. Trial schema (standard care and illustration of experimental interventions) 
 
 
Hs-cTnT: high-sensitivity cardiac troponin T, ECG: Electrocardiogram 
 
 
PhD Thesis. Dr Edward W. Carlton 
 
105 
 
3.4 Participant Selection 
 
3.4.1 Inclusion Criteria 
 
Potentially eligible patients were screened by ED and research staff who provided trial 
information and obtained written consent.  Consecutive patients attending the ED with 
suspected ACS were prospectively screened from July 2012 to August 2013.  Patients 
were included if they were at least 18 years of age and had at least 5 minutes of chest 
pain suggestive of ACS, and for whom the attending physician determined inpatient 
evaluation was required.  Possible cardiac symptoms included acute chest, epigastric, 
neck, jaw or arm pain, or discomfort or pressure without an apparent non-cardiac 
source, in accordance with the American Heart Association case definitions (Luepker et 
al. 2003).  Atypical symptoms (fatigue, nausea, vomiting, diaphoresis, faintness, and 
back pain) were not used as inclusion criteria in the absence of chest pain. 
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3.4.2   Exclusion Criteria 
 
1.  Age <18 or ≥80 years 
2.  STEMI or left bundle branch block not known to be old and ECG changes 
diagnostic of ischaemia (ST segment depression ≥1mm or T-wave inversion 
consistent with the presence of ischaemia) (Amsterdam et al. 2010) 
3. Arrhythmias (new-onset atrial fibrillation, atrial flutter, sustained 
supraventricular tachycardia, second-degree or complete heart block, or 
sustained or recurrent ventricular arrhythmias) 
4. hs-cTnT not suitable for analysis (e.g. haemolysis), 
5.  Atypical symptoms in the absence of chest pain or discomfort 
6.  An alternative cause of chest pain is suspected at presentation (e.g. pulmonary 
embolism, pneumonia, aortic dissection) 
7.  Refusal of patient consent 
8.  Renal failure requiring dialysis 
9.  Non-English speaking 
10.  Inability to be contacted after discharge 
11. Trauma with suspicion of myocardial contusion 
12.  Another medical condition that necessitates hospital admission 
13.  Prisoners 
14.  Pregnancy 
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3.5 Sample Size  
 
Estimated Study Size Prior to Study Commencement: 1200 Participants 
 
On commencement of the study the aim was to recruit 1200 consenting participants 
with data and blood tests suitable for full analysis.  
 
3.5.1 Justification of Sample Size 
 
In evaluating the accuracy of a diagnostic strategy in medicine, the sample size plays 
an important role either for estimation or testing of diagnostic accuracy. A small 
sample size produces an imprecise estimate of accuracy with wide confidence 
intervals (Jones et al. 2003) which is non-informative for clinicians who may wish to 
implement the diagnostic pathway in a clinical environment.  An unnecessarily large 
sample size is a waste of valuable research resources. 
In estimating the diagnostic accuracy and to obtain a desired level of statistical power 
to detect an effect size for testing the TRUST ADP, calculation of the minimum sample 
size is therefore required.  This calculation is reliant on 2 factors.  Firstly, the 
proportion of patients who may be suitable for early discharge using the TRUST ADP.  
Secondly the diagnostic accuracy of the rule-out pathway (in this case the precision 
estimate of test sensitivity (as discussed on Page 77).  It has been argued that when 
estimating sample size around test sensitivity the consideration of disease prevalence 
is not required (Jones et al. 2003). 
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To estimate the proportion of patients who may be suitable for early discharge, a 
retrospective analysis of 100 patients presenting to the Emergency Department with 
suspected cardiac chest pain was undertaken prior to study commencement.  The m-
Goldman Score was applied to each patient through adjudication from clinical notes by 
the student investigator.  From this analysis it was estimated that approximately 30% 
would be classified as low-risk, and therefore potentially suitable for early discharge.  
This target of 30% also improves upon the best performing ADP currently in the 
literature (Cullen et al. 2013). 
Three essential elements are required when estimating sample size according to test 
sensitivity (Hajian-Tilaki, 2013): 1) a pre-determined point estimate value of sensitivity, 
estimated from published research or clinical judgement, 2) the confidence interval (1-
α) for statistical judgement, where α is the probability of a Type 1 (false positive) error 
and 3) the precision estimates of sensitivity. 
Therefore to define the diagnostic accuracy of the TRUST ADP a point estimate target 
sensitivity for MACE was set at 99%; the cut-off at which the majority of emergency 
physicians may expect diagnostic strategies for the assessment of suspected ACS to 
achieve (Than et al. 2012b).   
The sample size was then calculated according to the precision estimates of the 
sensitivity of the TRUST ADP.  Assuming a 100% sensitivity of this ADP, for the 
identification of MACE, with a 95% confidence interval (α 0.05) that would extend no 
lower than 99%, 400 low-risk patients would be required to demonstrate statistical 
significance. With an estimated 30% of patients being eligible for discharge, a total 
sample size of 1200 patients was required.  
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3.5.2 Adjustment of Sample Size 
 
An interim analysis following recruitment of the first 700 participants was undertaken.  
This showed that a higher proportion of patients (41.4%) were classified as low risk.  
This enabled a reduction in the total numbers recruited to 966.   
Sackett et al. (2011) estimate that 20% of study participants will not provide data to 
the final analysis.  However, the observational nature of the TRUST study meant this 
number was far fewer.  The interim analysis identified the following reasons for data 
loss: 
a) Failure or loss of study blood sampling (0.28%) 
b) Haemolysis of research blood samples rendering them uninterpretable (4.85%) 
c) Loss to follow-up (2.6%) 
Therefore 7.76% of participants recruited at the time of interim analysis had 
incomplete data.  To take this into account the sample size was recalculated to 1040. 
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3.6 Recruitment 
 
In order to reduce the potential for selection bias (Laupacis et al. 1997 and Stiell and 
Wells 1999) recruitment to the TRUST study was undertaken 24 hours a day, 7 days a 
week.  This is the first large scale study of its kind to do so and was facilitated by a 
retrospective consent process.  Prior to study commencement it was estimated that 
2.5 participants would be recruited per day, acknowledging that up to 10% of eligible 
patients would be missed from the consent process.  Therefore approximately 400 
days were required for recruitment. 
 
The final recruitment period was: 18th July 2012 – 30th August 2013 
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3.7 Study Data 
 
3.7.1  Recording of the m-Goldman Score 
 
Data were collected prospectively using a published data dictionary (Cullen et al. 2010) 
and is available in Appendix 8.  ED physicians were also asked to complete the m-
Goldman risk score following their own initial patient assessment. Treating ED 
physicians completed the m-Goldman risk score on a pre-designed clinical report form 
to enable accurate recording of demographic data.  Where m-Goldman scores were 
not completed by treating physicians, adjudication of scores was carried out by study 
researchers blinded to patient outcomes and hs-cTnT results from ED records separate 
to hospital records. 
ED nursing staff undertaking initial assessment were also asked to record the m-
Goldman risk score on a case report form, at the time of patient presentation to the 
ED.  They were provided with written explanatory notes on how to complete the risk 
score but no specific training in the clinical evaluation of patients with chest pain.  The 
nursing risk score was kept separate from the clinical notes in a coloured envelope and 
removed by a member of the research team at the earliest opportunity.  No 
adjudication of nursing staff risk scores was undertaken.  Where possible, subjective 
elements of other risk scores were evaluated directly from data provided by the 
treating clinician. 
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3.7.2  Data for the Calculation of Other Risk Scores 
 
Risk scores were selected a priori if they were known to be in common clinical use 
(Dunham et al. 2010) and had been prospectively validated in large ED cohort studies.  
Index tests were pre-determined definitions of low-risk applied to each risk score 
(Summarised in Table 15) established from existing validation studies designed with 
the specific intention of improving ED efficiency: TIMI (Cullen et al. 2013); GRACE 
(Goodacre et al. 2012); HEART (Backus et al. 2013) and Vancouver (Cullen et al. 2014a).   
Where biomarker results were not included as a variable in the original score, hs-cTnT 
and hs-cTnI were incorporated accordingly using the 99th percentile cut-off value as a 
baseline.  As only patients with a non-ischemic ECG were recruited to the study, where 
ischemic ECG changes were included in the original risk scores, these variables were 
removed, as reflected in clinical practice where patients with ischemic ECG changes 
are immediately defined as high-risk (Amsterdam et al. 2010).  Data points for each risk 
score were included within primary data collection.  Where possible, ED clinician 
interpretation of individual elements of each risk score (such as typicality of chest pain) 
was used in order to incorporate subjective interpretation.  A computer-based 
algorithm was designed to calculate each score automatically from the admission data, 
without interpretation by the study investigator. 
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3.7.3 Assessing Typicality of Chest Pain 
 
Clinicians were requested to record, in a yes/no tick box, using their own clinical 
judgment and taking into account all factors from history and examination as to 
whether they thought the chest pain described was typical cardiac chest pain or 
atypical (question derived from the m-Goldman risk score).  The level of experience for 
assessing physicians was recorded.  Clinical experience was defined a priori as either 
“experienced” or “novice.”  Experienced ED physicians were either Consultants 
(Fellows of the UK College of Emergency Medicine) or Registrars with at least 2 years 
of ED experience.  Novice ED physicians were Senior House Officers with less than one 
years’ ED experience.  During the study period there were 12 experienced physicians 
and 32 novice physicians undertaking clinical assessments.   
Physician assessments were anonymized to protect staff identity (as requested by 
ethics board), therefore the number of assessments recorded by each individual could 
not be recorded.  Clinical data was recorded during the initial patient assessment and 
therefore treating physicians were blinded to the patient outcome.  As biochemical 
results were not available at the point of assessment, ED staff were also blinded to 
troponin results.   
 
3.7.4 High-Sensitivity Troponin Measurement 
 
The fourth generation Roche ELECSYS hs-cTnT assay (Roche, Basel, Switzerland), which 
has a Limit of Blank of 3ng/L, Limit of Detection of 5ng/L, 99th percentile of 14ng/L and 
10% coefficient of variation of <10% at 9ng/L, was used for both research 
(presentation) and clinical (6-hour) samples.  Clinical samples were reported to a lower 
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level of 14ng/L (where a sample was <14ng/L this was reported as such).  Research 
samples were reported down to a level of 3.0ng/L and were recorded to the degree of 
a single decimal point.  Research serum blood samples were spun down and tested for 
hs-cTnT upon receipt in the laboratory.  Remaining spun serum was frozen 
immediately and stored at -80⁰C.   
In December 2014, industry funding was obtained to test remaining frozen samples for 
high-sensitivity troponin I.  Stored presentation samples were tested for hs-cTnI using 
the Abbott ARCHITECT STAT High Sensitive Troponin-I assay (Abbott Laboratories, 
USA), which has a 99th percentile value of 26.2ng/L with a corresponding coefficient of 
variation of <5% and a limit of detection of 1.9ng/L.      
 
3.7.5 Patient Questionnaire 
 
This quantitative questionnaire was designed with closed answer questions with 
responses standardized along a 5-point Likert scale (Likert 1932) (Appendix 7).  In order 
to obtain the opinion of those patients who may have been eligible for immediate 
discharge, only those patients who were discharged within 36 hours, directly from the 
short stay ward, were asked to complete the questionnaire. Respondents were asked 
to complete the written survey upon discharge from the ward and hand it to a 
member of the ward team. 
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3.8 Statistical Analysis 
Baseline characteristics of the study population were analysed with conventional 
group descriptive statistics. 𝑥2 analyses were used to generate 2 x 2 tables for the 
calculation of sensitivity, specificity, negative predictive values (NPV) and positive 
predictive values (PPV), and negative (-LR) and positive (+LR) likelihood ratios.  For the 
majority of analyses the ability of the test to perform as a rule-out tool (sensitivity) is 
the result of primary interest.   Statistical significance was calculated using the Fisher’s 
exact test for contingency tables and Mann-Whitney U test for non-parametric data; 
all reported p-values are two-tailed.  Inter-observer reliability of variables between ED 
Physicians and Nurses were made using a Cohen’s Kappa score.  Binary logistic 
regression analysis was used to identify predictors of dissatisfaction with early 
discharge within the patient questionnaire.  All statistical analysis was carried out using 
SPSS version 20. 
The study database is available upon request and is in the form of an SPSS data file.  All 
patient identifiable data is anonymised.  All SPSS syntax files for calculation of 
endpoints are also available. 
3.8.1  Receiver-Operating Characteristic Curves 
 
Where applicable receiver-operating characteristic (ROC) curves were obtained by 
plotting sensitivity against 1-specificity.   The ROC provides information in the case of 
quantitative diagnostic tests (such as high-sensitivity troponin, or the m-Goldman 
score) as to what extent test results differ between patients who do or do not have the 
diagnosis of interest. The area under the ROC curve (AUC) was chosen as the primary 
measure of discriminatory value, as it gives a global measure of test performance.    
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The AUC was tested against the null hypothesis that the true AUC was 0.50 with a 
significance of <0.05.  AUC equals 0.5 when the diagnostic test corresponds to random 
chance (null hypothesis) and 1.0 indicates perfect diagnostic accuracy. 
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3.9  Follow-up 
Follow-up was undertaken by independent review of hospital electronic patient 
records, summary of health records from the patient’s General Practitioner (GP) 
obtained at least 6-months after attendance and a national clinical records search 
(which identifies death).    GPs were therefore requested to provide all information 
regarding presentation to other institutions with chest pain, cardiology outpatient 
review and cardiac testing, including angiography with or without intervention.  Where 
a participant had not attended hospital follow-up and/or a GP had failed to provide a 
health record/not GP-registered, the patient was regarded as lost to follow-up. 
3.10  Dissemination and Publication of Results 
This will be carried out according to the Declaration of Helsinki. Principle 27 
“Both authors and publishers have ethical obligations. In publication of the results of 
research, the investigators are obliged to preserve the accuracy of the results. Negative 
as well as positive results should be published or otherwise publicly available.” 
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Chapter 4. 
Results 
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4.1 Study Participants  
For the primary analysis, 964 consenting patients were recruited. Participants were 
predominantly white, older men who commonly had risk factors for coronary artery 
disease (Table 19).  Patients presented to the ED at a median of 2.4 hours (IQR 0.4-
4.29) after chest pain onset.   
 
4.2 Loss to Follow-Up 
Of the 964 patients recruited, 4 patients were lost to follow-up meaning that 99.6% 
were successfully monitored for 30 days.  In those patients lost to follow-up health 
records pertaining to presence of outcome measures were unobtainable despite 
repeated requests to General Practitioners for information. These patients were not 
included in the final statistical analysis, however, no patient lost to follow-up died 
within 30 days of attendance.   
 
4.3 Incidence of Major Adverse Cardiac Events 
 
97/960 (10.1%) had a MACE within 30 days.  Patients with MACE were significantly 
older, more likely to be male with hypertension, diabetes, dyslipidaemia and a prior 
history of coronary artery disease.  Frequency of MACE during initial hospital 
attendance or 30 day follow-up are shown in Table 20.  The 97 patients with MACE had 
a total of 139 events, the most common being fatal/non-fatal AMI (8.3% of total 
population).   
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Table 19.  Patient demographics as per primary outcome (MACE) 
 
MACE: Major Adverse Cardiac Events, SD: Standard Deviation, IQR: Interquartile Range 
 Total (N=960) MACE 
Negative at 30 
days 
(N=863) 
MACE 
Positive at 
30 days 
(N=97) 
Significance of 
difference between 
MACE positive and 
negative groups  
(p value) 
Age, yrs. (Mean±SD) 58.0  ± 13.3 57.4 ± 13.4 63.4 ± 10.6 <0.0001 
Sex (% male) 565 (58.9) 498 (57.7) 67 (69.1) 0.031 
Ethnicity (% British 
Caucasian) 
914 (95.2) 825 (95.6) 89 (91.8) 0.093 
Risk factors N (%)     
Hypertension 528 (55.0) 454 (52.6) 74 (76.3) <0.0001 
Diabetes 164 (17.1) 140 (16.2) 24 (24.7) 0.035 
Dyslipidaemia 635 (66.1)  557 (64.5) 78 (80.4) 0.002 
Smoking Current 231 (24.1) 209 (24.2) 22 (22.7) 0.737 
Smoker Ex 343 (35.1) 307 (35.6) 36 (37.1) 0.764 
Family History of Coronary 
Artery Disease 
354 (36.9) 318 (36.8) 36 (37.1) 0.959 
Medical History     
Angina 251 (26.1) 214 (24.8) 37 (38.1) 0.005 
Myocardial Infarction 204 (21.3) 171 (19.8) 33 (34.0) 0.001 
Percutaneous Coronary 
Intervention 
183 (19.1) 154 (17.8) 29 (29.9) 0.004 
Congestive Cardiac Failure 30 (3.1) 26 (3.0) 4 (4.1) 0.258 
Atrial Arrhythmia 119 (12.4) 109 (12.6) 10 (10.3) 0.340 
Stroke 63 (6.6) 57 (6.6) 6 (6.2) 0.875 
Coronary Artery Bypass 
Graft 
50 (5.2) 41 (4.8) 9 (9.3) 0.057 
Baseline Medications     
Aspirin 361 (37.6) 311 (36.0) 50 (51.5) 0.003 
Clopidogrel 112 (11.7) 102 (11.8) 10 (10.3) 0.661 
Beta Blocker 281 (29.3) 249 (28.9) 32 (33.0) 0.396 
ACE Inhibitor 272 (28.3) 236 (27.3) 36 (37.1) 0.043 
Statin 369 (38.4) 322 (37.3) 47 (48.5) 0.032 
Median Length of Hospital 
Stay (hrs.) (IQR) 
18.8 (2.6-35.0) 17.4 (8.7-
26.1) 
109.5 (54.3-
164.7) 
<0.0001 
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Table 20.  Frequency of major adverse cardiac events during initial hospital 
attendance or 30 day follow-up 
 
 Number of Events Frequency of Event 
Type (%) 
Acute Myocardial 
Infarction 
80 8.3 
Non-ST Elevation Myocardial 
Infarction 
77 8.0 
ST Elevation Myocardial 
Infarction 
3 0.03 
Emergency/Urgent 
Revascularization 
56 5.8 
Cardiovascular Death 1 0.01 
Ventricular Arrhythmia 1 0.01 
High atrioventricular block 0 0 
Cardiac Arrest 1 0.01 
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4.4 The Diagnostic Accuracy of the TRUST ADP 
 
For analysis of the diagnostic accuracy of the TRUST ADP, 964 consenting participants 
were recruited (Figure 10), 4 patients were lost to follow-up (health records pertaining 
to presence of outcome measures unobtainable) meaning that 99.6% were 
successfully monitored for 30 days.  However, no patient lost to follow-up died within 
30 days of attendance.  
 
Figure 10.  Participant recruitment flowchart (Primary Analysis) 
 
 
Primary Aim of the TRUST Study: To establish whether the TRUST 
ADP for suspected ACS patients consisting of hs-cTn, a non-
ischaemic ECG and the m-Goldman score, could successfully identify 
low-risk patients suitable for discharge after a single blood draw at 
presentation to the ED. 
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The TRUST ADP classified 382 (39.8%) of patients as at low-risk of MACE, with a 
sensitivity of 99.0% (95% CI 93.7-99.9) and NPV of 99.7% (95% CI 98.4-100) and had a 
similar diagnostic performance for the secondary outcome measure (AMI) (Table 
21/22).   
Figure 11 demonstrates that the combination of components that make up the ADP 
were more accurate at ruling-out patients for MACE (sensitivity) than the individual 
components themselves (m-Goldman score ≤ 1 and/or hs-cTnT <14 ng/L).  The m-
Goldman risk score, if used in isolation missed 28/457 (6.1%) of patients with MACE at 
day 30, whilst hs-cTnT missed 22/766 (2.9%).  This improved diagnostic accuracy for 
the rule-out of MACE was at the expense of a lower specificity of 44.1% (95% CI 43.6-
44.3) when compared to m-Goldman ≤ 1 (49.7%; 95% CI 48.6-50.6) and hs-cTnT <14 
ng/L (86.2%; 95% CI 85.2-87.0) alone. 
A single patient (0.3%) classified as low-risk by the TRUST ADP had a major adverse 
cardiac event.  This patient was a 78-year-old female classified as low-risk on the m-
Goldman score and had an hs-cTnT of 13ng/L at presentation. However, a minor hs-
cTnT elevation to 20ng/L (delta change 27%) occurred on the second hs-cTnT test at 6 
hours and was therefore diagnosed with an AMI.  The patient was medically managed 
and had no further complications.  
 
The TRUST ADP classified 382 (39.8%) of 
patients as at low-risk of MACE, with a 
sensitivity of 99.0% (95% CI 93.7-99.9) and 
NPV of 99.7% (95% CI 98.4-100). 
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Table 21.  Contingency tables demonstrating the occurrence of 30 day MACE and 
index AMI According to TRUST ADP and its component parts 
 
Index Test 
MACE No MACE Total 
TRUST ADP    
Not Low Risk 96 482 578 
Low Risk 1 381 382 
m-Goldman Score    
>1 69 434 503 
≤1 28 429 457 
hs-cTnT  
 
   
≥14 ng/L 75 119 194 
<14 ng/L 22 744 766 
 AMI No AMI Total 
TRUST ADP    
Not Low Risk 79 499 578 
Low Risk 1 381 382 
m-Goldman Score    
>1 54 449 503 
≤1 26 431 457 
hs-cTnT  
 
   
≥14 ng/L 67 127 194 
<14 ng/L 13 753 766 
MACE: Major Adverse Cardiac Events at 30 days, AMI: Acute Myocardial Infarction (Fatal/non-
fatal) occurring within 30 days 
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Table 22.  Diagnostic accuracy of the TRUST ADP and its components for the 
prediction of MACE and AMI 
 
MACE: Major Adverse Cardiac Events at 30 days, AMI: Acute Myocardial Infarction (Fatal/non-
fatal) occurring within 30 days 
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Figure 11.  The sensitivity and specificity of the TRUST ADP and its component parts 
for MACE at 30 days 
Error bars: 95% Confidence Intervals 
 
Table 23 illustrates the demographic differences between TRUST ADP low-risk groups 
and those not classified as low risk, with all being statistically significant except current 
smoking and family history of coronary artery disease. 
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Table 23.  Patient demographics as per TRUST ADP risk group 
 TRUST ADP not Low 
Risk (N=578) 
TRUST ADP Low Risk 
(N=382) 
Significance of 
difference 
between 
TRUST ADP 
groups (p 
value) 
Age, yrs. (Mean±SD) 60.4 ± 12.8 55.6 ± 19.4 <0.0001 
Sex (% male) 360 (62.3) 205 (53.7) 0.008 
Ethnicity (% British Caucasian) 549 (95.0) 365 (95.5) 0.687 
Risk factors N (%)    
Hypertension 319 (55.2) 123 (34.8) <0.0001 
Diabetes 124 (21.4) 40 (10.5) <0.0001 
Dyslipidaemia 429 (74.2) 206 (53.9) <0.0001 
Smoking Current 129 (22.3) 102 (26.7) 0.120 
Smoker Ex 229 (39.6) 114 (29.8) 0.002 
Family History of Coronary Artery 
Disease 
215 (37.2) 139 (36.4) 0.799 
Medical History    
Angina 207 (35.8) 44 (11.5) <0.0001 
Myocardial Infarction 174 (30.1) 30 (7.9) <0.0001 
Percutaneous Coronary Intervention 146 (25.3) 37 (9.7) <0.0001 
Congestive Cardiac Failure 25 (4.3) 5 (1.3) 0.009 
Atrial Arrhythmia 86 (14.9) 33 (8.6) 0.004 
Stroke 45 (7.7) 18 (4.7) 0.060 
Coronary Artery Bypass Graft 41 (7.1) 9 (2.4) 0.001 
Baseline Medications    
Aspirin 276 (47.8) 85 (22.3) <0.0001 
Clopidogrel 84 (14.5) 28 (7.3) 0.001 
Beta Blocker 210 (36.3) 71 (18.6) <0.0001 
ACE Inhibitor 195 (33.7) 77 (20.2) <0.0001 
Statin 276 (47.8) 93 (24.3) <0.0001 
Mean Length of Stay (Standard 
Deviation) 
56.9 (17.7-96.1) 26.1 (7.1-45.1) <0.0001 
Median Length of Hospital Stay (hrs.) 
(Interquartile Range) 
22.4 (-8.6-53.4)  14.1 (7.9-20.3) 0.009 
SD: Standard Deviation 
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4.5 Improving Efficiency with the TRUST ADP 
 
 
Patients identified as low risk by the TRUST ADP had a mean length of hospital stay of 
26.1 hours (SD 7.1-45.1) and a median of 14.1 hours (IQR 7.9-20.3).  Time and motion 
analysis (Figure 12) of real-time hs-cTnT laboratory testing identified that blood results 
would be available to the treating physician at a median of 2.06 hours (IQR 1.61-2.52) 
after arrival in the ED.  In a ‘doctor-on-demand’ scenario (Thokala et al. 2012), in which 
medical staff are available 24 hours a day to make a discharge decision within 60 
minutes of results being available, then discharge may be achieved within 2.66 hours 
(IQR 2.21-3.12) of attendance (Figure 13).   
 
 
 
 
 
 
 
 
 
 
Aim:  To establish potential improvements in system efficiency using 
the TRUST ADP through time-and-motion analysis of hs-cTnT testing. 
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Figure 12.  Time and motion analysis of hs-cTnT testing 
 
 
 
Figure 13.  A group scatter plot demonstrating the difference between actual length 
of stay and estimated TRUST ADP discharge time    
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4.6 Undetectable hs-cTnT Discharge Strategies 
 
 
The occurrence of MACE and AMI during the index hospital visit or at 30 days, 
according to hs-cTnT detection limits are shown in Table 24. The diagnostic 
performance of hs-cTnT limit of detection cut-off values in patients with a non-
ischaemic ECG are shown in Table 25. By using the limit of detection cut-off value of 
5ng/L for the primary outcome measure (MACE) the sensitivity was 96.8% (95%CI 90.6-
99.2) and 29.3% of patients were eligible for early discharge.  Three patients (1.1%) 
identified as suitable for discharge using this strategy required urgent revascularization 
(clinical characteristics summarized in Table 26), all had blood samples taken over 6 
hours from chest pain onset.  Using the limit of blank (<3ng/L) the sensitivity for MACE 
was improved to 98.6% (95%CI 91.9-99.9), but only 7.9% would have been eligible for 
early discharge.  One patient (1.4%) with an hs-cTnT <3ng/L required urgent 
revascularization.  Using the secondary outcome measure (AMI) both the limit of 
detection (<5ng/L) strategy and limit of blank (<3ng/L) strategy achieved 100% 
sensitivity.   
 
 
 
 
 
 
 
 
 
Aim:  To compare the diagnostic accuracy of the TRUST ADP 
with strategies utilising initial undetectable hs-cTnT levels. 
 
PhD Thesis. Dr Edward W. Carlton 
 
131 
 
Table 24.  Occurrence of 30 day MACE and index AMI according to hs-cTnT detection 
limits 
 
Index Test MACE No MACE Total 
Hs-cTnT<5ng/L*    
≥5ng/L 92 560 652 
<5ng/L 3 267 270 
Hs-cTnT<3ng/L*     
≥3ng/L 94 755 849 
<3ng/L 1 72 73 
 AMI No AMI Total 
Hs-cTnT<5ng/L*     
≥5ng/L 78 570 648 
<5ng/L 0 270 270 
Hs-cTnT<3ng/L*     
≥3ng/L 78 771 849 
<3ng/L 0 73 73 
 
*922/960(96%) results are reported for the hs-cTnT detection limits.  This was due to computer 
error whereby 38 results were only reported as <14ng/L. 
MACE: Major Adverse Cardiac Events at 30 days, AMI: Acute Myocardial Infarction (Fatal/non-
fatal) occurring within 30 days 
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Table 25.  Diagnostic accuracy of detection limit cut-offs of hs-cTnT for the prediction 
of MACE and AMI 
 
MACE: Major Adverse Cardiac Events at 30 days, AMI: Acute Myocardial Infarction (Fatal/non-
fatal) occurring within 30 days 
Table 26.  Clinical characteristics of patients diagnosed with MACE at 30 Days with an 
initial hs-cTnT<5ng/L 
 
 
*LAD: Left Anterior Descending Coronary Artery, RCA: Right Coronary Artery 
Hs-cTnT: High-sensitivity cardiac troponin T, MACE: Major Adverse Cardiac Event at 30 days 
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4.6.1 Comparison of the TRUST ADP and Undetectable hs-cTnT Discharge Strategies 
 
The TRUST ADP identified significantly more patients suitable for immediate discharge 
at 39.8% vs 29.3% (<5ng/L) and 7.9% (<3ng/L) (P<0.001) with a lower false-positive 
rate; specificity 44.1% (95%CI 43.6-44.3) vs 32.3% (95%CI 31.6-32.6) and 8.7% (95%CI 
8.1-8.8) respectively, whilst maintaining a high diagnostic accuracy for the rule-out of 
MACE (Figure 14). 
Figure 14.  Comparison of the diagnostic utility of the TRUST ADP and undetectable 
hs-cTnT discharge strategies for the detection of MACE 
 
 
Error bars: 95% Confidence Intervals 
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4.7 An Alternative High-Sensitivity Troponin Assay: Abbott hs-cTnI 
 
 
It is important to acknowledge that another commercially available high-sensitivity 
troponin assay (Abbott hs-cTnI) is available (NICE 2014), and this assay is in use in 
many clinical centres.  Therefore in order to establish the general applicability of the 
TRUST ADP, it is necessary to assess the performance of this assay in the TRUST study 
cohort and evaluate hs-cTnI in comparison to hs-cTnT. 
867 samples were suitable for Abbott hs-cTnI testing after transport to University 
College Dublin biochemistry laboratory (analysis performed in December 2014).  This 
represents 89.9% of the consenting study population (Figure 15). 
66/867 (7.6%) had the outcome event (AMI) within 30 days, including the initial 
hospital attendance.    
 
 
 
 
 
For all analysis incorporating Abbott hs-cTnI the 
outcome measure of fatal/non-fatal AMI has been 
used as a primary outcome measure, as opposed to 
MACE.  This outcome measure does not include 
revascularisation.  This is in an attempt to remove the 
bias associated with the use of Roche hs-cTnT in 
clinical practice where it would be used to guide 
referral for angiography and revascularisation 
decisions. 
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Figure 15.  Participant recruitment flow chart for Abbott hs-cTnI analysis 
 
 
 
 
4.7.1 Comparison of the Diagnostic Accuracy of hs-cTnT and hs-cTnI Assays at 
Presentation for the Detection of AMI  
 
Receiver-operating characteristic (ROC) curves for discrimination of fatal/non-fatal AMI 
for hs-cTnT and hs-cTnI at presentation are shown in Figure 16.  The area under the 
curve (AUC) for hs-cTnT and hs-cTnI at presentation were 0.925 (95%CI 0.899-0.950) 
and 0.903 (95%CI 0.860-0.947) respectively, and were not significantly different 
(p=0.575).  However at the 99th percentile cut-off hs-cTnT identified significantly more 
AMIs at presentation compared to hs-cTnI; 66/79 (83.5%) vs. 41/66 (62.1%) (P=0.004) 
with a higher sensitivity; 83.5% (95%CI 73.8-90.5) vs. 62.1% (95% CI 51.9-70.8).   
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Figure 16.  Receiver-operating characteristic curves for AMI using hs-cTnT and hs-cTnI 
results taken at presentation to the Emergency Department 
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4.7.2 Undetectable Troponin Rule-Out Strategies: Roche hs-cTnT vs. Abbott hs-cTnI 
 
The diagnostic utility of the levels of detection (LoD) for hs-cTnT and hs-cTnI are 
summarised in Figure 17.  It should be noted that the assay manufacturers, Abbott, do 
not provide a level of blank for their hs-cTnI assay.  The hs-cTnI assay identified 
significantly more patients suitable for early discharge when compared to hs-cTnT at 
the LoD; 39.3% vs. 29.3% (P<0.0001).  This improved efficiency was at the expense of a 
reduced sensitivity for the detection of AMI of 95.5%, compared to 100% for hs-cTnT, 
although it should be noted that the lower 95% confidence intervals for hs-cTnT 
include those of hs-cTnI, suggesting that performance of assays as a rule-out tool may 
be similar.  The clinical characteristics of the 3 patients with a diagnosis of AMI not 
detected using the LoD of the hs-cTnI assay are summarised in Table 27.    
 
Figure 17.  Comparison of the diagnostic utility of undetectable hs-cTnT and hs-cTnI 
discharge strategies for the detection of AMI 
 
Error Bars: 95% Confidence Intervals 
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Table 27.  Clinical characteristics of patients with a diagnosis of AMI not detected 
using the level of detection of the Abbott hs-cTnI assay 
 
*LMS: Left Main Stem, LAD: Left Anterior Descending Coronary Artery 
 
4.7.3  The TRUST ADP:  Comparing the use of Roche hs-cTnT and Abbott hs-cTnI 
 
The diagnostic accuracy of the TRUST ADP when either hs-cTnT or hs-cTnI are used is 
presented in Figure 18.  By integrating hs-cTnI at the 99th percentile cut-off value 
(26.2ng/L) for this assay the sensitivity of the TRUST ADP for the detection of AMI 
drops to 92.8% (95% CI 82.8-97.2) and 5 patients with AMI would have been missed.  
More patients were classified as low risk using hs-cTnI (44.4% vs 39.8%; P=0.046) with 
an improved specificity for the diagnosis of AMI (47.4% vs 43.3%). 
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Figure 18.  Comparison of the diagnostic accuracy of the TRUST ADP integrating hs-
cTnT and hs-cTnI at the 99th percentile cut-off value 
 
Error Bars: 95% Confidence Intervals,  
AMI: Acute Myocardial Infarction (fatal/non-fatal) within 30 days 
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4.8 A Diagnostic Comparison of Five Established Risk Scores and Two 
High-Sensitivity Assays 
 
 
 
 
For risk score summaries see Table 15, Page 70. 
 
Test performance of each risk score (m-Goldman, TIMI, GRACE, HEART and Vancouver) 
and their pre-defined cut-offs for determination of low risk status in combination with 
presentation Roche hs-cTnT and Abbott hs-cTnI are shown in Tables 28 and 29 
respectively. 
Figure 19 presents sensitivity vs. 1-specificity for each risk score and both hs-cTn 
assays. When considering the upper bounds of the 95% confidence intervals for test 
sensitivity, only two risk scores (GRACE<80 and HEART≤3) did not have the potential to 
achieve the threshold of 98% sensitivity for the diagnosis of AMI, when used in 
To define the clinical utility of each rule-out protocol a target miss-
rate of fatal or non-fatal AMI for each risk score as 0.5% or less was 
set (NPV>99.5%), this is the cut-off at which the majority of 
emergency physicians may expect diagnostic strategies for the 
assessment of suspected ACS to achieve (Than et al. 2012b).  Also, 
for a risk score to be of substantial benefit, significant numbers of 
patients need to be identified as low-risk, a target of >30% was set, 
in line with existing ADPs which incorporate hs-cTn testing (Cullen 
et al. 2013). 
 
Aim: To compare the ability of five established risk scores, when used in 
conjunction with either high-sensitivity troponin T (Elecsys hs-cTnT) or I 
(Architect hs-cTnI), to identify low risk patients with chest pain 
symptoms suggestive of ACS suitable for early discharge after a single 
blood draw at presentation to ED.  
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conjunction with hs-cTnT.  For hs-cTnI, three risk scores (m-Goldman≤1, TIMI≤1 and 
GRACE<80) did not have the potential to achieve this sensitivity threshold.  Within 
those tests that did have the potential to achieve a sensitivity threshold of 98% (Kline 
et al. 2005), there was a wide variation in test specificity.  This ranged from 10.6% (95% 
CI 10.1-10.6) for GRACE<60 with hs-cTnT to 53.5% (95%CI 52.8-53.8) for TIMI<1 with 
hs-cTnT. 
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Table 28.  Diagnostic accuracy for each risk score with pre-defined cut-offs for 
determination of low risk status in combination with presentation Roche hs-cTnT 
results for fatal/non-fatal AMI 
 
*Incomplete GRACE scores in 7 cases due to missing creatinine results 
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Table 29.  Diagnostic accuracy for each risk score with pre-defined cut-offs for 
determination of low risk status in combination with presentation Abbott hs-cTnI 
results for fatal/non-fatal AMI 
 
*Incomplete GRACE scores in 6 cases due to missing creatinine results 
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Figure 19.  Test performance of each risk score in combination with presentation A. 
hs-cTnT and B. hs-cTnI results as illustrated by sensitivity against 1-specificity 
 
Sensitivity threshold of 98% suggested by Kline et al. 2005 as the threshold at which the risks of 
false-positive testing (beyond biomarker analysis) outweigh the risk of untreated disease. 
Error Bars: 95% Confidence Intervals 
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4.8.1 Clinical Utility of Risk Scores and Presentation hs-cTn Testing 
 
The potential clinical utility of each risk score is shown in Figure 20. This demonstrates 
the percentage defined as suitable for discharge against the NPV for the diagnosis of 
fatal or non-fatal AMI.  When considering the upper bounds of the 95% confidence 
intervals for each test, TIMI 0 or ≤1 and m-Goldman≤1 with hs-cTnT, and TIMI 0 and 
HEART≤3, with hs-cTnI have the potential to achieve an NPV ≥99.5% while identifying 
>30% of patients as suitable for immediate discharge. 
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Figure 20.  Clinical utility of risk scores in combination with presentation A. hs-cTnT 
and B. hs-cTnI results 
 
Threshold of Clinical Utility: defined according to a miss-rate of fatal/non-fatal acute 
myocardial infarction of a negative predictive value ≥99.5% and >30% being eligible for 
discharge 
Each risk score has been tested in combination with the 99th percentile value of hs-cTnT or hs-
cTnI taken at presentation 
       Error Bars: 95% Confidence Intervals  
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4.9 Evaluating the Diagnostic Accuracy of Emergency Department 
Nursing Staff Risk Assessment  
 
 
Figure 21 depicts a participant recruitment flow chart according to physician and 
nursing assessments using the TRUST ADP.  912/960 (95.0%) had m-Goldman scores 
recorded by ED physicians and 745/960 (77.6%) by nursing staff.   
There were no significant differences between physician and nursing patient-groups in 
age, gender, risk factors for coronary artery disease, prior cardiovascular history and 
hospital length of stay (P>0.05 for all).   
 
 
 
 
 
 
 
 
 
 
Aim: To establish the diagnostic accuracy of ED nursing staff risk 
assessment, using the TRUST ADP, with regard to prediction of future 
MACE in patients with suspected ACS, and evaluate the inter-observer 
reliability of nursing and physician assessments within a chest pain 
specific risk score. 
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Figure 21.  Participant recruitment flow chart according to physician and nursing 
assessments using the TRUST ADP 
  
 
ADP:  The TRUST Accelerated Diagnostic Protocol, MACE: Major Adverse Cardiac Events 
occurring within 30 days 
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4.9.1 Diagnostic Accuracy of the TRUST ADP:  Comparison of Physician and Nursing 
Assessments 
 
Table 30 presents the statistical analysis of the TRUST ADP and it’s parameters for 
predicting MACE at 30 days according to assessor groups.  One patient in the physician 
group (0.3%), and three patients (1.1%) in the nursing group were classified as low risk 
by the ADP yet had MACE at 30 days.  There was a non-significant trend towards 
diagnostic accuracy being lower for nursing assessments with regard to sensitivity 
(99.2% vs. 96.7%) and specificity (44.6% vs. 40%), furthermore fewer patients were 
eligible for discharge (38.9% vs. 34.5%; P=0.144) when compared to physician 
assessments.  These findings are summarised graphically in Figure 22.   
As shown in Figure 23 the area under the curve (AUC) for the m-Goldman score 
(without incorporation of hs-cTnT) in predicting 30 day MACE was 0.647 (95% CI 0.594-
0.700) for physicians and 0.572 (95% CI 0.510-0.634) for nursing staff assessments.  
This difference did not reach statistical significance (P=0.09). 
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Table 30.  Diagnostic accuracy of the TRUST ADP and an m-Goldman Score of ≤1 for 
predicting MACE at 30 days according to assessor groups 
 Physician m-
Goldman Score 
≤1 
Nurse m-
Goldman 
Score ≤1  
Physician 
TRUST ADP 
Nurse TRUST 
ADP  
Number of 
Patients 
Assessed 
912 745 912 745 
Number of low 
risk patients 
with 30-day 
MACE missed 
(%) 
31/426  
(7.3) 
34/328  
(10.4) 
1/355  
(0.3) 
3/264  
(1.1) 
Sensitivity  
(95% CI) 
73.9  
(65.5-81.1) 
63.0  
(53.0-72.3) 
99.2  
(94.8-100) 
96.7  
(90.3-99.2) 
Negative 
predictive value 
(95% CI) 
92.7  
(90.4-94.7) 
89.6  
(86.8-92.2) 
99.7  
(98.3-100) 
98.9  
(96.6-99.7) 
Specificity 
(95% CI) 
49.8  
(48.5-50.9) 
45.0  
(43.6-46.3) 
44.6  
(44.0-44.8) 
40.0  
(39.1-40.3) 
Positive 
predictive value 
(95% CI) 
18.1  
(16.0-19.9) 
13.9  
(11.7-15.9) 
21.2  
(20.3-21.4) 
18.5  
(17.3-19.0) 
Negative 
Likelihood Ratio 
(95% CI) 
0.52  
(0.37-0.71) 
0.82  
(0.60-1.08) 
0.02  
(0.00-0.12) 
0.08  
(0.02-0.25) 
Positive 
Likelihood Ratio 
(95% CI) 
1.47  
(1.27-1.65) 
1.15  
(0.94-1.35) 
1.79  
(1.69-1.81) 
1.61  
(1.48-1.66) 
 
 
 
 
 
 
PhD Thesis. Dr Edward W. Carlton 
 
151 
 
Figure 22. Diagnostic accuracy of the TRUST ADP for predicting MACE at 30 Days 
according to physician and nursing assessments 
 
 
Error Bars: 95% Confidence Intervals 
Figure 23.  Receiver operating characteristic curves of the m-Goldman score (without 
incorporation of hs-cTnT analysis) according to assessor groups 
 
AUC: Area Under the Curve 
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4.9.2 Inter-Observer Reliability between Physicians and Nursing Staff 
 
Table 31 summarizes inter-observer reliability of individual components of the m-
Goldman score and those patients identified as low-risk (m-Goldman ≤1).  The degree 
of reliability varied with four components showing fair agreement, three showing 
moderate agreement and only one showing substantial agreement (though the finding 
of pain within 6 weeks of an AMI or revascularization was only present in 1.1% of the 
population).  Using the m-Goldman score alone without incorporating hs-cTnT results, 
there was fair agreement (Landis and Koch 1977) in the identification of low risk 
patients between physicians and nursing staff (kappa 0.31, 95% CI 0.24-0.38). 
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Table 31. Inter-observer reliability of the m-Goldman score between physician and 
nursing assessments 
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4.9.3 Breaking down the m-Goldman Score and its Components for the Prediction of 
MACE 
 
The occurrence of 30 day MACE according to each component of the m-Goldman score 
are shown in Table 32.  Through analysis of positive likelihood ratios to demonstrate 
the ability of each component to predict MACE, it is evident that some parts of the 
score have greater diagnostic value than others (Figure 24).  Pain the same as previous 
MI, pain not relieved by GTN, pain occurring with increasing frequency and the 
presence of hypotension all achieve statistical significance as positive predictors 
(confidence of positive likelihood ratio does not include 1.0) when assessed by 
physicians.  Whilst typical new onset chest pain at rest, pain lasting >60 minutes and 
acute shortness of breath do not achieve statistical significance.  The prevalence of 
pain within 6 weeks of a myocardial infarction or revascularisation is so low, occurring 
in only 10/912 (1.1%) of the total physician assessed population that it is difficult to 
draw any conclusions with regards to its additive value. 
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Table 32.  Occurrence of MACE at 30 Days according to each component of the m-
Goldman score 
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Figure 24.  Ability of component parts of the m-Goldman score to act as positive 
predictors of MACE  
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4.10 The Discriminatory Value of Physician Interpretation of Typicality 
of Chest Pain and the Impact of Clinical Experience 
 
   
 
 
 
912 participants had typicality of chest pain assessed by treating physicians (Figure 25).  
Of these, 114/912 (12.5%) had an AMI and 157/912 (17.2%) had angiographic 
assessment, of whom 90/157 (57.3%) had hs-cTn elevation and 67/157 (42.7%) didn’t.  
Of those patients without hs-cTn elevation assessed angiographically 31/67 (46.2%) 
had significant CAD, of whom 21 (67.7%) had percutaneous coronary intervention. 
Aim:  to establish the discriminatory value of physician interpretation of 
typicality of chest pain, in patients with a non-diagnostic ECG, considered to 
have a potential ACS, and the impact of clinical experience upon diagnostic 
accuracy, for the prediction of ACS. 
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Of typicality assessments, 227/912 (24.9%) were made by experienced ED physicians 
and 685/912 (75.1%) were made by novice ED physicians.  Table 33 summarizes 
recruited patient demographics according to physician provider group, there were no 
significant differences in clinical characteristics or outcomes (P>0.05 for all).   When 
assessed by experienced physicians a lower proportion of patients were identified as 
having typical chest pain when compared to novices (35.2% vs. 45.8%, p=0.005). 
Specific to this analysis and in order to overcome the diagnostic adjudication 
challenges associated with high-sensitivity troponin assays and small elevations in 
troponin (Mills et al. 2011) and evaluate the discriminatory ability of chest pain 
typicality in those patients without an hs-cTnT elevation who may have had 
clinically relevant CAD (Reichlin et al. 2013), a secondary diagnostic outcome 
measure for those patients assessed angiographically was included. This was the 
presence of significant CAD, either with high sensitivity troponin elevation (hs-cTnT 
≥ 14ng/L at either 0 or 6 hours) or without high-sensitivity troponin elevation (hs-
cTnT<14ng/L at presentation to ED and 6 hours later).  CAD was defined as ≥70% 
luminal diameter narrowing of at least one major coronary artery as reported on 
visual assessment by the operator. 
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Contingency tables showing the occurrence of AMI and CAD with and without hs-cTn 
elevation according to the presence or absence of typical chest pain are shown in 
Table 34.   
 
 
Figure 25.  Participant recruitment flowchart for the evaluation of chest pain 
typicality 
 
 
Experienced ED physicians:  Consultants (Fellows of 
the UK College of Emergency Medicine) or Registrars 
with at least 2 years of ED experience.   
Novice ED physicians: Senior House Officers with less 
than one years’ ED experience.   
During the study period there were 12 experienced 
physicians and 32 novice physicians undertaking 
clinical assessments. 
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Table 33.  Patient characteristics and outcome prevalence according to experienced 
and novice physician groups 
AMI: Index Acute Myocardial Infarction, CAD: Coronary Artery Disease 
 Total (N=912) Experienced 
Physicians 
(N=227) 
Novice 
Physicians 
(N=685) 
Age, yrs. (Mean/Standard Deviation) 58.0/SD 13.3 58.5/SD 12.8 57.8/SD 13.4 
Male Sex (%) 546 (59.9) 137 (60.4) 409 (59.7) 
Ethnicity (% White British) 869 (95.3) 219 (96.5) 650 (94.9) 
Risk factors N (%)    
Hypertension 505 (55.4) 126 (55.4) 379 (55.3) 
Hyperlipidemia 601 (65.9) 154 (67.8) 447 (65.3) 
Smoking Current 219 (24.0) 61 (26.9) 158 (23.1) 
Diabetes 152 (16.7) 31 (13.7) 121 (17.7) 
Family History of Coronary Artery Disease 340 (37.3) 78 (34.4) 262 (38.2) 
Medical History    
Angina 238 (26.1) 51 (22.5) 187 (27.3) 
Myocardial Infarction 194 (21.3) 42 (18.5) 152 (22.2) 
Percutaneous Coronary Intervention 173 (19.0) 40 (17.6) 133 (19.4) 
Atrial Arrhythmia 115 (12.6) 26 (11.5) 89 (13.0) 
Stroke 62 (6.8) 14 (6.2) 48 (7.0) 
Coronary Artery Bypass Graft 47 (5.2) 11 (4.8) 36 (5.3) 
Typical Chest Pain Present 394 (43.2) 80 (35.2) 314 (45.8) 
Outcomes    
Fatal/Non-fatal AMI 114 (12.5) 34 (14.9) 80 (11.6) 
Significant CAD with Troponin Elevation 64 (7.0) 19 (8.3) 45 (6.5) 
Significant CAD Without Troponin Elevation 28 (3.1) 10 (4.4) 18 (2.6) 
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Table 34.  Contingency tables showing the occurrence of AMI and significant CAD 
according to the presence of typical chest pain 
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4.10.1 Discriminatory Value of Typicality of Chest Pain 
Receiver-operating characteristic curves demonstrating the discriminatory ability of 
typicality of chest pain, assessed by all physicians in the ED, as a diagnostic tool for AMI 
and CAD without hs-cTn elevation are presented in Figure 26, together with the AUC’s 
according to provider groups for all outcomes.   When tested against the null 
hypothesis that the true AUC is 0.50, the P-value for all providers is >0.05, suggesting 
that typicality of chest pain has limited discriminatory ability in the diagnosis or 
exclusion of AMI, CAD with and without hs-cTn elevation in this cohort.   
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Figure 26.  Discriminatory ability of typicality of pain for the diagnosis AMI and 
significant CAD with and without hs-cTnT elevation 
 
AMI: Acute Myocardial Infarction, CAD: Coronary Artery Disease, AUC: Area Under the Curve 
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4.10.2 Diagnostic Accuracy and Impact of Clinical Experience 
 
Figure 27 presents the sensitivity, specificity, positive and negative likelihood ratios for 
typicality of chest pain as a diagnostic tool, when assessed by experienced and novice 
physicians.  Specificity of the finding of typical chest pain for the diagnosis of AMI was 
significantly higher for experienced physicians at 65.8% (95%CI 63.1-68.7) compared to 
novices 55.4% (53.9-56.8).  There was also a non-significant trend towards increasing 
test specificity when typicality was assessed by experienced physicians for CAD 
without hs-cTn elevation (66.7% vs. 46.7%).  There was no significant difference in test 
sensitivity for any outcome measure.  Confidence intervals for both positive and 
negative likelihood ratios across all provider groups and all outcomes include 1.0, 
suggesting that in this patient cohort, typicality of chest pain has little positive or 
negative value in the prediction of AMI, or CAD either with or without hs-cTn 
elevation. 
 
 
 
 
 
 
 
 
 
PhD Thesis. Dr Edward W. Carlton 
 
165 
 
Figure 27.  Predictive value and likelihood ratios of typicality of chest pain for AMI 
and significant CAD with and without hs-cTnT elevation 
 
Error Bars: 95% Confidence Intervals 
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4.11 Patient Perspectives on Early Discharge after Rapid Rule-Out 
Testing 
 
739 patients were requested to complete the survey, 278 (37.6%) responded.  Mean 
age 56.6 years (SD 13.4), 263/278 (94.6%) White British, mean length of stay 15.5 
hours (SD 6.6), 6/278 (2.2%) had MACE at 30 days. There was a greater proportion of 
female responders compared to non-responders (49.6% vs 37.5%, P=0.001), otherwise 
groups were matched in age, cardiac risk factors, length of stay and the presence of 
MACE (P>0.05 for all).  
Table 35 summarises the overall questionnaire results, with satisfaction for the 
concept of safe early discharge represented in Figure 28.  197/278 (70.8%) would have 
been satisfied or very satisfied with early discharge directly from the ED, with 36/278 
(13.0%) expressing dissatisfaction with a proposed rapid rule-out protocol.  However, 
249/277 (89.9%) of responders were reassured by admission to the ward and 112/273 
(41.0%) felt they could not have spent any less time in hospital.  
 
 
 
 
 
Aim: To investigate patient perspectives on whether early 
discharge after a rapid rule-out biomarker testing is 
acceptable in a low-risk short-stay suspected ACS population. 
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Table 35.  Summary of written questionnaire results 
 
 Strongly 
Disagree  
N (%) 
Disagree 
 
N (%) 
Neither 
Agree or 
Disagree 
N (%) 
Agree 
 
N (%) 
Strongly 
Agree 
N (%) 
I could have spent less time in hospital 26 
(9.5) 
86  
(31.5) 
102  
(37.4) 
52  
(19.0) 
7  
(2.6) 
I felt reassured when I was admitted to the ward 
for a period of observation 
4  
(1.4) 
3  
(1.1) 
21  
(7.6) 
128  
(46.2) 
121 
(43.7) 
 Very 
Dissatisfi
ed 
 
N (%) 
Dissatisfi
ed 
 
 
N (%) 
Neither 
Satisfied or 
Dissatisfie
d 
N (%) 
Satisfied 
 
 
N (%) 
Very 
Satisfied 
 
 
N (%) 
If you could have been discharged earlier, 
directly from the Emergency Department, with 
the same degree of safety, how satisfied with 
your treatment would you have been? 
11  
(4.0) 
25 
 (9.0) 
45  
(16.2) 
59 
(21.2) 
138  
(49.6) 
 
Figure 28.  Patient satisfaction with the concept of a proposed early discharge 
decision  
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Through binary logistic regression analysis (Table 36) potential predictors of 
dissatisfaction with early discharge were analysed, these were sex, age, severity and 
type of pain at presentation, previous ischaemic heart disease, family history; none 
were found to be significant (95% confidence interval for the odds ratio of all 
predictors includes 1.0). 
 
Table 36. Binary logistic regression analysis of potential predictors of dissatisfaction 
with early discharge 
Predictor Variable Odds Ratio 95% Confidence Interval 
of Odds Ratio 
Sex 1.03 0.48-2.17 
Age 1.02 0.99-1.06 
Pain Score at Presentation  1.03 0.86-1.22 
Pain Score on Discharge 
from ED 
1.01 0.82-1.24 
Typical Ischaemic Chest 
Pain 
0.81 0.31-2.12 
Previous Ischaemic Heart 
Disease 
0.59 0.18-1.92 
Family History of 
Ischaemic Heart Disease 
1.01 0.46-2.21 
Heart Rate at Presentation 1.01 0.99-1.04 
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4.12 Study Population Outcomes and Follow-up Testing 
 
4.12.1  Discharge Diagnoses in Patients without MACE 
 
642/960 (66.9%) of patients received a discharge diagnosis of a benign cause of chest 
pain (Figure 30).  Data with regards to specific benign causes of chest pain were not 
recorded, however, it was noted that patients classified as having benign chest pain 
were often described by treating physicians as “atypical,” “musculoskeletal,” “non-
cardiac” and “gastro-oesophageal reflux.”  
 
44/960 (4.5%) of patients had a diagnosis of unstable angina at discharge from hospital 
but did not fulfil the criteria for MACE, of these 37 had angiographic assessment 
(Figure 30) within 30 days and 9 required elective percutaneous coronary intervention.  
26/960 (2.7%) had a prior history of angina or ischaemic heart disease but after 
evaluation this presentation was not thought to be due to unstable angina (stable 
coronary artery disease). 
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Figure 29.  Discharge diagnosis of patients without MACE 
 
 
* Important/Treatable non-ACS cardiac and non-cardiac diagnoses are summarized in Table 37 
(below) 
 
Figure 30. Angiographic outcome of patients diagnosed with unstable angina at 
hospital discharge 
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Of the total study population, 113/960 (11.8%) patients had an important treatable 
non-ACS cause for their chest pain presentation identified, these are summarized in 
Table 37. 
 
Table 37.  Frequency of Important/Treatable Non-Acute Coronary Syndrome Cardiac 
and Non-Cardiac Discharge Diagnoses Identified as Potential Cause of Chest Pain 
Non-ACS Cardiac Diagnosis Frequency  Non-Cardiac Diagnosis Frequency 
Atrial Tachyarrhythmia (Atrial 
Fibrillation/Supraventricular 
Tachycardia) 
2.6% Sepsis/hypovolaemia 1.6% 
Bradyarrhythmia 0.4% Pneumonia 1.6% 
Hypertrophic Cardiomyopathy 0.1% Respiratory Failure 0.3% 
Takotsubo’s Cardiomyopathy 0.1% Biliary Pathology 1.1% 
Severe Valvular Disease 0.3% Stroke 0.3% 
Myo/pericarditis 2.2% Pulmonary Embolism 0.4% 
Coronary Spasm 0.2% Lung Cancer 0.1% 
Total Frequency 5.4% Total Frequency 6.3% 
Non-ACS: Non-Acute Coronary Syndrome 
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4.12.2 Confirmatory Testing 
 
 
After inpatient admission for 6 hour troponin testing, current clinical practice dictates 
a proportion of patients will be referred for further confirmatory testing, in order to 
identify clinically relevant ischaemia in the absence of troponin elevations.  For this 
analysis, significant coronary artery disease (CAD), defined as ≥70% luminal diameter 
narrowing of at least one major coronary artery as reported on visual assessment by 
the operator, and percutaneous coronary intervention were the outcomes of interest 
(true positive tests). During the study period, treating physicians had available exercise 
tolerance testing (ETT), stress nucleotide myocardial perfusion imaging (MIBI), stress 
echocardiography (SECHO), CT coronary angiography (CTCA) and invasive angiography 
as options for confirmatory testing.   
 
Of patients identified as low risk by the TRUST ADP, 152/382 (39.8%) had confirmatory 
testing within 30 days of attendance with chest pain.  No patient was referred directly 
for invasive angiography without first undergoing a non-invasive test.   A total of 205 
confirmatory tests were performed in 152 patients with no additional MACE detected, 
5 additional patients were identified as having significant CAD, and 3 of these required 
Due to the observational nature of the TRUST study it 
is important to recognise that many patients 
identified as low risk by the TRUST ADP had 
confirmatory cardiac testing from exercise tolerance 
testing to advanced imaging. This has important 
implications in applying the ADP in clinical practice 
and the need for follow-up.  This section summarises 
to follow-up undertaken during the study period. 
PhD Thesis. Dr Edward W. Carlton 
 
173 
 
outpatient elective revascularization.  Therefore, confirmatory testing had a 2% pick-
up rate of significant CAD and 1.4% for percutaneous coronary intervention in the 
TRUST ADP low risk group.  Given the prevalence of coronary heart disease in the UK 
population which, in 2006, was 6.5% across all age groups (Townsend et al. 2012), the 
utility of confirmatory testing in TRUST ADP low risk patients may be limited. Figure 31 
summarises the outcome of confirmatory test results in the TRUST ADP low risk group.   
 
Figure 31.  The outcome of further testing in patients identified as low risk by the 
TRUST ADP 
 
A test was described as “positive” if a positive test led to detection significant CAD at invasive 
angiography (reference test); ETT: Exercise Tolerance Test, MIBI: Stress Nucleotide Myocardial Perfusion 
Imaging, SECHO: Stress Echocardiography, CTCA: Computed Tomography Coronary Angiography 
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4.12.3 Non-Recruited Patients 
 
Due to lack of research staff availability 132 patients who fulfilled eligibility criteria 
were discharged prior to providing written, informed consent.  Simple demographic 
data and m-Goldman scores for these patients were obtained, with ethics board 
approval, and compared with recruited patients (chi-squared) to ensure no significant 
differences between consenting and non-consenting groups existed.  Significance 
testing for this analysis is summarized in Table 38.  There were no statistically 
significant differences in m-Goldman scores and demographics between recruited and 
non-recruited patients, except for dyslipidaemia which was slightly more prevalent in 
the recruited group (66.1% vs 56.3% p=0.03).  This is likely to represent a spurious 
result of multiple significance testing (Bland and Altman, 1995) and is unlikely to have 
implications in the interpretation of study results. 
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Table 38.  Comparison of demographics and m-Goldman scores between recruited 
and non-recruited patients  
Demographic Significance when tested 
against consenting patients 
(p value) 
Age, yrs. (Mean±Standard Deviation) 0.332 
Sex  0.127 
Risk factors N (%)  
Hypertension 0.113 
Diabetes 0.097 
Dyslipidaemia 0.030 
Smoking Current 0.368 
Family History of Coronary Artery Disease 0.240 
Medical History  
Angina 0.591 
Myocardial Infarction 0.908 
Percutaneous Coronary Intervention 0.399 
Sum of m-Goldman Score  0.182 
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Chapter 5. 
Discussion 
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5.1 The Diagnostic Accuracy of the TRUST ADP and Improving 
Efficiency 
 
This study demonstrates that the TRUST ADP for suspected ACS may successfully 
identify 40% of patients as low-risk after just a single hs-cTnT taken at presentation to 
the ED, with a sensitivity of 99.0% (95% CI 93.7-99.9) (Table 22, Page 125).   
These results suggest that the introduction of this ADP has the potential to reduce the 
length-of-stay for low risk patients (demonstrated as 14 hours in this study) after a 
single laboratory-based troponin and avoid the necessity for two separate blood 
draws.  Uptake of this protocol may have significant benefits for healthcare services 
worldwide by reducing hospital admission rates, ED overcrowding, duplication of staff 
time and resource use.  Furthermore, by using ED physicians to carry out risk-
stratification and real-time troponin sampling with 24-hour recruitment it has been 
demonstrated that this ADP is truly applicable.   
Prior studies investigating high-sensitivity troponin testing have relied on the use of 
frozen serum samples.  As a result few studies have been able to illustrate the 
temporal impact a rapid discharge strategy incorporating central laboratory high-
sensitivity troponin testing taken at presentation may have.  As shown in Figure 12, 
Page 129, through real-time troponin testing the TRUST study demonstrates that even 
though laboratory processing times are quoted as 18 minutes (NICE 2014), in a real-
world clinical environment, results will not be available until at least 2-hours after 
arrival.  This may explain why strategies that rely on two blood samples taken 2-hours 
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apart may have little impact on patient length of stay until 6-hours after patient arrival 
(Figure 6, page 67) (Than et al. 2014a).   
 
 
 
 
 
 
 
 
 
 
 
 
The TRUST ADP, which incorporates a 
structured risk-assessment and single 
presentation hs-cTnT blood draw, has the 
potential to allow early discharge in 40% of 
patients with suspected ACS. 
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5.2 High-Sensitivity Troponin Cut-off Values  
The cut-off value for hs-cTnT used in the TRUST ADP of <14ng/L (99th percentile value) 
was chosen prior to study commencement due to international guideline bodies 
suggesting this cut-off value for clinical use despite limited evidence for this (Thygesen 
et al. 2012b).  As shown in Table 22, Page 125, in common with previous studies, the 
99th percentile cut-off value has limited value in isolation as a diagnostic tool at 
presentation, but has the potential to be an effective cut-off for use in combination 
with a clinical risk score (m-Goldman). 
It must be noted that the 99th percentile value of 14ng/L was derived from healthy 
blood donors, while a population presenting to hospital with chest pain will almost 
certainly differ from this in both age and comorbidities.  One study of patients aged 
greater than 70 who did not have a final diagnosis of AMI, 51% had hs-cTnT levels 
above the 99th percentile (Reiter et al. 2011), while 52% of patients admitted to 
hospital without a cardiac diagnosis may have hs-cTnT levels above the 99th percentile 
value (Iversen et al. 2013).  The decreased specificity of hs-cTn assays remains a 
limitation to their use and further research is required to establish age, sex and 
potentially race-specific cut-off values.   
As a confirmation that this is a very active area on the literature, in early 2015, Zhelev 
and colleagues published a meta-analysis of the diagnostic accuracy of a single 
baseline measurement of high-sensitivity troponin T (hs-cTnT) for the diagnosis of AMI 
in the ED.  This work complemented the recent NICE guidance (NICE 2014) on the use 
of high-sensitivity assays and highlights the potential benefits of their introduction into 
clinical practice.  However, the results of the TRUST study demonstrate that the 
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author’s assertion that an initially undetectable hs-cTnT result may be used as a 
diagnostic strategy to reduce the number of patients undergoing further testing and 
therefore relieve pressure on EDs- should be treated with caution.  The reasons for this 
are two-fold: 
Firstly, the single outcome measure used in the Zhelev meta-analysis (AMI) and lack of 
incorporation of urgent revascularisation as an endpoint failed to realise and represent 
the full spectrum of ACS.  As a result the clinical application of the undetectable hs-
cTnT strategy may be limited.  As demonstrated by the TRUST study, in the context of 
undetectable troponin levels clinicians may be encouraged to disregard important risk 
stratification factors gathered from clinical evaluation. Revascularisation as an 
endpoint is important as it has been demonstrated patients with unstable angina with 
a change in hs-cTnT of as little as 2ng/L in the first hour of presentation to the ED still 
have up to a 16% risk of AMI and death at 30 days (Reichlin et al. 2013), and this may 
explain why the sensitivity of undetectable hs-cTnT, when urgent revascularisation is 
included as an endpoint may be as low as 90%.     
Secondly, the authors of this meta-analysis point out that reducing the cut-off value of 
high-sensitivity troponin T from 14ng/L to 5ng/L, may be of value helping physicians 
rule out AMI early in the triage process.  However, the test specificity is reduced from 
77.1% to 42.4%.  While the authors acknowledge that this “threshold effect” is a trade-
off, the cost-benefit implications of this cannot be ignored.  Evidence now confirms 
that rule-out tests with poor specificity lead to increased downstream costs and 
increasing need for time-consuming additional confirmatory tests.  For example, one 
study demonstrated that a rapid rule-out biomarker strategy for suspected ACS 
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achieved a 20% reduction in hospital admissions (Collinson et al. 2012). However, this 
was countered by an increase in coronary care bed use and outpatient clinic follow-ups 
- paradoxically increasing overall costs by approximately £200 per patient (Fitzgerald et 
al. 2011).  
When comparing the TRUST ADP to strategies using undetectable hs-cTnT in Figure 14, 
Page 133, more patients are eligible for early discharge with lower false-positive rates, 
suggesting this approach has greater clinical utility.  Furthermore, by incorporating 
clinical risk stratification, the TRUST ADP has improved accuracy in identifying those 
who require urgent revascularization.  With the short-comings of an undetectable hs-
cTnT rule-out strategy in mind, the TRUST ADP becomes an inviting alternative rule-out 
strategy by allowing the detection of patients with a requirement for revascularization 
and lowering the false positive rates and identifying a greater proportion of low risk 
patients.   
 
 
 
 
 
 
The TRUST ADP has superior clinical utility 
when compared to undetectable hs-cTnT 
strategies.  Future research should focus 
on methodologies that incorporate clinical 
assessment with high-sensitivity troponin 
testing rather than troponin testing alone. 
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5.3 Using an Alternative High-Sensitivity Troponin Assay 
Whilst the primary aim of the TRUST study was to test the diagnostic performance of 
an ADP which incorporated the Roche hs-cTnT, it is important to acknowledge that 
another commercially available high-sensitivity troponin assay (Abbott hs-cTnI) is 
available (NICE 2014).  Therefore in order to establish the general applicability of the 
TRUST ADP, it was necessary to assess the performance of this assay in the TRUST 
study cohort and evaluate hs-cTnI in comparison to hs-cTnT. 
Although Figure 16, Page 136, shows that the area under the curve for each high-
sensitivity troponin assay does not differ significantly between Roche hs-cTnT and 
Abbott hs-cTnI, this analysis highlights important differences in accuracy for the 
detection of AMI that may have important clinical implications.  It must be stated that 
any comparison of hs-cTnT with hs-cTnI in this study is limited by the fact that 
outcome adjudication for AMI was made using the Roche hs-cTnT assay that was in 
clinical use at the time of the study.  Despite this, the finding that sensitivity of hs-cTnI 
at presentation (including in those presenting early after symptom onset) for the 
diagnosis of AMI is lower than that of hs-cTnT at the 99th percentile value is consistent 
with the findings of Aldous and colleagues (2011b) who re-adjudicated AMI using each 
individual assay.  However, the finding that hs-cTnI only achieves a sensitivity of 95.5% 
for AMI when the level of detection cut-off is used (Figure 17, Page 137) is in contrast 
to the only available comparative analysis, where this assay achieved 100% sensitivity 
at this cut-off (Rubini Giminez et al. 2013).  The reasons for this may be twofold: 
Firstly, the cases of AMI missed by the hs-cTnI may have been false positive cases 
adjudicated using the hs-cTnT assay.  This may apply to two of the three missed AMI 
cases, in whom there was no other evidence of myocardial infarction other than a mild 
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delta change in hs-cTnT.  However, this is unlikely to be the case in the third, in which 
there was angiographic evidence of severe left main stem disease and is therefore 
likely to be a genuine false negative not detected with the hs-cTnI assay. 
Secondly, given that the number of patients with undetectable levels of Abbott hs-cTnI 
in the TRUST cohort is much greater than those in the study by (Rubini Giminez et al. 
2013) at nearly 40% vs 10%, the issue of batch variation cannot be ignored.  Although 
one simple explanation for this may be differences in the demographics of the two 
study populations (e.g. Rubini Giminez recruited high risk patients with abnormal 
ECGs) batch variation may be especially important at low levels of detection at which 
there is decreased analytical reproducibility and may also lead to a greater proportion 
of patients with undetectable troponin levels. 
A further consideration in the interpretation of hs-cTnI results within this analysis is 
the potential effect of long-term storage and freezing upon the stability of cardiac 
troponin I.  Whilst hs-cTnT testing was carried out immediately after sampling, hs-cTnI 
analysis was carried out after serum samples had been frozen at -80 degrees 
centigrade for a period of 12 months.  There is some data to suggest that prolonged 
freezing of >12 months may falsely lower troponin results using third generation 
assays (Basit el al. 2007).  Although changes are likely to be very small and therefore 
have minimal clinical impact, this effect may be of great importance when using level 
of detection strategies. However, the consequences of prolonged storage of serum on 
high-sensitivity troponin testing remains unclear. 
One of the strengths of the TRUST study is the outcome adjudication using a high-
sensitivity assay in conjunction with available clinical data, to ensure even those 
patients with small AMIs could be identified.  Therefore, this variation in performance 
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between assays is also likely to be population-specific and is of great importance to 
clinicians who may not be able to select, or may not be aware, which assay is used in 
their institution.   
 
 
 
 
 
 
 
 
 
 
 
Variations in diagnostic accuracy exist 
between the two commercially available 
high-sensitivity troponin assays when taken 
at presentation to the ED.  This has 
implications in the clinical use of rapid rule-
out protocols. 
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5.4 Other Accelerated Diagnostic Protocols 
No previous study has integrated presentation high-sensitivity troponin assay results 
with multiple established risk scores to provide a diagnostic comparison.  This analysis 
has demonstrated that it may be possible to identify over 30% at low risk of AMI with a 
miss-rate of <0.5% (NPV >95.5%) after a single blood draw (Figure 20, Page 146). These 
findings support the use of formal risk stratification in combination high-sensitivity 
troponin testing, but also highlight important variation in the performance of existing 
risk scores, together with performance variation in hs-cTn assays which will have 
implications in the introduction of rapid rule-out protocols. 
While the focus of such pathways should be on safety, and a number of pathways 
achieved 100% NPV (albeit with wide confidence intervals), in reality there will always 
be a small percentage of patients with ACS that are not identified during routine 
clinical assessment (Pope et al. 2000).  Although evidence is limited regarding which 
miss-rate is acceptable, a miss-rate of 0.5% (equating to an NPV of >99.5%) was 
chosen, which appears to be acceptable to the majority of ED physicians (Than et al. 
2012b).  By using a clinically applicable miss-rate, together with the necessity to 
identify over 30% of patients as low-risk, this analysis has demonstrated that the 
TRUST ADP (with hs-cTnT) is the most clinically applicable single blood draw rule-out 
strategy in this cohort. 
Risk scores such as TIMI and GRACE were originally developed as ‘rule-in’ tools in 
patients with confirmed ACS and as such their use in a low risk cohort may be counter-
intuitive.  Both fail to take into account patient history, are influenced heavily by age or 
the presence of risk factors for chronic coronary disease, which may not be as 
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predictive for ACS as previously thought (Body et al. 2008).  In fact, despite guideline 
recommendations for its use (NICE 2010), previous evidence suggests that the GRACE 
score may be little better than age alone as a predictor of MACE at 30-days in a low-
risk ED cohort (Goodacre et al. 2012).   Results shown in Figure 19, Page 144, confirm 
that even at very low score cut-offs the diagnostic performance of GRACE as a rule-out 
tool in combination with high-sensitivity troponin is poor. 
In comparison with the largest and most independent validation of the HEART score 
(Six et al. 2013), results from this cohort are similar, with a missed event rate of 
approximately 1.5% and 30% eligible for early discharge, using a cut-off of ≤3.  The 
previous validation by Six et al. (2013) used 3rd generation rather than high-sensitivity 
troponin, therefore it does not appear that use of a high-sensitivity assay improves the 
diagnostic accuracy of the HEART score as a rule-out tool.  In contrast with the 
conclusions of the authors of the previous validation of the HEART score (Six et al. 
2013), who suggested clinical use of the score, given the low event rates in the low risk 
group, it may be argued that other scores perform better in this regard whilst 
maintaining a similar, if not improved diagnostic accuracy.    
This analysis also confirms that the Vancouver Chest pain rule has excellent diagnostic 
accuracy for the rule-out of AMI, and it is the only risk score to achieve 100% NPV 
using the Abbott hs-cTnI assay (Figure 20, Page 146).  This supports the findings of a 
similar external validation study (Cullen et al. 2014a).  However, the low proportion of 
patients (approximately 15%) identified as suitable for early discharge may limit clinical 
applicability in comparison to other strategies tested here. 
Ideally, the single hs-cTn rule-out strategies tested in this cohort should be directly 
compared in a diagnostic randomized controlled trial.  The data presented here may be 
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useful in directing which head-to-head comparisons should be made.  However, with 
ever-increasing pressure on emergency departments such controlled trials may be one 
step too far in the trail of evidence.  At some point, pragmatic decisions about using 
these single hs-cTn rule-out strategies in practice must be made.  This evidence 
suggests that when this does occur clinicians must take into account local population 
factors, assay availability and pathways must be subject to continuous audit and 
evaluation to ensure safety. 
 
  
 
 
 
 
 
 
 
 
It may be possible to identify over 30% of low-
risk patients with an NPV of >99.5% for the 
diagnosis of AMI using an hs-cTn result taken 
at presentation to the ED, in combination with 
established risk scores. There is important 
variation in the performance of risk scores and 
hs-cTn assays which has implications in the 
clinical use of rapid rule-out protocols. 
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5.5 Nursing Staff in Risk Assessment 
This analysis (Table 30, Page 150) demonstrates that the diagnostic accuracy of ED 
nursing staff risk assessment, using the TRUST ADP to identify low-risk patients with 
suspected ACS, is slightly lower than that of ED physicians.  However, with only a 1.1% 
miss-rate for MACE and fair inter-observer reliability of nursing and physician 
assessments in the identification of low-risk patients, the future role of nursing staff in 
rapid rule-out pathways holds promise.    
This analysis breaks new ground in investigating the role of nursing staff in the 
assessment of suspected ACS and is the first to compare the use of an ADP between 
physician and nursing staff.  The results suggest that in this setting, ED nursing staff 
with no specific training in the assessment of suspected cardiac chest pain are not yet 
able to have discharge decision making authority in this patient group.  However, with 
tailored educational interventions it may be possible for the diagnostic accuracy of 
nursing staff to be improved.  Studies investigating simple training interventions, such 
as workshops, in non-specialist ED nursing staff have consistently demonstrated 
improved correlation between physician and nurse ordering, as well as more accurate 
test interpretation (Seaberg and MacLeod 1998, Zhang and Hsu 2013 and Varvaroussis 
et al. 2014).  As such, further research is required which incorporates formal training in 
chest pain assessment for nursing staff, and focuses on the identification of low risk 
patients who may be suitable for early discharge.        
This analysis is also important in highlighting inter-observer reliability of chest pain 
assessment (Table 31, Page 153), which remains under-reported in the literature.  The 
m-Goldman risk score uses elements of chest pain history to identify those patients 
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without unstable features, it therefore requires some clinical judgment and 
subjectivity in interpretation.   Although nursing staff received no specific training in 
the use of the m-Goldman score, all nursing participants were experienced in the 
primary assessment of ED patients with chest pain.  Therefore the only fair agreement 
between assessors may be seen as unexpected.  This finding will not be limited to the 
TRUST ADP, as other commonly used risk scores also incorporate elements which 
require clinical judgment.  Examples include the TIMI score (Antman et al. 2000), 
HEART Score (Backus et al. 2013) and Vancouver chest pain rule (Cullen et al. 2014a).   
 
 
 
 
 
 
 
 
 
 
 
The diagnostic accuracy of ED nursing staff risk 
assessment, using the TRUST ADP to identify low-risk 
patients with suspected ACS, is lower than that of ED 
physicians.  However, with only a 1.1% miss-rate for 
MACE and fair inter-observer reliability of nursing and 
physician assessments in the identification of low-risk 
patients, the future role of nursing staff in rapid rule-out 
pathways holds promise. 
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5.6 Typicality of Chest Pain 
The terms “typical” and “atypical” chest pain are commonly used in the assessment of 
suspected ACS and stem from historical teachings.  Physicians rely upon chest pain 
history to make management decisions in patients with ACS where the diagnosis is not 
immediately apparent through ECG and troponin testing.  The results presented in 
Figure 26, Page 163, show that in emergency patients considered to have a potential 
ACS with a non-diagnostic ECG and without knowledge of troponin testing, typicality of 
chest pain is of limited discriminatory value when assessed subjectively by treating 
physicians.  Diagnostic accuracy for the rule-in of AMI and significant CAD without 
troponin elevation may be improved with greater clinical experience but this finding is 
likely to have limited clinical applicability. 
Chest pain history is embedded in medical teaching, with Heberden (Silverman, 1987) 
in 1768 providing the first description of ischemic chest pain: “a painful sensation in 
the breast accompanied by a strangling sensation, anxiety, and occasional radiation of 
pain to the left arm.”   This description has barely evolved over three centuries of 
medical practice and contains the features commonly referred to as “typical” cardiac 
chest pain.  Interpretation of whether chest pain is typical or atypical is subjective and 
influenced by cognitive biases, which in turn may influenced by clinical context and 
experience (Elstein and Schwartz, 2002).     
It is increasingly evident that unstructured clinical assessment or ‘gestalt’ is important 
in the risk stratification of patient’s chest pain (Kline and Stubblefield 2013 and Body et 
al. 2014b).  Interpretation of whether chest pain is typical or atypical is subjective and 
therefore influenced by cognitive biases, which in turn may influenced by clinical 
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context and clinical experience (Elstein and Schwartz, 2002).  Studies investigating the 
diagnostic value of chest pain symptoms have, in the main, used data collected by 
research staff to analyze individual components of the chest pain history and have 
therefore failed to take into account this subjective assessment (Chun and McGee 
2004, Swap and Nagurney 2005, Body et al. 2010, Greenslade et al. 2012 and Rubini 
Gimenez et al. 2014).  This may have unseen influence on trial outcomes and affect the 
clinical applicability of results.  Where studies have evaluated these subjective findings 
they are either in a context that cannot be applied to the acute situation e.g. 
outpatients; where the prevalence and perceived risk of disease may be lower (Pryor 
et al. 1993) or have failed to take into account clinical experience (Hess et al. 2012a).  
The failure of previous studies to take into account the cognitive and contextual 
influences on clinical assessment may have unseen influence on trial outcomes and 
affect the clinical applicability of results (Hajjaj et al. 2010).   
Physicians are taught, as students, to take a meticulous history and perform a skilled 
examination to make a provisional diagnosis and initiate a management plan.  In 
practice however, physicians may intuitively adopt a Bayesian approach to diagnosis, 
making an immediate diagnosis based on probabilities and then adjust the 
probabilities as more information becomes available (Sackett et al. 2011).  Such an 
approach will be influenced by context and clinical experience (Elstein and Schwartz 
2002).  The importance of pre-test probability assessment becomes even greater in the 
era of high-sensitivity troponin assays.  Until recently, contemporary cardiac troponin 
assays could be used reliably to identify those patients with a non-ischemic ECG who 
were at high risk for AMI and adverse events with low false positive rates (Panju et al. 
1998).  However, the development of high-sensitivity cardiac troponin assays, with 
PhD Thesis. Dr Edward W. Carlton 
 
192 
 
high precision at the 99th percentile clinical cut point and which can detect troponin in 
over 50% of apparently illness-free individuals (Korley and Jaffe 2013), has highlighted 
the problems around binary positive and negative interpretation of results.  The 
potential for multiple acute conditions to cause elevations in hs-cTn (Newby et al. 
2012), necessitates improved estimates of pre-test probability to allow improved 
management decisions based on elevated hs-cTn results.  These results suggest that 
typicality of chest pain may be of limited use in this regard.   
With the advent of high-sensitivity assays, there was hope that in clinical practice, their 
use may make the diagnosis of unstable angina obsolete (Twerenbold et al. 2012).  By 
using hs-cTn to adjudicate the primary endpoint (AMI) and confirm the findings in a 
subset of patients who have undergone angiographic assessment two important 
findings have been demonstrated.  Firstly, almost half of patients with acute chest pain 
have angiographically significant disease in the absence of troponin elevations, and a 
significant proportion of these require intervention.  Secondly, in these patients, whom 
treating physicians most rely on the discriminatory value of the chest pain history, 
typicality of chest pain may be of limited use.  Therefore the focus of clinical 
assessment must be on the application of risk scores, such as m-Goldman, which 
incorporate multiple variables from the history, ECG, observations and examination, to 
accurately risk stratify patients with suspected ACS, rather than using chest pain 
history alone.  
It is important to recognize that this analysis included only patients with chest pain and 
a potential ACS with a non-diagnostic ECG who were admitted to a ward for delayed 
biomarker testing.  As a result, the treating clinician had already used their clinical 
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judgment to identify patients with chest pain in whom there was a high index of 
suspicion for ACS and therefore required further inpatient evaluation.  Those patients 
with diagnostic ECGs and those discharged directly from the ED with “non-concerning” 
histories were, as a result, intentionally excluded from analysis.  Although this 
population may therefore be subject to significant selection bias, the analysis has 
intentionally focused on a cohort of patients that provide the greatest diagnostic 
challenge for acute physicians on a day-to-day basis.  While it is likely that the 
discriminatory value of typicality of chest pain would be improved if those patients 
with clinically evident ACS had been recruited for analysis, by excluding those patients 
in whom there was no diagnostic uncertainty this has resulted in a novel insight into an 
everyday clinical problem. 
 
 
 
 
 
 
 
Physician interpretation of ‘typicality of chest pain’ 
is of limited discriminatory value in patients being 
assessed for potential ACS, in the context of a non-
diagnostic ECG. Greater clinical experience improves 
accuracy as a rule-in tool for AMI but this does not 
improve overall discriminatory ability. 
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5.7 Patient Perspectives on Early Discharge after Rapid Rule-Out 
Testing 
It is evident from the results presented in Figure 28, Page 167, that approximately 10% 
of patients would be dissatisfied with early discharge after rapid rule-out testing, and 
in Table 36, Page 168, that no demographic or clinical factors can be used to predict 
dissatisfaction (although the study may have been underpowered to detect this). 
Strategies are needed that improve patient information and incorporate patient 
opinion with discharge decision-making.  A recent study by Hess and colleagues (Hess 
et al. 2012b), demonstrated that when patients with acute chest pain are informed 
and involved in decisions, they are less likely to want to be admitted to hospital.  Yet, 
patient decision aids that describe options and give personalised risk information are 
rarely, if ever, used in clinical practice.  Barriers to adoption of decision aids into 
clinical practice include concerns about time taken to make decisions and lack of 
interest amongst patients (Gravel et al. 2006).  However, with national health policy 
(Department of Health 2012) and cardiac specialty (Brindis and Spertus 2010) 
initiatives incentivising shared decision-making, these barriers must be overcome.  
With the advent of rapid rule-out chest pain protocols shared decision-making with 
patients is feasible (Hess et al. 2012b), however, this analysis demonstrates that there 
may be implications in matching resource use with some patients’ preferences. 
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A small proportion of patients may be dissatisfied with 
rapid rule-out strategies. Within the development of 
rapid rule-out chest patient protocols, future research 
should incorporate the concept of shared patient-
clinician decision-making. 
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5.8 The Need for Confirmatory Testing in TRUST ADP Low Risk Patients 
Due to the observational nature of the TRUST study it is important to recognize that 
40% of patients identified as low-risk by the TRUST ADP had confirmatory cardiac 
testing. This has important implications in applying the TRUST ADP in clinical practice 
and the rationalizing the need for outpatient follow-up.   
The results presented in Figure 31, Page 173 demonstrate that the diagnostic yield 
from advanced testing in this cohort was extremely low, with no additional MACE 
detected and a 1.4% yield for CAD requiring intervention.  This brings into question the 
need for confirmatory testing in TRUST ADP low-risk patients.  American Heart 
Association guidelines (2010) state that “the role of confirmatory testing as part of an 
ADP [sic] is to further minimize the likelihood of ACS to a level so low that discharge is 
safe.”  Therefore questioning the need for confirmatory testing is provocative, 
however, results from our analysis are strikingly similar to those of Hermann et al. 
(2013) who demonstrated a diagnostic yield from confirmatory testing for obstructive 
coronary artery disease of <1% in low-risk ED patients with chest pain.  There is also 
increasing recognition that biomarker testing alone may identify patients safe for 
discharge with very low adverse event rates (Scheuermeyer et al. 2012 and Redberg 
2012), making further risk-stratification attempts redundant.  Confirmatory testing is 
also not without risk, with potential harms including radiation exposure, false-positive 
tests (4.9% in this cohort), contrast-induced nephropathy and resource utilization 
(Pauker and Kassirer, 1980).  It may therefore be time to question the need for 
confirmatory testing in this already low-risk patient group and the approach of 
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discharge without secondary testing should be done through a rigorously designed 
randomized controlled trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The role of confirmatory testing in TRUST ADP low-
risk patients may be limited.  This limited testing 
strategy requires evaluation as part of a rigorously 
designed randomised controlled trial. 
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Chapter 6. 
Limitations 
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6.1 Diagnostic Accuracy 
 
The fundamental barrier to implementation of the TRUST ADP into clinical practice is 
the lower limit of the 95% confidence intervals (CI) of the sensitivity for the diagnosis 
of MACE.  This extends down to 93.7% (Table 22, Page 125), which has important 
prognostic implications for patients and medicolegal implications for clinicians.  The 
95% CI can be used to estimate the likelihood of a type II (false negative) statistical 
error, and is determined by the sample size.  The relatively wide CIs therefore suggest 
that either the miss-rate for MACE may be higher than suggested or the study is not 
adequately powered due to deficiencies in the sample size.  Whilst the number of 
patients recruited is approaching the required number from the initial sample size 
calculation, this calculation made the assumption that no adverse events would occur 
in the TRUST ADP low-risk group, which in retrospect was erroneous.  The TRUST ADP 
must therefore be prospectively validated in large independent populations prior to 
clinical implementation.  
 
 
 
 
The 95% confidence interval is a 
range of values around an 
estimate that have a 95% 
probability of encompassing the 
‘‘true’’ value of that estimate. 
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6.2 Study Design 
The TRUST study is a single centre diagnostic observational study which analysed the 
performance of an ADP/Clinical decision rule.  Using the Oxford Centre for Evidenced-
based medicine (2009) classification (Table 39) this is a Level 1b study.   
Despite achieving Level 1b, it may be suggested, that a multicenter randomized 
diagnostic controlled trial (RCT) design would have offered a more appropriate 
evaluation of the TRUST ADP. 
Publication of RCTs which evaluate diagnostic interventions is very rare (Rodger et al. 
2012) and the reasons for this are likely to be due to the increased resources required-
as is the case with the TRUST study; together with uncertainty surrounding the safety 
of new diagnostic tests-the principle of clinical equipoise (Freedman 1987).  Despite 
this it has been suggested that diagnostic RCT’s are critical in the evaluation of novel 
diagnostic techniques in the presence of standard care (Rodger et al. 2012).  The 
reasons for this become evident when comparing the merits of observational 
diagnostic accuracy cohort studies and RCTs (Table 40). 
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Table 39.  Levels of evidence for diagnostic studies 
Level Diagnostic Study 
1a Systematic Review of Level 1 diagnostic 
studies or multicenter validation of a clinical 
decision rule  
1b Validating cohort study with good reference 
standards; or clinical decision rule tested 
within one centre 
1c A diagnostic finding whose 
Sensitivity/specificity is so high that a 
Negative/positive result rules-out/in the 
diagnosis. 
2a Systematic Review of > Level 2 studies 
2b  Exploratory cohort study with good reference 
standards; a clinical decision rule validated 
on split sample databases only 
3a Systematic review of 3b and better studies 
3b Non-consecutive study; or without 
consistently applied reference standards 
4 Case-control study, poor reference standard 
5 Expert opinion 
Adapted from Oxford Centre for Evidence Based Medicine 2009 
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Table 40.  Comparative advantages and disadvantages of observational and 
randomized diagnostic trials 
Diagnostic observational cohort 
study 
Diagnostic Randomized Controlled 
Trial 
Advantages 
 Simple to run 
 Inexpensive 
 Accepted amongst medical 
community 
 Allow calculation of diagnostic 
accuracy  
 Tests safety of a novel test 
when clinical equipoise* may 
not justify a randomized design 
Advantages 
 Remove threats to validity that occur 
with observational studies 
 Permit direct comparison of 
experimental and standard tests 
with clinically relevant outcomes 
 Can result in the experimental test 
being better than the reference 
standard 
 Can be conducted when there is no 
accepted reference standard 
 Can accurately determine cost 
effectiveness/efficiency 
improvements 
Disadvantages 
 Simply compares experimental 
test to reference standard 
 Does not measure hard patient 
outcomes 
 Difficult to establish cost-
effectiveness 
 No new diagnostic test can beat 
the reference standard 
Disadvantages 
 Expensive 
 
 Resource heavy 
 
 Can only be performed if the 
diagnostic test is known to be 
safe (clinical equipoise*) 
*Clinical equipoise means there is genuine uncertainty within the medical community as to 
whether the diagnostic test will be safe (Freedman 1987). 
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Examples of where diagnostic RCTs can provide information that observational studies 
are unable, within the field of accelerated diagnostic protocols in chest pain, are 
provided by two large diagnostic studies.  The first, the randomised assessment of 
treatment using panel assay of cardiac biomarkers (RATPAC) study (Fitzgerald et al. 
2011) was able to robustly demonstrate a reduction in length of stay in patients 
assessed using a rapid biomarker rule-out strategy but a paradoxical increase in 
downstream testing was revealed.  The second, by Than et al. (2014a) demonstrated 
that a 2-hour accelerated diagnostic protocol only achieved reduction in length of stay 
after 6 hours (Figure 6, Page 67).  Neither of these effects would have been robustly 
demonstrated through an observational design. 
The TRUST study’s observational design also may have resulted in threats to both 
internal and external validity as summarized in Table 41.  Diagnostic RCTs may 
eliminate or reduce the likelihood for many of the potential biases that threaten 
internal validity of diagnostic accuracy cohort studies (Rodger et al. 2012). 
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Table 41.  Threats to validity of the TRUST Study 
Threat Definition In context of TRUST 
Study 
Internal Validity (bias)   
Context bias Experimental test more likely 
to be reported as abnormal in 
populations with high disease 
prevalence 
False-positive high-
sensitivity troponin 
elevations 
Clinical review bias Experimental test or reference 
standard interpreted with 
knowledge of participant 
clinical characteristics 
6 hour troponin result 
interpreted after notes 
review 
Test review bias Experimental test interpreted 
with knowledge of the 
reference standard test results 
Un-blinding of presentation 
troponin results to assess 
change over time 
Diagnostic review bias Reference standard test 
interpreted with knowledge of 
the experimental test results 
Clinicians blinded to 
experimental (presentation 
troponin) test results 
External validity 
(generalisability) 
  
Spectrum of participants Disease severity, participant 
demographics or participant 
co-morbidity influence 
experimental test accuracy 
Limited due to single centre, 
predominantly white 
Caucasian population 
Age>80 excluded 
Confounding Potential study participants 
with confounders known to 
influence experimental test 
accuracy excluded from study 
Patients with abnormal ECG 
excluded 
Age>80 excluded 
 
Adapted from Rodger et al. 2012 
It is therefore important to recognise that the TRUST ADP ideally requires validation as 
part of a multicentre randomised controlled trial.  However, it may be argued that 
without first analysing the safety of this diagnostic strategy through an observational 
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cohort design, the principle of clinical equipoise may not have justified a randomised 
study design (Freedman 1987). 
A suggested design to test the TRUST ADP within an RCT is included in Figure 35.  The 
aim of this RCT would be to compare the effectiveness of two investigative pathways 
for the assessment of patients with suspected cardiac chest pain.  Effectiveness would 
be established through measurement of the primary outcome measure: discharge 
within 4 hours of attendance without MACE at 30 days.  As demonstrated in Figure 32, 
the TRUST ADP could be compared with multiple standard care processes by 
incorporating multiple centres. In order to achieve maximal clinical applicability this 
trial design follows the CONSORT extension statement for pragmatic trials 
(Zwarenstein et al. 2008), and therefore clinical management would not strictly be 
controlled.  Although pathways for the intervention and control arms would be 
provided, the final management decision, based on either subjective or structured 
clinical assessment, as well as test results, would be at the discretion of the treating 
physician.   
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Figure 32.  Suggested trial schema to test the TRUST ADP within a diagnostic 
randomized control trial against standard care   
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6.3 Study Population 
In the evaluation of a diagnostic strategy, such as the TRUST ADP, the study population 
should be representative of the population who would receive the test in routine 
practice (Goodacre 2009). If the population is highly selected then this will bias 
estimates of sensitivity and specificity.  By recruiting consecutive patients with 
appropriate inclusion and exclusion criteria the generalizability of the TRUST study 
results has been maximized.  However, the generalizability of the TRUST ADP may still 
be limited by the characteristics of the population selected.   
Participants were only recruited if treating physicians planned to investigate as an 
inpatient, therefore patients discharged directly from the ED at the discretion of the 
ED doctor were not included.  It should be noted that this direct discharge group may 
in fact have a miss-rate for acute coronary syndromes of up to 5% (Christenson et al. 
2004) which in itself is not insignificant.   
6.3.1 Demographics 
 
An integral part of the TRUST ADP and the analysis of typicality of pain are patient 
reported symptoms.  It is known that symptoms reported by patients are varied and 
are influenced by factors such as age, sex and medical history.  Women with AMI may 
be more likely to report atypical rather than typical symptoms (Rubini Gimenez et al. 
2014).  While older patients and those with various chronic diseases may make cardiac 
symptoms more difficult to recognise (Horne et al. 2000).   These factors may 
therefore limit the TRUST study’s applicability. 
The inclusion of predominantly British Caucasian patients may also limit the 
applicability to international settings.  The high proportion (>95%) British Caucasian 
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patients is reflective of the local population demographic and is greater than that of 
the majority of the UK (Dorset County Council 2011) this has important implications in 
applying the study findings to more diverse populations.  For example, (Greenslade et 
al. 2012) identified cross-cultural differences in symptoms reported by patients with 
suspected ACS.  Furthermore reference values for high-sensitivity troponin assays have 
been determined in Western populations and limited data is available regarding 
expected values in Asian populations (Gaggin et al. 2014). 
6.3.2 Exclusion of Patients over 80 years 
 
 
The upper age cut-off of ≥80 years was chosen for pragmatic reasons.  In our 
institution, patients above this age are admitted to a separate and dedicated 
assessment area.  The TRUST Study is therefore guilty of not recruiting the fastest 
growing sector of the population, and furthermore physiologically the elderly cannot 
be classed as equivalent to those decades younger (Watts 2012).  This consideration is 
of great importance with regard to high-sensitivity troponin assays, where it is known a 
high proportion of patients have elevations in troponin due to sub-clinical disease 
(deFilippi et al. 2010).  Therefore it is recognized that this may affect the applicability 
of the findings in those >80 years of age and any clinical uptake of the protocols 
described should therefore not be applied to those over the age of 80 years. 
As a counterpoint to this, it may also be argued that older people must not be 
discharged overnight due to welfare concerns (Banerjee et al. 2013), and given that 
As a result of the exclusion of patients > 80 years, a “Safety Point” has 
been added to the published TRUST ADP.  This ensures clinicians are 
aware the ADP is not validated in the elderly. 
PhD Thesis. Dr Edward W. Carlton 
 
209 
 
over 40% of the TRUST cohort presented outside 0800-1800 hours, an ADP in this age-
group may have minimal impact on length of hospital stay.  If the TRUST study were to 
be repeated however, careful consideration of the positive inclusion of elderly 
patients, in order to address these issues, would be appropriate. 
6.3.3 Exclusion of Patients with an Ischaemic Electrocardiogram 
 
Patients were only recruited if they had a non-ischaemic ECG at presentation - thereby 
reducing the prevalence of MACE in the study population.  This may be described as a 
significant limitation of the TRUST study.  However, expansion of the inclusion criteria 
to include those patients with ECG changes consistent with ACS would have added 
little practical value because this group are not suitable for early discharge anyway.   
Patients with a clear diagnosis of ACS, were intentionally excluded, to focus on a 
particular group that remain a major diagnostic challenge.  
In fact, it has been argued that recruiting patients with an ECG that is diagnostic for 
ischaemia is a limitation of prior papers that have evaluated the clinical features of 
acute chest pain (Goodacre et al. 2009).  This is because clinical features that simply 
help to confirm the diagnosis of ACS in a patient with a diagnostic ECG are likely to be 
of limited practical value.  
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6.4 Outcome Selection and Adjudication Challenges 
6.4.1 Major Adverse Cardiac Events 
 
On commencement of the study the primary outcome chosen for analysis of the TRUST 
ADP was the presence of MACE at 30 days, including the initial hospital visit.  This was 
defined according to prior large-scale studies investigating rapid rule-out protocols 
(Than et al. 2011, Collinson et al. 2012 and Cullen et al. 2013).  This definition may be 
open to criticism, specifically for the use of urgent revascularization-which may be 
argued is subjective and may be influenced by adjudication bias.  Subjective ischemic 
endpoints such as revascularization are likely to be driven by local practices, and in the 
case of this study, the hs-cTnT assay in clinical use.  As a result of this, for the paper 
summarizing the diagnostic accuracy of the TRUST ADP published in BMJ Heart 
(Carlton et al. 2015) the primary outcome was switched to fatal/non-fatal AMI.   
It may be argued, however, that the inclusion of revascularization is important, as 
patients with a requirement for revascularization are known to be a short term risk of 
death and AMI, even in the absence of elevations in high-sensitivity troponin (Reichlin 
et al. 2013).  Therefore, when assessing suitability for discharge from the ED 
revascularization should still be included as an outcome measure. 
Subtle variations in the use of MACE within published literature have also been 
identified and should be accounted for by the reader.  For example, in a recent 
validation of the Manchester Acute Coronary Syndromes (MACS) rule (Body et al. 
2014a), MACE included patients with >50% coronary stenosis in the absence of 
revascularization.  There is an evident requirement for a Universal Definition of MACE. 
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6.4.2 Acute Myocardial Infarction 
 
The initial intention was to undertake blinded adjudication of AMI according to only 
those high-sensitivity troponin results taken at 6 hours after attendance.  Whilst this 
blinded approach would have been methodologically correct (Stiell and Wells 1999), it 
was adjudged significant flaw in the study design.  The 3rd Universal Definition of AMI 
requires a rise or fall in troponin to be detected over time (Thygesen et al. 2012a), 
therefore AMI adjudication using just one 6 hour sample would not be guideline 
driven.  It was therefore decided to un-blind the adjudication process. 
This lead to a further problem in selecting an appropriate “significant” change over 
time for the hs-cTnT assay used for outcome adjudication.  Current consensus 
guidance (Thygesen et al. 2012b) suggest the use of a delta change of 20% over a 
period of 3-6 hours and this approach was selected.  However, it should be 
acknowledged that evidence for this comes from third generation assays and is not 
specific to the hs-cTnT assay used in the TRUST study.  Another approach considered 
was the use absolute change of 9ng/L, over time which may lead to improve 
specificity, however this approach is experimental and requires validation (Mueller et 
al. 2012). 
 
6.4.3 Significant Coronary Artery Disease 
 
Significant CAD was used as an outcome measure in the analysis of typicality of chest, 
in order to provide an anatomical outcome measure and overcome the adjudication 
challenges associated with high-sensitivity troponin assays (Mills et al. 2011).  For this 
outcome measure, those patients selected for coronary angiography were done so 
according to the results of biomarker testing, stress testing or the clinical suspicion of 
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treating cardiologists.  Therefore this outcome may have been subject to ‘referral’ or 
‘verification’ bias.  Furthermore, interpretation of degree of stenosis was made 
according to visual assessment.  Heterogenicity due to differences between providers 
in angiography referral criteria and interpretation of degree of stenosis may have 
therefore influenced these results.  However the proportion identified as having 
significant coronary artery disease at angiography (58.2%) is in line with a recent study 
in a stable chest pain population which analysed typicality of chest pain (Genders et al. 
2011). 
 
    
6.5 Follow-up 
It may be suggested that patient follow-up, which did not involve direct patient 
contact, may lead to potential missed outcome events.  The ethics committee did not 
grant permission for direct patient contact as they felt that comprehensive follow-up 
data relating to adverse events could be obtained accurately through GP records.  This 
is because in the U.K., GPs hold comprehensive records for individuals relating to 
primary, secondary and tertiary care.  GP records have been demonstrated to be more 
accurate at reporting hospital admissions, including those for cardiac related events, 
than patients (Taylor et al. 2003). 
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6.6 Evaluation of Other Risk Scores 
Although data for each risk score was collected prospectively from data derived from 
that recorded by the treating physician at initial assessment, only the m-Goldman 
score was performed by the physician themselves.  The approach of deriving risk 
scores from large prospective datasets is commonplace in the literature (Goodacre et 
al. 2012, Six et al. 2013 and Cullen et al. 2014a).  Accepting that subjective 
interpretation may be important in risk-stratifying patients with chest pain (Kline and 
Stubblefield 2013 and Body et al. 2014b), this methodological approach may be 
flawed, and only resolved through direct comparison of each pathway through 
pragmatic randomized controlled trials. 
 
6.7 Evaluation of Chest Pain Typicality 
It may be argued that the use of a binary yes/no answer to evaluate chest pain 
typicality severely limits the interpretation of these results.  As a result of this potential 
methodological flaw, the focus of discussion moved towards the potential impact of 
context and cognitive biases.  This resulted in the expansion of the analysis to 
incorporate clinician experience and therefore a greater utility in the conclusions.  
However, it should be recognised that the assessment of unstructured clinician 
judgement may have been better assessed using a 5-point Likert scale, as performed 
by (Body et al. 2014b), in their analysis of clinician gestalt and if this analysis were to 
be repeated alterations of the methods to include this would be appropriate. 
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6.8 Patient Survey 
Given the low response rate of this survey, non-response bias should be considered 
when interpreting the data.  Despite the written nature of the survey, no screening 
was undertaken to account for illiteracy or those whose first language was not English.   
The quantitative nature of the questionnaire will also provide a limited interpretation 
of patient perspectives which may be improved with qualitative methodology.  In any 
study of this kind, there will be factors leading to further potential limitations, these 
will include the patient socio-demographic factors, patient experiences during 
admission, institutional reputation, ED crowding, staff attitudes and the fact that all 
respondents were recruited to a clinical trial.   
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Conclusions 
 
The TRUST ADP, which incorporates a structured risk-assessment and single 
presentation hs-cTnT blood draw, has the potential to allow early discharge in 40% of 
patients with suspected acute coronary syndromes.  Uptake of this protocol may have 
significant benefits for healthcare services worldwide by reducing hospital admission 
rates, ED overcrowding, duplication of staff time and resource use.  Furthermore, by 
using ED physicians to carry out risk-stratification and real-time troponin sampling with 
24-hour recruitment it has been demonstrated that this ADP is truly applicable.  The 
TRUST ADP has superior clinical utility when compared to undetectable hs-cTnT 
strategies and other existing risk scores in this cohort.  Future research should focus on 
methodologies that incorporate clinical assessment with high-sensitivity troponin 
testing rather than troponin testing alone, and the comparison of early rule-out 
strategies using diagnostic randomised controlled trials. 
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Chapter 7. 
Publication and Future Directions 
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7.1  Presentation at International Scientific Conferences 
Presentation of results from the TRUST Study has taken place at the American College 
of Cardiology Scientific Sessions 2014 (poster: Appendix 9), World Congress of 
Cardiology 2014 (poster: Appendix 10) and the International Conference on Emergency 
Medicine 2014 (oral presentation). 
 
7.2 Publication in Print  
Clinical and translational work such as the TRUST Study may quickly become outdated.  
Therefore there must be a focus on progressing to publication in high-impact peer 
reviewed medical journals.  The following papers have been published or are in print: 
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7.2.1   A Novel Diagnostic Protocol to Identify Patients Suitable for Discharge after a 
Single High-Sensitivity Troponin 
 
Carlton EW, Cullen L, Than M, Gamble J, Khattab A, Greaves K. 
Heart. 2015 Feb 17. pii: heartjnl-2014-307288. 
Abstract: 
Objective 
To establish whether a novel accelerated diagnostic protocol (ADP) for suspected acute 
coronary syndrome (ACS) could successfully identify low-risk patients suitable for discharge 
after a single high-sensitivity troponin T (hs-cTnT) taken at presentation to the Emergency 
Department (ED). We also compared the diagnostic accuracy of this ADP with strategies 
utilising initial undetectable hs-cTnT.  
 Methods 
This prospective observational study evaluated the ability of the Triage Rule-out Using high-
Sensitivity Troponin (TRUST) ADP to identify low-risk patients with suspected ACS.  The ADP 
incorporated a single presentation hs-cTnT of <14ng/L, a non-ischaemic electrocardiogram and 
a modified Goldman risk score.  Diagnostic performance of the ADP was compared with the 
detection limit cut-offs of hs-cTnT (<5ng/L and <3ng/L).  The primary endpoint was fatal/non-
fatal acute myocardial infarction (AMI) within 30 days. 
Results  
960 participants were recruited, mean age 58.0 years, 80 (8.3%) had an AMI.  The TRUST ADP 
classified 382 (39.8%) as low-risk with a sensitivity for identifying AMI of 98.8% (95%CI 92.5-
99.9).  hs-cTnT detection limits (<5ng/L and <3ng/L) had a sensitivity of 100% (94.3-99.9) and 
100% (94.4-100) respectively.  The TRUST ADP identified more patients suitable for early 
discharge at 39.8% vs 29.3% (<5ng/L) and 7.9% (<3ng/L) (P<0.001) with a lower false-positive 
rate for AMI detection; specificity 43.3% (95%CI 42.7-43.4) vs 32.1% (95%CI 31.6-32.1) and 
8.6% (95%CI 8.1-8.6) respectively. 
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Conclusion 
The TRUST ADP, which incorporates structured risk-assessment and a single presentation hs-
cTnT blood draw, has potential to allow early discharge in 40% of patients with suspected ACS 
and has greater clinical utility than undetectable hs-cTnT strategies. 
 
(Full Manuscript: Appendix 11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PhD Thesis. Dr Edward W. Carlton 
 
220 
 
7.2.2 ‘Chest Pain Typicality’ in Suspected Acute Coronary Syndromes and the Impact of 
Clinical Experience 
 
Carlton EW, Than M, Cullen L, Khattab A, Greaves K. 
American Journal of Medicine 2015.  doi: 10.1016/j.amjmed.2015.04.012. 
Abstract: 
Background 
Physicians rely upon chest pain history to make management decisions in patients with 
suspected acute coronary syndromes, particularly where the diagnosis is not immediately 
apparent through ECG and troponin testing. 
Objective 
To establish the discriminatory value of ‘typicality of chest pain’ and the effect of clinician 
experience, for the prediction of acute myocardial infarction and presence of significant 
coronary artery disease.  
Methods 
Prospective single-center observational study undertaken in a U.K. General Hospital emergency 
department. We recruited consecutive adults with chest pain and a non-diagnostic ECG, for 
whom the treating physician determined delayed troponin testing was necessary. Using their 
own clinical judgment, physicians recorded whether the chest pain described was typical or 
atypical for acute coronary syndrome. Physicians were defined as “experienced” or “novice” 
according to postgraduate experience. Acute myocardial infarction was adjudicated using a 
high-sensitivity troponin (hs-cTn) assay, while coronary artery disease was adjudicated 
angiographically.  
Results 
Overall, 912 patients had typicality of chest pain assessed, of whom 114/912 (12.5%) had an 
acute myocardial infarction and 157/912 (17.2%) underwent angiography. In patients 
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undergoing angiography, 90/157 (57.3%) had hs-cTn elevation, of whom 60 (66.7%) had 
significant coronary artery disease. 67/157 (42.7%) patients had angiography without hs-cTn 
elevation, of these 31 (46.2%) had significant coronary artery disease. For the diagnosis of 
acute myocardial infarction, chest pain typicality had an area under the curve (AUC) of 0.54 
(95%CI 0.49-0.60). For the prediction of significant coronary artery disease with hs-cTn 
elevation AUC: 0.54 (0.40-0.67), and without hs-cTn elevation AUC: 0.45 (0.31-0.59). When 
assessed by experienced physicians, specificity for the diagnosis of acute myocardial infarction 
was higher at 65.8% (63.1%-68.7%) vs. 55.4% (53.9%-56.8%) for novices.   
Conclusions 
Subjective interpretation of ‘typicality of chest pain’ is of limited discriminatory value in the 
assessment of suspected acute coronary syndromes, in the context of a non-diagnostic ECG. 
Greater clinical experience improves accuracy as a rule-in tool but does not improve overall 
discriminatory ability. 
 
(Full Manuscript: Appendix 12) 
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7.2.3 Beyond Triage:  The Diagnostic Accuracy of Emergency Department Nursing Staff 
Risk Assessment in Patients with Suspected Acute Coronary Syndromes 
 
Carlton EW, Khattab A, Greaves, K. 
Accepted Manuscript In Print: Emergency Medicine Journal 
Abstract: 
Objectives 
To establish the accuracy of emergency department (ED) nursing staff risk-assessment, using 
an established chest pain risk score alone and when incorporated with presentation high-
sensitivity troponin testing as part of an accelerated diagnostic protocol (ADP).   
Design 
Prospective observational study comparing nursing and physician risk-assessment using the  
modified Goldman (m-Goldman) score and a pre-defined ADP, incorporating presentation high-
sensitivity troponin.   
Setting 
A U.K. District ED. 
Patients 
Consecutive patients, aged ≥18, with suspected cardiac chest pain and non-ischaemic ECG, for 
whom the treating physician determined serial troponin testing was required. 
Outcome Measures 
30 day major adverse cardiac events (MACE). 
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Results 
960 participants were recruited. 912/960 (95.0%) had m-Goldman scores recorded by 
physicians and 745/960 (77.6%) by nursing staff.  The AUC of the m-Goldman score in 
predicting 30 day MACE was 0.647 (95% CI 0.594-0.700) for physicians and 0.572 (95% CI 
0.510-0.634) for nursing staff (P=0.09). When incorporated into an ADP, sensitivity for the rule-
out of MACE was 99.2% (95% CI 94.8-100) and 96.7% (90.3-99.2) for physicians and nurses 
respectively. One patient in the physician group (0.3%), and three patients (1.1%) in the nursing 
group were classified as low-risk yet had MACE..  There was fair agreement in the identification 
of low-risk patients (kappa 0.31, 95% CI 0.24-0.38). 
Conclusion 
The diagnostic accuracy of ED nursing staff risk-assessment is similar to that of ED physicians 
and inter-observer reliability between assessor groups is fair.  When incorporating high-
sensitivity troponin testing, a nurse-led ADP has a miss-rate of 1.1% for MACE at 30 days. 
 
(Full Manuscript:  Appendix 13)  
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7.2.4 Identifying Patients Suitable for Discharge after a Single High-Sensitivity Troponin 
Result: A Comparison of Five Established Risk Scores and Two High-Sensitivity Assays 
 
Carlton EW, Khattab A, Greaves K. 
In Press:  Annals of Emergency Medicine 
Abstract: 
Objective 
To compare the ability of five established risk scores to identify patients with suspected acute 
coronary syndromes (ACS) suitable for discharge after a single presentation high-sensitivity 
troponin (hs-cTn) result.  
Methods 
Prospective observational study conducted in a U.K. District General Hospital Emergency 
Department.  Consecutive adults recruited with suspected ACS whom attending physicians 
determined evaluation with serial troponin testing was required.  Index tests were definitions of 
low risk applied to Goldman, TIMI, GRACE, HEART and Vancouver risk scores, incorporating 
either hs-cTnT or hs-cTnI results.  The endpoint was acute myocardial infarction (AMI) within 30 
days.  A test sensitivity threshold for AMI of 98% was chosen. Clinical utility was defined as a 
negative predictive value (NPV) ≥99.5% and identification of >30% suitable for discharge.  
Results 
959 patients underwent hs-cTnT and 867 hs-cTnI analysis.  In the hs-cTnT group, 79/959 (8.2%) 
had an AMI and 66/867 (7.6%) in the hs-cTnI group.  Two risk scores (GRACE<80, HEART≤3) did 
not have the potential to achieve a sensitivity of 98% with hs-cTnT and three scores 
(Goldman≤1, TIMI≤1, GRACE<80) with hs-cTnI.  TIMI 0 or ≤1 and m-Goldman≤1 with hs-cTnT, 
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and TIMI 0 and HEART≤3, with hs-cTnI have the potential to achieve an NPV ≥99.5% while 
identifying >30% for discharge. 
Conclusion 
Using established risk scores, it may be possible to identify >30% of patients suitable for 
discharge with an NPV ≥99.5% for the diagnosis of AMI using a single hs-cTn result taken at 
presentation. There is variation in hs-cTn assays which may have implications in introducing 
rapid rule-out protocols. 
 
(Full Manuscript:  Appendix 14) 
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7.2.5 External Validation of the Manchester Acute Coronary Syndromes Rule 
 
Carlton E, Body R, Greaves K. 
Accepted Manuscript In Print: Academic Emergency Medicine 
Abstract: 
Objectives 
The Manchester Acute Coronary Syndromes (MACS) decision rule has been shown to be a 
powerful diagnostic tool in emergency department (ED) patients with suspected acute coronary 
syndromes (ACS).  It has the potential to improve system efficiency by identifying patients 
suitable for discharge after a single blood draw, for high-sensitivity troponin and heart-type 
fatty acid binding protein analysis, at presentation to the ED.  We aimed to externally validate 
the MACS decision rule and establish its diagnostic accuracy as a discharge tool in a new set of 
prospectively recruited ED patients. 
Methods 
In this post-hoc analysis of a prospectively recruited single-centre cohort we included 
consecutive ED patients ≥18 years with suspected ACS. Testing for heart-type fatty acid binding 
protein and high-sensitivity troponin T was undertaken on serum drawn on arrival and clinical 
features required to calculate the MACS rule recorded.  The primary outcome was major 
adverse cardiac events (MACE) within 30 days (acute myocardial infarction (AMI), death or 
revascularisation). The secondary outcome was AMI alone, adjudicated using 6 h troponin 
results.   
Results 
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Of the 782 participants included, 78 (10.0%) developed MACE and 61 (7.8%) had an AMI.  Of 
participants, 133 (17.0%) were identified as ‘very low risk’ and therefore suitable for immediate 
discharge with a 0% incidence of MACE or AMI.  The sensitivity was 100% (95% CI 95.4-100) for 
MACE at 30 days and 100% (95% CI 94.1-100) for AMI.  Of the ‘high risk’ group, 53.3% had a 
MACE within 30 days. The area under the ROC curve was 0.87 (95% CI 0.83 – 0.91) for the 
MACS rule in the prediction of MACE. 
Conclusion 
In this prospectively recruited cohort, the MACS decision rule identifies a significant proportion 
of patients who are suitable for immediate discharge after a single blood draw at presentation, 
with a 0% risk of MACE.  The rapid assessment and discharge of these patients is likely to 
reduce healthcare resource burden and costs. 
 
(Full Manuscript:  Appendix 15) 
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7.3  Collaborative Research Work  
 
The TRUST Study has stimulated world-wide interest.  Active collaboration is underway 
with the following researchers in the field for the following projects: 
7.3.1 The Investigation of the Incremental Benefit of the use of Sex-Specific Versus 
Overall Cut Points for High-Sensitivity Troponin I Assays in Predicting Short and Long-
Term Events in Emergency Department Patients 
  
This prospective analysis combines data from the TRUST Study with large cohorts in 
Australia and New Zealand to investigate the benefits of se-specific cut-offs.  Follow-up 
from the TRUST Study has been extended to include 12 month outcomes for this 
analysis.  This analysis is funded by Abbott Technologies who supplied the Troponin I 
assay for the TRUST Study.  
Manuscript accepted for publication: BMJ Heart 
Collaborator:  Associate Professor Louise Cullen, Emergency Department, Royal 
Brisbane and Women’s Hospital, Brisbane, Australia. 
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7.3.2 Rapid rule-out of AMI in chest-pain patients using single undetectable high-
sensitivity troponin T concentrations:  external validation in multiple centres  
 
An informal collaborative which aims to externally validate, in six countries, a strategy 
for the rapid rule-out of acute myocardial infarction utilizing an undetectable initial high-
sensitivity troponin T  result and non-ischemic ECG in patients presenting to emergency 
departments  with chest pain.  Data from the TRUST Study has been incorporated into 
this analysis and publication of the results is imminent. 
 
Collaborator:  Professor Martin Than, Emergency Department, Christchurch Hospital, 
New Zealand. 
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7.4  Proposed Future Research 
The student investigator is developing an NIHR grant application to run the following 
study: 
 
The Level of Detection of Troponin in the Emergency Department (LoD-ED) Assessment of 
Chest Pain Randomised Controlled Trial 
 
Rationale for Research 
Current data suggest that the diagnostic accuracy of the cut-off of hs-cTnT (Roche Elecsys 
assay) in common clinical use (the 99th centile value: 14ng/L), when used in isolation is too low 
to allow immediate discharge of patients presenting to ED after a single blood draw on arrival 
(Reichlin et al. 2009 and Keller et al. 2009).  However, the hs-cTnT assay has enabled more 
reliable detection of very low concentrations of troponin T and multiple observational studies 
have tested the Level of Detection (LoD:  lowest analyte concentration likely to be reliably 
distinguished at which detection is feasible) of 5ng/L. In a meta-analysis published in 2015 
(Zhelev et al. 2015) gave a pooled sensitivity for the rule-out of acute myocardial infarction 
(AMI) of 97.4% using the LoD.  However, diagnostic accuracy may be further improved by 
incorporating the finding of an electrocardiogram (ECG) on arrival with no evidence of cardiac 
ischemia.  This strategy was tested in a recent retrospective analysis (Bandstein et al. 2014) of 
14,636 chest pain patients who presented to EDs in Sweden. Sixty one percent (8,907) of 
patients had an initial hs-cTnT level of <5 ng/l (LoD) and no ST-segment changes indicating 
myocardial ischemia on their ECG. Subsequent analysis of hospital records and registry data 
showed a minimal occurrence of AMI (0.2%) or death (0%) in these patients within 30 days of 
arrival at the ED.  Our group has validated this approach through analysis of pooled results 
from a series of international prospectively collected data in 5 geographically diverse cohorts.  
In an as yet un-published analysis incorporating 6275 participants, the index test of no new 
ischaemia on an initial ECG and hs-cTnT <5ng/L achieved a negative predictive value for major 
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adverse cardiac events (MACE) of between 98.3-99.7% with between 11.4% and 73.5% of 
patients being suitable for early discharge.  
Whilst these results are promising, the effectiveness of the level of detection diagnostic 
strategy requires testing in a pragmatic randomised controlled trial (RCT).  This will enable us 
to establish whether such a strategy works under real-life conditions.  A key feature in this 
study design is that, although pathways for the intervention and control arms are provided, 
management will not be strictly controlled.  The final management decision, after test results, 
will be at the discretion of the treating clinician.  Clinicians do not predictably follow protocols 
or act on test results as expected (Than et al. 2014a).  Therefore the critical question this trial 
will answer is whether the new pathway works in practice, with clinicians actually discharging 
patients early, without subsequent harm or increased downstream resource use, in significant 
numbers.  Results from this RCT are more likely to promote knowledge translation than an 
observational trial. 
Aims 
To compare the effectiveness, when applied to clinical practice, of a Level of Detection of high-
sensitivity troponin T rapid rule-out strategy against the existing diagnostic process used in 
three centres – specific objectives are: 
1. Compare the rate of successful discharge at 4 hours after ED attendance. 
2. Measure hospital bed usage, length of stay, resource use, cost effectiveness and rate 
of major adverse cardiac events at 30 days. 
Research Design and Methods 
Participants:  Consenting adults presenting to the ED with chest discomfort suggestive of 
acute coronary syndrome (Luepker et al. 2003) in whom the attending clinician(s) (after initial 
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assessment) intends to perform serial troponins, as part of the existing chest pain investigation 
pathway for possible acute myocardial infarction. 
Exclusion criteria:  ST Segment Elevation Myocardial Infarction (STEMI); persisting pain and 
patients requiring admission regardless of a negative ECG/Troponin, due to other medical or 
social reasons; arrhythmias (new-onset atrial fibrillation, atrial flutter, sustained 
supraventricular tachycardia, second-degree or complete heart block, or sustained or 
recurrent ventricular arrhythmias); refusal or inability to provide informed consent; inability to 
be contacted after discharge. 
Interventions:  Participants will be randomised to have a diagnostic assessment using either:  
a) Level of Detection strategy (experimental pathway) or b) existing chest pain investigation 
pathway (control pathway).  In order to achieve maximal clinical applicability this trial design 
follows the CONSORT extension statement for pragmatic trials (Zwarenstein et al. 2008), 
therefore clinicians will not have to follow trial pathways if they believe they are not best for 
the patient. (Intention to diagnose analysis will be used). 
 1.  Control Pathway: These are existing diagnostic pathways in use in recruiting 
centres, these may have subtle variations between centres and will not be altered for research 
use.  These pathways include ECG assessment on arrival, followed by clinical assessment and 
serial hs-cTnT testing at presentation and after 3-6 hours of observation, as per consensus 
guidelines to identify patients who are low-risk and then suitable for discharge/outpatient 
investigations. The cut-off of hs-cTnT used to definitively rule out acute myocardial infarction 
in usual care is the 99th centile value (<14ng/L). 
 2.  Experimental Pathway:  Patients in the experimental arm are defined as low-risk 
following a single blood draw at presentation to the ED if they have (i) no new ischaemic ECG 
changes and (ii) an hs-cTnT below the Level of Detection (<5ng/L) and (iii) the treating clinician 
thinks discharge is safe.  Low-risk patients will be eligible for early discharge/outpatient 
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investigations.  Patients who do not fulfil low-risk criteria in the experimental arm will require 
further hs-cTnT testing after 3-6 hours of observation as per standard care. 
 
 
Primary Outcome:  The proportion of patients successfully discharged home within 4 hours of 
arrival with no MACE during the following 30 days. 
Secondary Outcomes: (i) MACE (death, acute myocardial infarction, ventricular arrhythmia, 
emergency revascularisation),  (ii) non-trauma hospital re-attendance within 30 days, (iii) 
length of stay in hospital, (iv) use of advanced cardiac testing (stress testing, CT coronary 
angiography and invasive angiography) and (v) cost-effectiveness. 
Patients who suffer MACE after discharge will not be classified as “successful” discharge home 
because it is possible that they may have benefitted from hospital admission. 
Assessment of Outcomes 
Research nurses will record baseline data, the results of initial assessment (and tests), and 
admission/discharge from the ED.  Electronic patient records will be used to record 
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management decisions at initial attendance, and identify subsequent attendances/admissions.  
Patient status at 30 days will be confirmed using national clinical records, hospital information 
systems, telephone follow-up and GP records.  Structured adjudication of all final diagnoses 
including AMI, and other adverse events will be performed by two blinded reviewers. 
Sample Size 
Current research gives estimates of the proportion suitable for discharge in the experimental 
arm of the RCT from between 10% and 40% (Zhelev et al. 2015).  Even if the experimental arm 
were to only achieve early discharge in 10% of patients then this would be an important 
difference.  This study will be powered to detect a 10% difference between the early discharge 
rates with a β=0.10 (90% power) and a 2-tailed α=0.05.  This will require 286 patients in each 
arm and 572 patients in total.  Based on recruitment in our previous study and with 
recruitment 0900-1700 Monday to Friday this will take 3 centres (e.g. Southmead Hospital, 
Bristol Royal Infirmary and Royal United Hospital, Bath) 10 months to complete.  
Anticipated Outcomes 
Implementation of positive study findings will decrease admissions and processing times for 
patients with chest pain.  This will positively impact upon the Department of Health ED 4-hour 
target and also upon hospital and ED overcrowding.  There is an urgent need for improvement 
in this area.  In addition to scientific publications wider dissemination of positive study findings 
will be achieved in the UK through the medical royal colleges and the National Institute for 
Health and Care Excellence.  
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